(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 3 October 2002 (03.10.2002)

PCT

(10) International Publication Number WO 02/077204 A2

(51) International Patent Classification⁷: C12N 5/00

(21) International Application Number: PCT/GB02/01195

(22) International Filing Date: 25 March 2002 (25.03.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0107299.0 23 March 2001 (23.03.2001) GB 0107296.6 23 March 2001 (23.03.2001) GB 0109346.7 17 April 2001 (17.04.2001) GB

- (71) Applicant (for all designated States except US): AXOR-DIA LIMITED [GB/GB]; Firth Court, Western Bank, Sheffield S10 2TN (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): ANDREWS, Peter [GB/GB]; University of Sheffield, Western Bank, Sheffield S10 2TN (GB). WALSH, James [GB/GB]; University of Sheffield, Western Bank, Sheffield S10 2TN (GB). GOKHALE, Paul [GB/GB]; University of Sheffield, Western Bank, Sheffield S10 2TN (GB).

- (74) Agent: HARRISON GODDARD FOOTE; 31 St. Saviourgate, York YO1 8NQ (GB).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

 without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

2/077204 A2 |||||||

(54) Title: STEM CELL

(57) **Abstract:** There is provided a method to modulate the differentiation state of embryonic stem cells in culture by the providing ligands which bind receptors in the *Notch* and *Wnt* pathways.

STEM CELL

The invention relates to a method to modulate the differentiation state of embryonic stem cells.

5

10

15

20

During mammalian development those cells that form part of the embryo up until the formation of the blastocyst are said to be totipotent (e.g. each cell has the developmental potential to form a complete embryo and all the cells required to support the growth and development of said embryo). During the formation of the blastocyst, the cells that comprise the inner cell mass are said to be pluripotential (e.g. each cell has the developmental potential to form a variety of tissues).

Embryonic stem cells (ES cells, those with pluripotentiality) may be principally derived from two embryonic sources. Cells isolated from the inner cell mass are termed embryonic stem (ES) cells. In the laboratory mouse, similar cells can be derived from the culture of primordial germ cells isolated from the mesenteries or genital ridges of days 8.5-12.5 post coitum embryos. These would ultimately differentiate into germ cells and are referred to as embryonic germ cells (EG cells). Each of these types of pluripotential cell has a similar developmental potential with respect to differentiation into alternate cell types, but possible differences in behaviour (eg with respect to imprinting) have led to these cells to be distinguished from one another. Hereinafter embryonic stem cells will encompass both these stem cell – types.

25 Typically ES cell cultures have well defined characteristics. These include, but are not limited to; maintenance in culture for at least 20 passages when maintained on fibroblast feeder layers; produce clusters of cells in culture referred to as embryoid bodies; the ability to differentiate into multiple cell types in monolayer culture; and express ES cell specific markers.

Until very recently, *in vitro* culture of human ES cells was not possible. The first indication that conditions may be determined which could allow the establishment of human ES cells in culture is described in WO96/22362. The application describes cell lines and growth conditions which allow the continuous proliferation of primate ES cells which exhibit a range of characteristics or markers which are associated with stem cells having pluripotent characteristics.

More recently Thomson *et al* (1998) have published conditions in which human ES cells can be established in culture. The above characteristics shown by primate ES cells are also shown by the human ES cell lines. In addition the human cell lines show high levels of telomerase activity, a characteristic of cells which have the ability to divide continuously in culture in an undifferentiated state. Another group (Reubinoff et. al., 2000) have also reported the derivation of human ES cells from human blastocysts. A third group (Shamblott et. al., 1998) have described EG cell derivation.

A feature of ES cells is that, in the presence of fibroblast feeder layers, they retain the ability to divide in an undifferentiated state for several generations. If the feeder layers are removed then the cells differentiate. The differentiation is often to neurones or muscle cells but the exact mechanism by which this occurs and its control remain unsolved. It would be desirable to have a reliable culture system which does not require the presence of fibroblast feeder cells but includes the addition of a factor(s) which maintain ES cells in an undifferentiated state. A prerequisite to the successful exploitation of ES cells in tissue engineering is to provide a reliable and defined cell culture system which can be used to control the differentiation of ES cells into a selected cell-type. The identification of gene targets involved in maintaining ES cells as ES cells and the identification of gene targets involved in differentiation will facilitate this objective.

We have identified a regulatory pathway involved in the mechanism by which ES cells are maintained as ES cells in culture and which also influences the differentiation of said cells in culture. The regulatory pathway comprises two families of genes referred to as *Notch* and *Wnt*.

5

10

15

20

25

30

The *Notch* gene is a *Drosophila* prototype for a family of homologues found in diverse species, encoding large, single-span, transmembrane receptors (reviewed in Weinmaster, 199-7). Within the extracellular domain, located distally from the transmembrane region, are found multiple (10-36), tandem arrays of epidermal growth factor-like repeats (Wharton et al., 1985; Kopezynski et al., 1988). More proximally are found 3 cysteine-rich, Lin-12/Notch repeats and two conserved cysteine residues. The intracellular domain contains, from proximal to distal with respect to the transmembrane region, a subtransmembrane region (STR), six ankyrin repeats and a region rich in proline, glutamic acid, serine and threonine (PEST). The generic Notch structure is illustrated in Figure 1.

Wnt genes encode diffusible, extracellular signalling molecules of around 350-400 amino acids in length, defined by a characteristic pattern of conserved cysteine residues, along with other invariant amino acids (see http://www.stanford.edu/~rnusse/wntwindow.html.

In the 1970s, the wingless (wg¹) mutation of Drosophila melanogaster was described, in which affected individuals showed aberrant wing and haltere development (Sharma, 1973; Sharma and Chopra, 1976). When the gene disrupted by this mutation was subsequently identified, the predicted 468aa peptide sequence exhibited remarkable similarity to that of a murine gene, int-1 (Cabrera et al., 1987; Rijsewijk et al., 1987), including an identical pattern of 23 conserved cysteine residues. int-1 had earlier been identified as a common integration site of the murine mammary tumour virus, and a likely cellular oncogene (Nusse and Varmus, 1982; van Ooyen and Nusse, 1984). Thus, the two prototypic members of the Wnt gene family were described. Since that time, numerous homologues of wingless/int-1 have

been identified in divergent organisms, including Caenorhabditis elegans, Drosophila melanogaster, Xenopus laevis, chicken, mouse and humans (reviewed in Cadigan and Nusse, 1997; Wodarz and Nusse, 1998). Lower organisms appear to possess a limited repertoire of Wnt genes in comparison to higher organisms, presumably reflecting their lesser developmental complexity. Additionally, vertebrates appear to express multiple, closely related orthologues of certain Wnts. The Wnt family is composed of more than 60 members, with 14 human homologues alone. Well-documented roles exist for Wnt signalling in a variety of developmental processes, including cell fate specification and patterning within the central nervous system.

5

10

15

20

Wnt ligands interact with membrane-bound receptors of the frizzled family, leading to activation of a cytoplasmic protein, Dishevelled. Dishevelled inhibits Notch activation (2) and also inhibits the activity of an Axin-APC-GSK-3b complex, promoting formation of a bipartite transcriptional activator comprising b-catenin and TCF (4). Wnt signalling may be antagonised by extracellular molecules that compete for Wnt binding, including frizzled related proteins (FRP), Wnt inhibitory factors (WIF), Dickkopf and Cerberus. Expression of *Wnt* target genes may also be regulated by other proteins that bind to and alter the function of TCF. CREB-Binding Protein (CBP) exhibits a mutually antagonistic binding affinity for TCF with b-catenin and converts TCF into a repressor of target genes (8). Additionally, Notch activation may induce transcriptional repression by TCF, even in the presence of b-catenin, through expression of the TLE class of putative target genes (5,7).

As a model system to test the involvement of *Notch* and *Wnt* genes in the differentiation of ES cells we have used embryonal carcinoma cells which are stem cells of teratocarcinomas. The stem cells of early embryos and the stem cells of teratocarcinomas have been demonstrated experimentally to be capable of substituting for one another in their respective roles. Thus, an embryonic stem cell introduced to a syngeneic host may give rise to a teratocarcinoma containing all of the elements that would be found in a spontaneous tumour of this type (Mintz et al.)

1978). Likewise, embryonal carcinoma cells derived from a spontaneous germ cell carcinoma may participate in embryonic development, and generate normal somatic tissue following injection into a blastocyst (Brinster 1974; Mintz and Illmensee 1975; Papaioannou et al 1975). This clearly demonstrates that murine EC cells may respond to developmental cues in an appropriate manner, and that their differentiation may provide information pertinent to normal embryogenesis. Similarly, human EC cells may provide an insight into the processes that regulate human development.

5

10

15

20

30

The TERA2 cell line was derived from a lung metastasis of a human teratocarcinoma in the mid 1970s (Fogh and Trempe, 1975). Morphologically, TERA2 cultures are quite divergent from the characteristic EC phenotype and display significant heterogeneity, suggesting that these cells undergo spontaneous differentiation (Andrews et al., 1980). However, a tumour containing both embryonal carcinoma cells and differentiated derivatives was produced following injection of TERA2 into a nude mouse host (Andrews et al., 1983a; Andrews et al., 1983b; Andrews et al., 1984). A cell line established from the EC component of this tumour, named NTERA2, closely resembled and maintained the characteristic EC phenotype in culture and, unlike the parent line, was able to produce teratocarcinoma in nude mice with high frequency (Andrews et al., 1983a; Andrews et al., 1983b; Andrews et al., 1984). Additionally, various subclones of NTERA2 exhibit the ability to differentiate extensively *in vitro* following treatment with chemical inducers (eg retinoic acid (RA), HMBA) (Andrews, 1984; Andrews et al., 1986).

The expression of human *Notch* homologues were examined in NTERA2 to determine their involvement in ES cell differentiation.

We have discovered that members of the *Notch* gene family, *Notch1*(Genbank accession number AF308602), *Notch2* (Genbank accession number NM_024408) and *Notch3* (Genbank accession number NM_000435) are expressed in EC cells and NTERA2 cells. *Notch1* expression was detected as a mRNA band of around 7Kb in both EC and differentiated cultures of NTERA2. *Notch3*, like *Notch1*, was

PCT/GB02/01195 WO 02/077204

examined in EC cells. A transcript of around 8Kb was readily detected in all samples. The endoderm-specific Notch4 (Genbank accession number XM 004207) was not.

All three Notch homologues expressed by NTERA2 showed altered transcription 5 during differentiation in response to retinoic acid. In each case, however, these changes were modest and expression was evident in both EC and differentiated cultures. The role of the Notch pathway in directing EC/ES differentiation may thus depend to a greater extent on the level of signalling activation rather than the abundance of the receptors. In order to investigate this possibility, the expression of candidate ligands for Notch receptors were examined. For example, dlk (Genbank accession number U15979) was detected at high levels in EC cultures, but its expression was almost extinguished by 3 days following RA treatment. Low levels were also observed through 7 and 14 days post-RA. However, by 21 days, dlk was up-regulated to the level seen in EC cultures. These profound changes may reflect an important role for dlk and other DSL ligands in regulating EC/ES differentiation through altered Notch signalling activation. This data is suggestive that the Notch signalling pathway is involved in regulating EC cell differentiation and, by extrapolation, human ES cell differentiation.

.10

15

30

20 A degenerate PCR strategy was used to investigate the possible expression of novel Wnt genes in the NTERA2 system. The expression of a single Wnt gene, Wnt-13, was detected in NTERA2. Wnt-13 was absent in EC cells, but showed induction and subsequent up-regulation following both retinoic acid and HMBA treatment. Both of these agents bring about extensive differentiation of NTERA2, accompanied by the 25 loss of typical human EC surface markers.

We have examined the expression of components of the Wnt pathway and of transcripts corresponding to other proteins known to interact with Wnt signalling in NTERA2 cells. These cells are a model system for aspects of human embryogenesis and differentiate extensively in vitro in response to chemical inducers. Among the

cell types produced following retinoic acid treatment are functional, post-mitotic, CNS neurons (1,6,17).

The modulation of the *Notch* and *Wnt* signalling pathways may facilitate manipulation of embryonic stem cell differentiation. The term modulation refers to either the maintenance of embryonic stem cells as embryonic stem cells or the facilitation of differentiation of embryonic stem cells along defined cell lineages.

According to an aspect of the invention there is provided a method to modulate the phenotype of an embryonic stem cell comprising contacting said cell with a ligand binding domain of a polypeptide wherein said domain binds its cognate receptor expressed by said cell to modulate said phenotype.

According to a further aspect of the invention there is provided a method to modulate the differentiation of an embryonic stem cell comprising:

- i) providing a culture of embryonic stem cells;
- ii) providing at least one ligand, or the active binding fragment thereof, capable of binding its cognate receptor polypeptide expressed by said embryonic stem cell;
- 20 iii) forming a culture comprising embryonic stem cells and said ligand; and
 - iv) growing said cell culture.

In a preferred method of the invention said ligand is encoded by a nucleic acid molecule selected from the group consisting of:

- 25 i) a nucleic acid molecule as represented in Figure 22;
 - ii) a nucleic acid molecule which hybridises to the nucleic acid in (i) and which encodes a ligand capable of binding a Wnt receptor; and
 - iii) nucleic acid molecules which are degenerate as a result of the genetic code to the sequences defined in (i) and (ii) above.

In a preferred method of the invention said ligand is selected from the group consisting of: WNT 1; WNT 2, WNT 3; WNT 4; WNT 5A; WNT 6; WNT 7A; WNT 8B; WNT 10B; WNT 11; WNT 14; WNT 16.

5 In a further preferred method of the invention said ligand is WNT 13.

In an alternative preferred method of the invention said ligand is encoded by a nucleic acid molecule selected from the group consisting of:

- i) a nucleic acid molecule as represented in Figures 2, 4, 5, 7, 10, 12, 14, 16, or 18.
- ii) a nucleic acid molecule which hybridises to the nucleic acid in (i) and which encodes a ligand capable of modulating embryonic stem cell differentiation; and
- iii) nucleic acid molecules which are degenerate as a result of the genetic code to the sequences defined in (i) and (ii) above.

In a further preferred method of the invention said ligand is selected from the group represented by the amino acid sequences in Figures 3, 6, 8, 9, 11, 13, 15, 17, 19, or polypeptide variants thereof.

20

25

30

10

Polypeptide variants are polypeptide sequences having at least 75% identity with the polypeptide sequences as herein disclosed, or fragments and functionally equivalent polypeptides thereof. In one embodiment, the polypeptides have at least 85% identity, more preferably at least 90% identity, even more preferably at least 95% identity, still more preferably at least 97% identity, and most preferably at least 99% identity with the amino acid sequences illustrated herein.

In a further preferred method of the invention said cells are induced to differentiate by the addition of at least one agent selected from the group consisting of: retinoic acid; HMBA; bone morphogenetic proteins; bromodeoxyuridine; lithium; sonic hedgehog.

Optionally the inducing agent and the ligand are added simultaneously to a culture of embryonic stem cells. Alternatively, the ligand is added before addition of said inducing agent.

- 5 According to a further aspect of the invention there is provided a method for modulating the differentiation of embryonic stem cells comprising:
 - i) providing a cell transfected with a nucleic acid molecule selected from the group consisting of:
 - a) a nucleic acid molecule as represented in Figures 2, 4, 5, 7, 10, 12, 14, 16, 18.
- b) a nucleic acid molecule which hybridises to the nucleic acid in (ii) and which encodes a ligand capable of modulating embryonic stem cell differentiation; and
 - c) nucleic acid molecules which are degenerate as a result of the genetic code to the sequences defined in (a) and (b) above.
- ii) forming a culture comprising the cell identified in (i) above with an embryonic stem cell; and
 - iii) growing said culture under conditions suitable for the maintenance and/or differentiation of said embryonic stem cell.

According to a yet further aspect of the invention there is provided a method for modulating the differentiation of embryonic stem cells comprising:

- i) providing a cell transfected with a nucleic acid molecule selected from the group comprising:
 - a) a nucleic acid molecule as represented by the sequence in Figure 22;
 - b) a nucleic acid molecule which hybridises to the nucleic acid in (a) and which encodes a ligand capable of binding a Wnt receptor; and
 - c) nucleic acid molecules which are degenerate as a result of the genetic code to the sequences defined in (a) and (b) above.
- ii) forming a culture comprising a cell as identified in (i) above with an embryonic stem cell; and
- 30 iii) growing said culture under conditions suitable for the maintenance and/or differentiation of embryonic stem cells.

In a preferred method of the invention said cell expresses Wnt-13.

5

- 15

20

30

Optionally the cells expressing the ligand(s) are mixed with a culture of undifferentiated embryonic stem cells. This is followed by addition of the inducing agent (eg retinoic acid; HMBA, bone morphogenetic proteins; bromodeoxyuridine; lithium; sonic hedgehog).

In a preferred method of the invention said nucleic acid molecule hybridises under stringent hybridisation conditions to the nucleic acid molecules represented in (a), (b) or (c) above.

Stringent hybridisation or washing conditions are well known in the art. For example, nucleic acid hybrids that are stable after washing in 0.1xSSC, 0.1% SDS at 60°C. It is well known in the art that optimal hybridisation conditions can be calculated if the sequence of the nucleic acid is known. For example, hybridisation conditions can be determined by the GC content of the nucleic acid subject to hybridisation. Please see Sambrook *et al* (1989) Molecular Cloning; A Laboratory Approach. A common formula for calculating the stringency conditions required to achieve hybridisation between nucleic acid molecules of a specified homology is:

$$T_m = 81.5^0 \text{ C} + 16.6 \text{ Log [Na}^+] + 0.41 [\% \text{ G} + \text{C}] - 0.63 (\% \text{formamide})$$

In a further preferred method of the invention the nucleic acid molecule is genomic DNA or cDNA.

In a preferred method of the invention the nucleic acid molecule encodes a ligand of human origin.

In a further preferred method of the invention said embryonic stem cells are of human origin.

In a yet further preferred method of the invention the cell transfected with the nucleic acid according to the invention is a mammalian cell. Preferably the cell is selected from the following group: a chinese hamster ovary cell; murine primary fibroblast cell; human primary fibroblast cell; transformed mouse fibroblast cell-line STO.

According to a further aspect of the invention there is provided a method for inhibiting the differentiation of embryonic stem cells or embryonal carcinoma cells comprising:

10

25

5

- i) providing at least one polypeptide, or active fragment thereof, wherein said polypeptide is an inhibitor of the *Wnt* signalling pathway.
- ii) forming a culture comprising the polypeptide identified in (i) above with an embryonic stem cell; and
- 15 iii) growing said culture under conditions suitable for the maintenance of embryonic stem cells in an undifferentiated state.

In a preferred method of the invention said inhibitor of Wnt signalling is selected from the group comprising the active binding fragments thereof of the following polypeptides: frizzled related polypeptides (FRP); Wnt Inhibitory Factors (WIF); Dickkopf; Cerebrus.

In a further preferred method of the invention said inhibitor of Wnt signalling is selected from the group comprising the active binding fragments thereof of the following polypeptides: SFRP1; SFRP4; FRZB; SFRP2; FZD1; FZD2; FZD9; FZD3; FZD5; FZD4; FZD6; FZD7; DVL2; DVL3; GSK3B; AXIN1; APC; TCF1; WIF-1; CER 1; DKK1-4; SARP 2; SARP 3.

According to a further aspect of the invention there is provided a method for inhibiting the differentiation of embryonic stem cells or embryonal carcinoma cells comprising:

i) providing a cell transfected with a nucleic acid molecule selected from the group consisting of:

a) a nucleic acid molecule encoding a Wnt inhibitory polypeptide;

5

15

20

25

30

- b) a nucleic acid molecule which hybridises to the nucleic acid in (a) and which encodes a polypeptide capable of inhibiting *Wnt* signalling; and
- c) nucleic acid molecules which are degenerate as a result of the genetic code to the sequences defined in (a) and (b) above.
- ii) contacting the cell of (i) above with a culture of embryonic stem cells; and
- 10 iii) growing said culture under conditions suitable for the maintenance of embryonic stem cells in an undifferentiated state.

In a preferred method of the invention said cells express at least one Wnt inhibitory polypeptide selected from the group comprising the active binding fragments thereof of the following polypeptides: frizzled related polypeptides (FRP); Wnt Inhibitory Factors (WIF); Dickkopf; Cerebrus. Preferably said cells express at least one Wnt inhibitory polypeptide selected from the group comprising the active binding fragments thereof of the following polypeptides: SFRP1; SFRP4; FRZB; SFRP2; FZD1; FZD2; FZD9; FZD3; FZD5; FZD4; FZD6; FZD7; DVL2; DVL3; GSK3B; AXIN1; APC; TCF1; WIF-1; CER-1; DKK1-4

In a further preferred method of the invention the nucleic acid molecule is encoded by a nucleic acid molecule which hybridises under stringent hybridisation conditions to the nucleic acid molecules represented in (a), (b) or (c) above. Preferably said inhibitors are human.

According to a further aspect of the invention there is provided a vector comprising the nucleic acid molecule according to the invention. Preferably the vector is an expression vector adapted for the expression of the polypeptide encoded by said nucleic acid molecule.

Typically said adaptation includes, by example and not by way of limitation, the provision of transcription control sequences (promoter sequences) which mediate cell/tissue specific expression. These promoter sequences may be cell/tissue specific, inducible or constitutive.

5

10

15

Promoter is an art recognised term and, for the sake of clarity, includes the following features which are provided by example only, and not by way of limitation. Enhancer elements are *cis* acting nucleic acid sequences often found 5' to the transcription initiation site of a gene (enhancers can also be found 3' to a gene sequence or even located in intronic sequences and is therefore position independent). Enhancers function to increase the rate of transcription of the gene to which the enhancer is linked. Enhancer activity is responsive to *trans* acting transcription factors (polypeptides) which have been shown to bind specifically to enhancer elements. The binding/activity of transcription factors (please see Eukaryotic Transcription Factors, by David S Latchman, Academic Press Ltd, San Diego) is responsive to a number of environmental cues which include, by example and not by way of limitation, intermediary metabolites (eg glucose, lipids), environmental effectors (eg light, heat,).

- Promoter elements also include so called TATA box and RNA polymerase initiation selection (RIS) sequences which function to select a site of transcription initiation. These sequences also bind polypeptides which function, *inter alia*, to facilitate transcription initiation selection by RNA polymerase.
- 25 Adaptations also include the provision of selectable markers and autonomous replication sequences which both facilitate the maintenance of said vector in either the eukaryotic cell or prokaryotic host. Vectors which are maintained autonomously are referred to as episomal vectors. Episomal vectors are desirable since these molecules can incorporate large DNA fragments (30-50kb DNA). Episomal vectors of this type are described in WO98/07876. Alternatively, the 30 vector is an integrating vector.

Adaptations which facilitate the expression of vector encoded genes include the provision of transcription termination/polyadenylation sequences. This also includes the provision of internal ribosome entry sites (IRES) which function to maximise expression of vector encoded genes arranged in bicistronic or multi-cistronic expression cassettes.

These adaptations are well known in the art. There is a significant amount of published literature with respect to expression vector construction and recombinant DNA techniques in general. Please see, Sambrook et al (1989) Molecular Cloning: A Laboratory Manual, Cold Spring Harbour Laboratory, Cold Spring Harbour, NY and references therein; Marston, F (1987) DNA Cloning Techniques: A Practical Approach Vol III IRL Press, Oxford UK; DNA Cloning: F M Ausubel et al, Current Protocols in Molecular Biology, John Wiley & Sons, Inc.(1994).

15

20

10

5

Conventional methods to introduce DNA or vector DNA into cells are well known in the art and typically involve the use of chemical reagents, cationic lipids or physical methods. Chemical methods which facilitate the uptake of DNA by cells include the use of DEAE –Dextran (Vaheri and Pagano Science 175: p434). DEAE-dextran is a negatively charged cation which associates and introduces the DNA into cells but which can result in loss of cell viability. Calcium phosphate is also a commonly used chemical agent which when co-precipitated with DNA introduces the DNA into cells (Graham et al Virology (1973) 52: p456).

The use of cationic lipids (eg liposomes, Felgner (1987) Proc.Natl.Acad.Sci USA, 84:p7413) has become a common method since it does not have the degree of toxicity shown by the above described chemical methods. The cationic head of the lipid associates with the negatively charged nucleic acid backbone of the DNA to be introduced. The lipid/DNA complex associates with the cell membrane and fuses with the cell to introduce the associated DNA into the cell. Liposome mediated DNA transfer has several advantages over existing methods. For example, cells which are

recalcitrant to traditional chemical methods are more easily transfected using liposome mediated transfer.

More recently still, physical methods to introduce DNA have become effective means to reproducibly transfect cells. Direct microinjection is one such method which can deliver DNA directly to the nucleus of a cell (Capecchi (1980) Cell, 22:p479). This allows the analysis of single cell transfectants. So called "biolistic" methods physically shoot DNA into cells and/or organelles using a particle gun (Neumann (1982) EMBO J, 1: p841). Electroporation is arguably the most popular method to transfect DNA. The method involves the use of a high voltage electrical charge to momentarily permeabilise cell membranes making them permeable to macromolecular complexes. However physical methods to introduce DNA do result in considerable loss of cell viability due to intracellular damage. These methods therefore require extensive optimisation and also require expensive equipment.

15

20

10

. 5

More recently still a method termed immunoporation has become a recognised techinque for the introduction of nucleic acid into cells, see Bildirici et al, Nature 405, 769. The technique involves the use of beads coated with an antibody to a specific receptor. The transfection mixture includes nucleic acid, typically vector DNA, antibody coated beads and cells expressing a specific cell surface receptor. The coated beads bind the cell surface receptor and when a shear force is applied to the cells the beads are stripped from the cell surface. During bead removal a transient hole is created through which nucleic acid and/or other biological molecules, eg polypeptides, can enter. Transfection efficiency of between 40-50% is achievable depending on the nucleic acid used.

Other non-liposome based, chemical transfectant agents have become available, for example ExGen500 (polyethylenimine), produced by MBI Fermentas. ExGen500 is particularly effective for transfection of human ES cells (Eiges, 2001).

According to a further aspect of the invention there is provided a method for the production of the polypeptide encoded by the nucleic acid molecule according to the invention comprising:

- i) providing a cell transformed/transfected with a nucleic acid molecule
 5 according to the invention;
 - ii) growing said cell in conditions conducive to the manufacture of said polypeptide; and
 - i) purifying said polypeptide from said cell, or its growth environment.

In a preferred method of the invention said nucleic acid molecule is the vector according to the invention.

In a further preferred method of the invention said vector encodes, and thus said recombinant polypeptide is provided with, a secretion signal to facilitate purification of said polypeptide.

15

20

According to a further aspect of the invention there are provided host cells which have been transformed/transfected with the vector according to the invention, so as to include at least part of the polypeptide according to the invention, so as to permit expression of at least the functional part of the polypeptide encoded by said nucleic acid molecule.

Ideally said host cells are eukaryotic cells, for example, insect cells such as cells from a species *Spodoptera frugiperda* using the baculovirus expression system.

According to a further aspect of the invention there is provided a therapeutic cell composition comprising differentiated or differentiating embryonic stem cells derived by the method according to the invention. Preferably said composition is for

use in the treatment of: Parkinson's disease; Huntington's disease; motor neurone disease; heart disease; diabetes; liver disease (eg cirrhosis); renal disease; AIDS.

According to a further aspect of the invention there is provided a method of treatment of an animal comprising administering a cell composition comprising embryonic stem cells which have been induced to differentiate into at least one cell-type.

According to a yet further aspect of the invention there is provided condition medium obtained by culturing embryonic stem cells according to any of the methods hereindisclosed.

An embodiment of the invention will know be described by example only and with reference to the following figures:

15 Figure 1 is a schematic represenation of conserved domains in Notch polypeptides;

Figure 2 is the nucleic acid sequence of murine notch ligand delta-like 1;

Figure 3 is the amino acid sequence of murine notch ligand delta-like 1;

20

10

Figure 4 is the nucleic acid sequence of murine notch ligand jagged 1;

Figure 5 is the nucleic acid sequence of human notch ligand jagged 1 (alagille syndrome) (JAG1);

25

Figure 6 is the amino acid sequence of human notch ligand jagged 1 (alagille syndrome);

Figure 7 is the nucleic acid sequence of human notch ligand jagged 2 (JAG2)

30

Figure 8 is the amino acid sequence of human notch ligand jagged 2 (JAG2);

Figure 9 is the amino acid sequence of murine notch ligand jagged 1; Figure 10 is the nucleic acid sequence of murine notch ligand jagged 2; 5 Figure 11 is the amino acid sequence of murine notch ligand jagged 2; Figure 12 is the nucleic acid sequence of human notch ligand delta-like 3 (DLL3); Figure 13 is the amino acid sequence of human notch ligand delta-like 3 precursor 10 polypeptide; Figure 14 is the nucleic acid sequence of human notch ligand delta-1 (DLL1); 15 Figure 15 is the amino acid sequence of murine notch ligand delta-like 1; Figure 16 is the nucleic acid sequence of human notch ligand delta-like 4 (DLL4); Figure 17 is the amino acid sequence of human notch ligand delta-like 4 (DLL4); 20 Figure 18 is the nucleic acid sequence of murine notch ligand delta-like 4(DLL4); Figure 19 is the amino acid sequence of murine notch ligand delta-like 4(DLL4); 25 Figure 20 is a western blot of cell extracts of various EC cell-lines probed with Notch 2 antisera;

Figure 21 represents northern blot analysis of the expression patterns of notch genes (Notch 1,2,3) and notch ligands (Dlk, jagged 1) in EC cells and EC cells treated with

30

retinoic acid (RA);

Figure 22 represents the nucleic acid sequence of human Wnt 13;

- Figure 23 is a diagramatic representation of the Wnt signalling pathway;
- 5 Figure 24 represents northern blot analysis of *Wnt 13* and mRNA's corresponding to Frizzled receptors and Frizzled related protein antagonists of Wnt signalling in NTERA 2 cells various Wnt inhibitors after exposure of NTERA 2 cells;
- Figure 25 represents a northern blot analysis of intracellular components of Wnt signalling pathway in NTERA 2 cells;
 - Figure 26 represents the nucleic acid sequence of human dickkopf1;
 - Figure 27 represents the nucleic acid sequence of human dickkopf2;

15

- Figure 28 represents the nucleic acid sequence of human dickkopf3; and
- Figure 29 represents the nucleic acid sequence of human dickkopf4;
- Figure 30 represents the nucleic acid sequence of WNT-1;
 - Figure 31 represents the amino acid sequence of WNT-1;
 - Figure 32 represents the nucleic acid sequence of WNT-2;

- Figure 33 represents the amino acid sequence of WNT-2;
- Figure 34 represents the nucleic acid sequence of WNT 2B;
- Figure 35 represents the amino acid sequence of WNT 2B;

Figure 36 represents the nucleic acid sequence of WNT 3; Figure 37 represents the amino acid sequence of WNT 3; 5 Figure 38 represents the nucleic acid sequence of WNT 4; Figure 39 represents the amino acid sequence of WNT 4; Figure 40 represents the nucleic acid sequence of WNT 5A; 10 Figure 41 represents the amino acid sequence of WNT 5A; Figure 42 represents the nucleic acid sequence of WNT 6; 15 Figure 43 represents the amino acid sequence of WNT 6; Figure 44 represents the nucleic acid sequence of WNT 7A; Figure 45 represents the amino acid sequence of WNT 7A; 20 Figure 46 represents the amino acid sequence of WNT 7B; Figure 47 represents the nucleic acid sequence of WNT 8B; 25 Figure 48 represents the amino acid sequence of WNT 8B; Figure 49 represents the nucleic acid sequence of WNT 10B; Figure 50 represents the amino acid sequence of WNT 10B; 30 Figure 51 represents the nucleic acid sequence of WNT 11;

Figure 52 represents the amino acid sequence of WNT 11; Figure 53 represents the nucleic acid sequence of WNT 14 5 Figure 54 represents the amino acid sequence of WNT 14; Figure 55 represents the nucleic acid sequence of WNT 16; Figure 56 represents the amino acid sequence of WNT 16; 10 Figure 57 represents the nucleic acid sequence of FZD 1; Figure 58 represents the amino acid sequence of FZD 1; 15 Figure 59 represents the nucleic acid sequence of FZD 2; Figure 60 represents the amino acid sequence of FZD 2; 20 Figure 61 represents the nucleic acid sequence of FZE 3; Figure 62 represents the amino acid sequence of FZE 3; Figure 63 represents the nucleic acid sequence of FZD 4; 25 Figure 64 represents the amino acid sequence of FZD 4; Figure 65 represents the nucleic acid sequence of FZD 5; 30 Figure 66 represents the amino acid sequence of FZD 5;

Figure 67 represents the nucleic acid sequence of FZD 6;

- Figure 68 represents the amino acid sequence of FZD 6;
- 5 Figure 69 represents the nucleic acid sequence of FZD 7;
 - Figure 70 represents the amino acid sequence of FZD 7;
 - Figure 71 represents the nucleic acid sequence of FZD 8;
- Figure 72 represents the amino acid sequence of FZD 8;

10

- Figure 73 represents the nucleic acid sequence of FZD 9;
- 15 Figure 74 represents the amino acid sequence of FZD 9;
 - Figure 75 represents the nucleic acid sequence of FZD 10;
- Figure 76 represents the amino acid sequence of FZD 10;
- Figure 77 represents the nucleic acid sequence of FRP;
 - Figure 78 represents the amino acid sequence of FRP;
- Figure 79 represents the nucleic acid sequence of SARP 1;
 - Figure 80 represents the amino acid sequence of SARP 1;
 - Figure 81 represents the nucleic acid sequence of SARP 2;
- 30 Figure 82 represents the amino acid sequence of SARP 2;

Figure 83 represents the nucleic acid sequence of FRZB;

Figure 84 represents the amino acid sequence of FRZB;

Figure 85 represents the nucleic acid sequence of FRPHE;

Figure 86 represents the amino acid sequence of FRPHE;

Figure 87 represents the nucleic acid sequence of SARP 3;

Figure 88 represents the amino acid sequence of SARP 3;

Figure 89 represents the nucleic acid sequence of CER 1;

Figure 90 represents the amino acid sequence of CER 1;

Figure 91 represents the nucleic acid sequence of DKK1;

Figure 92 represents the amino acid sequence of DKK1;

- Figure 93 represents the nucleic acid sequence of DKK 2;
 - Figure 94 represents the amino acid sequence of DKK 2;
- 25 Figure 95 represents the nucleic acid sequence of DKK 3;
 - Figure 96 represents the amino acid sequence of DKK 3; Figure 97 represents the nucleic acid sequence of DKK 4;
- 30 Figure 98 represents the amino acid sequence of DKK 4;

Figure 99 represents the nucleic acid sequence of WIF-1;

Figure 100 represents the amino acid sequence of WIF-1;

5 Figure 101 represents the nucleic acid sequence of SRFP 1;

Figure 102 represents the amino acid sequence of SRFP 1;

Figure 103 represents the nucleic acid sequence of SRFP 4;

10

Figure 104 represents the amino acid sequence of SRFP 4; and

Figure 105 represents a diagram depicting the pCMV-tracer vector.

15 <u>Materials and Methods</u>

Table 1 Cell lines derived from germ cell tumours.

Cell Line	Biopsy Site	Biopsy Histology	Xenograph	Reference
			Histology	
2102Ep	Testis	EC, T, Y	EC	(Andrews et al.,
		`		1980)
833KE	Testis	EC, T, C, S	EC	(Andrews et al.,
				1980)
TERA-1	Lung	EC, T		(Fogh and
				Trempe, 1975)
NTERA2 cl. D1	Lung	EC, T	EC, T	(Fogh and
				Trempe, 1975)
				(Andrews, 1984)

Abbreviations used: EC, embryonal carcinoma, T, teratoma, S, seminoma, C, choriocarcinoma, Y, yolk-sac carcinoma

Cell Lines derived from gestational choriocarcinomas.

BEWO	Corresponds to gestational choriocarcinoma	(Pattillo and Gay,	
		1968)	

5 <u>List of Antibodies Used</u>

Antibody	Reference	References
SSEA-3	Andrews et. al., 1982	12
SSEA-4	Kannagi et. al., 1983	18
Tra-1-60	Andrews et. al., 1984	25
Tra-1-81	Andrews et. al., 1984	25
Tra-2-54	Andrews et. al., 1984	20
Tra-2-49	Andrews et. al., 1984	20
A2B5	Fenderson et. al., 1987	
ME311	Fenderson et. al., 1987	•
Vin-is-56	Andrews et. al., 1990	44
Vin-is-53	Andrews et. al., 1990	. 44
Vin-2PB-22	Andrews et. al., 1990	44
Thy-1	Andrews et. al., 1983	· 10

Expression Vectors

10 The following mammlian expression vectors are used in the expression of ligands hereindisclosed:

Purchased from Stratagene Inc. pExchange-1; pExchange-2; pExchange-3A, 3B, 3C; pExchange-4A, 4B, 4C; pExchange-5A, 5b,5C; pExchange-6A, 6B, 6C; pExchange module EC-hyg; pExchange module EC-Puro; pExchange module EC-Neo; pCMV-

15 Script; pCMV-Tag1; pCMV-Tag2; pCMV-Tag3; pCMV-Tag4; pCMV-Tag5; pCMVLACI, pOPRSVI/MCS, pOPI3-CAT; pERV3; pEGSH.

Purchased from Invitrogen Inv.

T-REX System vectors

pcDNA4/TO; pcDNA4/TO/myc-His; pcDNA6/TR; pT-Rex-DEST30; pT-Rex-DEST31; pcDNA4/TO-E; pcDNA5/FRT/TO; pcDNA5/FRT/TO-TOPO.

Geneswitch System vectors

pGene/V5-His A, B, C; pSwitch

5 Ecdysone-Inducible System

PVgRXR; pIND; pIND(SP1); pIND/V5-His; pIND/V5-His-TOPO; pIND/GFP; pIND(SP1)/GFP.

10 PShooter vectors

pRF/Myc/Nuc; pCMV/Myc/nuc; pEF/myc/mito; pCMV/myc/mito; pEF/myc/ER; pCMV/myc/ER; pEF/myc/cyto; pCMV/myc/cyto.

15 <u>Invitrogen inc</u>

pTet-off; pTet-on; ptTA-2//3 /4; pTet-tTS; pTRE2hyg PTRE2pur; pTRE2; pLP-TRE2; PTRE-Myc; pTRE-HA; pTRE-6xHN pTRE-d2EGFP; pBI; pBI-EGFP; pBI-G; pBI-L;pTK-Hyg

20

25

"Living colours" vectors.

pDsRed2-N1; pDsRed2-C1; pECFP-N1; pEGFP-N1; pEGFP-N2; pEGFP-N3 pEYFP-N1; pECFP-C1; pEGFP-C1; pEGFP-C2; pEGFP-C3 pEYFP-C1; pd1EGFP-N1; pd1ECFP-N1; pd2EGFP-N1; pd2EYFP-N1 pd4EGFP-N1; pCMS-EGFP; pHygEGFP; pEGFPLuc; pNF-κB-dsEGFP pIRES2-EGFP; pIRES-EYFP

Maintenance of cell lines

30

All cells were grown in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% by volume foetal calf serum (Gibco BRL) and 2mM L-glutamine. Tissue culture flasks were incubated in a humidified atmosphere of 10% CO_2 in air at $37^{\circ}C$.

Treatment of NTERA2 Cells

Retinoic acid

Medium was aspirated from confluent flasks of EC cells and the cells rinsed in sterile PBS. 1ml of 0.25% (w/v) trypsin in 2mM EDTA was added per 75cm² flask and the flask incubated at room temperature for up to 5 minutes. Vigorous shaking was subsequently used to dislodge the cells. Cells were suspended in 9ml of supplemented DMEM per ml of trypsin used and counted in a haemocytometer. Cells were seeded at 10⁶ cells per 75cm² flask, in medium containing 10⁻⁵M all-transretinoic acid (Eastman Kodak), diluted from a 10⁻²M stock solution in dimethyl sulfoxide (DMSO). Flasks were incubated as described above and the media replaced as and when required.

15 Hexamethylene bisacetamide (HMBA)

Cells to be treated with HMBA were prepared as described for retinoic acid, but grown in medium supplemented with 10⁻³M HMBA instead of RA.

Harvesting of cells

Cells were dislodged from the culture vessel with trypsin and suspended in 9ml culture medium per ml of trypsin solution used, as described above. The cell suspension was then centrifuged at 400 x g for 3 minutes and the medium aspirated from the resulting cell pellet. Cells were then rinsed in 5ml PBS and centrifuged again at 400 x g for 1 minute. The PBS rinse was aspirated and the cells stored at – 80°C or used immediately.

Total RNA preparation

Where possible, all vessels and all solutions used in RNA preparation and storage were treated with a 0.01% (v/v) solution of diethylpyrocarbonate (DEPC) in distilled water, and subsequently autoclaved.

TRI reagent (Sigma) was added to pelleted cells in a quantity corresponding to 1ml per 75cm² flask. The lysate was agitated until homogenous. 0.2ml of chloroform was added per ml of TRI reagent used and the vessel vortexed for 10 seconds. After 10 minutes at room temperature, the lysate was centrifuged at 12000 x g for 15 minutes at 4°C. Following centrifugation, the aqueous (uppermost) phase was transferred to a fresh vessel and 0.5ml of isopropanol added per ml of TRI reagent used. The sample was incubated at room temperature for 10 minutes, then centrifuged at 12000 x g for 10 minutes at 4°C. Following centrifugation, the supernatant was removed and the pellet washed in 70% ethanol. RNA was dissolved in DEPC-treated, double-distilled water.

Isolation of mRNA

5

10

15

20

25

30

100mg oligo dT cellulose (Ambion) was suspended in 25ml binding buffer. Up to 2mg of total RNA was then added to the binding buffer and the suspension gently agitated at room temperature for 45 minutes. The suspension was then centrifuged at 3000 x g for 10 minutes and the supernatant discarded. The resulting pellet was resuspended in a further 25ml of binding buffer and agitated at room temperature for 60 minutes. The suspension was again centrifuged at 3000 x g and the supernatant discarded. The pellet of oligo dT cellulose was transferred to a spin column using a minimal quantity of binding buffer to re-suspend. The column was spun at maximum speed in a desktop microfuge for 30 seconds and the eluate discarded. This was repeated until the cellulose was dry. $200\mu l$ of wash buffer was then added to the cellulose and mixed in with a pipette tip. The column was spun at maximum speed for 1 minute and the eluate discarded. $200\mu l$ of DEPC-treated, double-distilled H_2O was then added to the cellulose and mixed in, as before. The column was then spun at maximum speed for 2 minutes and the eluted mRNA collected.

Precipitation of RNA

To the RNA solution was added 0.1x volume of 5M LiCl and 2.5x volume of 100% ethanol. After vortexing briefly, the sample was incubated at -20°C for >60 minutes

to precipitate. Precipitated RNA was centrifuged at maximum speed in a bench top microfuge for 30 minutes. The supernatant was discarded and the pellet rinsed in 70% ethanol, then dissolved in H₂O.

Quantitation of nucleic acid

5

10

A Beckman DU 650 spectrophotometer was used for the quantitation of both DNA and RNA. The machine was set to measure absorbence at wavelengths of 260nm and 280nm. After blanking the machine on an appropriate solution, diluted DNA or RNA samples in a volume of $100\mu l$ were added to the cuvette and measured. The absorbence at 260nm was used to calculate nucleic acid concentration in $\mu g/\mu l$, as shown below:

[Nucleic acid] =
$$(A^{260} \times N \times DF) \div 1000$$

Where N is 33 for single-stranded DNA, 50 for double-stranded DNA and 40 for RNA and DF is the dilution factor for the sample added to the cuvette.

Northern blot analysis

Blot preparation

10ml of 10x MOPS buffer and 5ml H₂O by boiling. After cooling to around 70°C, 10ml of 10x MOPS buffer and 5ml of formaldehyde were added, and the gel cast. 1-5μg of each mRNA sample was mixed with an appropriate quantity of 10x RNA loading buffer to give a final volume of no more than 30μl. The RNA was then denatured at 95°C for 2 minutes and quenched on ice for 10 minutes. The gel was placed in an electrophoresis tank containing 1x MOPS buffer and the samples loaded into each well of the gel, along with appropriate molecular weight markers in the outermost wells. 80V were applied across the gel for 2-3 hours or as required. Following electrophoresis, the outermost lanes containing the molecular weight markers were removed using a scalpel and submerged in double-distilled H₂O containing ethidium bromide at 0.5μg/ml. The remainder of the gel was submerged in >5 volumes of double-distilled H₂O, which was replaced every 5 minutes for a total

of 25 minutes. An appropriately sized piece of GeneScreen Plus (DuPont) membrane, just larger than the area of gel to be blotted, was cut. The membrane was hydrated by briefly submerging in double-distilled H₂O, then transferred to 10x SSC, concurrent with the last 15 minutes of gel washing. The blotting apparatus was assembled as shown in Figure 2.1, with the gel upside-down, using 10x SSC transfer buffer. After transfer of at least 6 hours, the absorbent material was removed from the membrane. After marking the position of the wells using a pencil, the membrane was removed from the gel and washed briefly in 2x SSC. Whilst still damp, the RNA was fixed to the membrane by UV crosslinking. The membrane was then baked at 80°C for 3 hours.

The excised marker lanes were de-stained by soaking in a large volume of double-distilled H_2O for around 3 hours, after which they were visualised on a UV transilluminator and photographed.

15

20

25

10

5

Probe preparation

Random-primed DNA labelling was carried out using the Prime-a-Gene kit from Promega. Approximately 25ng of template DNA (PCR or restriction digest product) was denatured at 95°C for 2 minutes, then quenched on ice for 10 minutes. The reaction mix was then assembled on ice, in the order indicated below:

10μl of 5x labelling buffer

H₂O to give a final volume of 50μl

2μl unlabelled dNTP mix (0.5mM each)

25ng of denatured/quenched template DNA

2μl 10mg/ml BSA

5μl αP³²dATP 3000Ci/mmol (NEN DuPont)

1μl DNA polymerase 1 large (Klenow) fragment

The labelling reaction mix was incubated at room temperature for 2 hours. After this period, unincorporated nucleotides were removed using Pharmacia S-300 MicroSpin columns. Columns were placed in a microfuge tube and pre-spun at 735 x g for 1 minute. The column was then transferred to a fresh tube and the entire labelling reaction added. The column was then spun at 735 x g for a further 2 minutes and the purified, labelled DNA collected. Labelled DNA was denatured at 95°C for 2 minutes, then quenched on ice for 15 minutes.

Hybridisation and washing procedure

10

15

20

5.

Northern blots were equilibrated in 150ml of 2x SSC at 42°C for 15 minutes in a hybridisation oven at 8 RPM. The SSC was exchanged for 25ml of hybridisation buffer, pre-warmed to 42°C, and the filter incubated for a further 30 minutes at the same temperature. The entire volume of purified probe solution was then added to the hybridisation buffer and the blot incubated overnight at 42°C/8 RPM. The hybridisation solution was then discarded and the blot washed as follows:

2x SSC at room temperature for 20 minutes 2x SSC at room temperature for 20 minutes

2x SSC/1% SDS at 65°C for 45 minutes

2x SSC/1% SDS at 65°C for 45 minutes

0.1x SSC at room temperature for 20 minutes

0.1x SSC at room temperature for 20 minutes

25 Filters were exposed to a Bio Rad BI phosphor-imager screen overnight and, in most cases, subsequently exposed to X-ray film (Kodak X-omat AR).

Loading controls for Northern blots

30 All Northern blots used in this study were probed with β-actin as a loading control. Table 2.5 (overleaf) lists the figures to which each control probing (panel A to T, Figure 2.2) corresponds. Northern blot data presented in this study have not, in all

٠ و ,-

cases, been subject to repeat experiments using RNA isolated from different batches of cells. These data may not be regarded as conclusive, since reproducibility has not been proven.

5 Method for Analysis of the Requirement for Notch Ligands in the Differentiation of Embryonic Stem, Embryonal Carcinoma and their Differentiated Derivatives.

CHO are transfected with constructs encoding either membrane bound or soluble forms of the Notch ligands. These cell lines are used to support the growth of either Embryonal carcinoma cells (EC) e.g NTERA2/cl.D1 or Human embryonic stem cells (hES).

The transfected CHO cells (CHO(DSL)) are used in the following way. To assess membrane bound forms of the Notch ligands the CHO(DSL) cells are used as feeder cells (i.e. the EC or hES will be grown on top of the CHO(DSL) cells). To assess the soluble forms of the Notch ligands either supernatant from the transfected CHO cells or concentrated ligand molecules derived from the supernatant are added to the culture medium of the EC and hES cells.

20

25

15

Notch Ligand Constructs.

The following cloned Notch ligands were obtained from Dr. Shigeru Chiba, Department of Hematology, Oncology and Cell Therapy, Transplantation Medicine. Graduate School of Medicine. University of Tokyo.

Delta1-FLAG

Jagged1-FLAG

Jagged2-FLAG

30

Soluble Delta1-Fc

Soluble Jagged1-Fc

Soluble Jagged2-Fc

These had been cloned into the vector pTRACER-CMV from Invitrogen, Fig 30).

The clones used consisted either of the full length ligand linked to a histidine tag (FLAG, Kodak Inc.), or a ligand lacking the membrane spanning and intracellular portion of the protein thus rendering the ligand soluble. These had been linked to the Fc portion of human IgG.

10 Generation of Notch Ligand expressing Cell lines

The Chinese Hamster Ovary derived cell line AA8 was maintained in MEM Alpha medium with Glutamax-1 supplemented with ribonucleosides and deoxyribonucleosides (Lifetechnologies) and 10% Foetal Bovine Serum (FBS)(Lifetechnologies).

Plasmid was transfected into the AA8 cells using either Fugene (Roche) or Lipofectin (Lifetechnologies) or Superfect (Qiagen) according to manufacturers protocols.

20 Assessment of Transiently Transfected Cell lines for Ligand Production.

Both soluble and membrane bound forms of the Notch ligand's production are assayed by western blotting and chemiluminesent detection.

25 Cells transfected with the ligand encoding constructs are harvested and the proteins extracted. Due to the tagging of the ligands proteins are able to be run out on an SDS-PAGE gel, blotted and probed with either mouse anti-FLAG antibody and detected using a anti-mouse HRP secondary or an HRP-secondary antibody. Both methods use electro-chemiluminecence (ECL) as the detection method.

Concentration of Soluble Notch ligand from the Supernatant of Transfected CHO cells.

Fc-labelled Notch ligand can be purified from transfected CHO cells supernatant using a HiTrap protein G HP column (Amersham Pharmacia Biotech). A sample can be analysed by western blotting as described above.

Embryonic Cell culture.

5

20

Human Embryonal Carcinoma NTERA2/D1 cells are maintained in Dulbecco's modified Eagles medium (DMEM), supplemented with 2mM 1-glutamine, 10% Foetal Bovine Serum (Lifetechnologies) and at 37°C under 10% CO₂ in air. Cells were passaged by scraping from the surface of the tissue culture flask with 3mm glass beads and reseeded at 5 x 10⁶ cells per 75cm³ flask. For specific seeding densities cells were passaged using 0.25% Trypsin (Lifetechnologies) in Dulbecco's Phosphate Buffered Saline (PBS) supplemented with 1mM EDTA.

Human Embryonic Stem Cells are maintained on irradiated mouse embryonic fibroblasts in serum free conditions, with 80% F12:DMEM (Lifetechnologies), 20% Knockout SR (Lifetechnologies), 1% Non-essential amino acid solution (Lifetechnologies), 1 mM L-glutamine, 0.1mM β-mercaptoetanol (Sigma) 4 ng/ml bFGF (Sigma). The cells are passaged using collagenase IV and scraping.

Flow Cytofluorimetry

Cells were removed from their adherent culture surface and incubated with suitable primary antibody for 1 hour at 4C. Cells are washed in PBS with 5% FCS and incubated for a further hour with a suitable FITC-conjugated labelled secondary antibody, and analysed on a EPICS Elite ESP Flow Cytometer (Coulter Electronics). Colonies were assessed for the presence of embryonal stem cell markers such as SSEA-3, -4, Tra-1-60 and for appearance of markers of differentiated marker antigens such as A2B5, ME311 and N901.

Design of oligonucleotide primers

Primers for use in PCR were designed on a Macintosh Power PC, using the "Primer Select" program of the DNASTAR software package (DNASTAR Inc.). All primers used in this study are shown in Table 2

Table 2 List of oligonucleotide primers

Gene	GenBank accession	Primer direction	Prinmer location	Primer sequence 5' to 3'
Wnt-13	Z71621	Forward	1159-1178	Tgagtggttcctgtactctg
		Reverse	1503-1484	Actcacactgggtaacacgg
SFRP4	XM_004706	Forward	858-880	Agaggagtggctgcaatgaggtc
		Reverse	1159-1142	Gcgcccggctgttttctt
Waf1	U03106	Forward	487-506	Cagggtcgaaaacggcggca
		Reverse	947-928	Aggagccacacccctccaga
β-actin	NM_001101	Forward	326-357	Atctggcaccacaccttctacaatgagctgc
		Reverse	1163-1132	Cgtcatactcctgcttgctgatccacatctgc
neuroD1	NM_002500	Forward	240-263	Aagccatgaacgcagaggaggact
		Reverse	818-799	Agctgtccatggtaccgtaa

All PCR data presented in this study were duplicated in independent experiments to eliminate the possibility of methodological error. However, duplicate experiments were performed on identical samples and do not, therefore, control for variability between separate batches of cells. Polymerase chain reactions from which quantitative interpretations were to be made were controlled by parallel amplification of the cyclin-dependent kinase inhibitor, Waf1. This transcript has been demonstrated by other workers in the laboratory to be constitutively expressed by NTERA2 EC cells and differentiated derivatives (unpublished data). Furthermore, Waf1 has been shown to exhibit an approximately 20-fold lower abundance in the NTERA2 system than the more widely used control, β -actin, and is therefore well suited to the analysis of rare transcripts.

20

15

10

5

PCR Reaction conditions

PCR mixes were assembled on ice, with the following components per reaction:

5μl of 25mM MgCl₂

5μl of 10x reaction buffer

 $5\mu l$ of 1mM dNTPs

3μl of forward primer at 5pmol/μl

3μl of reverse primer at 5pmol/μl

0.3µl of Taq polymerase at 1 unit/µl (Promega)

template and H₂0 to give 50µl final volume

A premix was made containing all reaction components bar the template. Premix was then added to the reaction vessels containing the template, on ice. The reaction vessels were then transferred to the thermal cycler. The PCR programs used are shown in Table 3, with cycling from T1 \rightarrow T2 \rightarrow T3.

Table 3 PCR thermal cycling programs

15

5

	Program 1	Program 2	Program 3	Program 4
T1	96°C/30 seconds	94°C/60 seconds	94°C/90 seconds	95°C/90 seconds
(temp/duration)				
T2	50°C/15 seconds	55°C/90 seconds	60°C/90 seconds	63°C/60 seconds
(temp/duration)				
T3	60°C/240 seconds	72°C/60 seconds	72°C/120 seconds	72°C/60 seconds
(temp/duration)				
Cycles	25	35	35	35

List of DNA and protein accession numbers of genes used in results

Gene Name	Description	cDNA Accession Number	Protein Accession Number
WNT2B	wingless-type MMTV integration site family, member 2B	AB045116	Q93097

	member 2B		
SFRP1	secreted frizzled- related protein 1	AF056087	AAC12877
SFRP4	secreted frizzled- related protein 4	AF026692	AAC04617
FRZB	frizzled-related protein	NM 001463	NP 001454
SFRP2	secreted frizzled- related protein 2		
FZD1	frizzled (Drosophila) homolog 1	AB017363	BAA34666
FZD2	frizzled (Drosophila) homolog 2	NM_001466	NP_001457
FZD9	frizzled (Drosophila) homolog 9	HSU82169	AAC51174
FZD3	frizzled (Drosophila) homolog 3	Kirikoshi et. al., 2000	Kirikoshi et. al., 2000
FZD5	frizzled (Drosophila) homolog 5		
FZD4	frizzled (Drosophila) homolog 4	NM_012193	NP_036325
FZD6	frizzled (Drosophila) homolog 6	AB012911	BAA25686
FZD7	frizzled (Drosophila) homolog 7	AB017365	BAA34668
DVL2	dishevelled 2 (homologous to Drosophila dsh)	NM_004422	NP_004413
DVL3	dishevelled 3 (homologous to Drosophila dsh)	NM_004423	NP_004414
GSK3B	glycogen synthase kinase 3 beta	NM_002093	NP_002084
AXIN1	axin	AF009674	AAC51624
APC	adenomatosis polyposis coli	NM_000038	NP_000029
TCF1	transcription factor 1, hepatic; LF-B1, hepatic nuclear factor (HNF1), albumin proximal factor	M57732	AAA88077

Examples

5

Expression of a single Wnt gene, Wnt-13(2B) was detected. This transcript was absent in NTERA2 EC cells, but showed marked up-regulation following RA treatment, figure 24. Members of the FRP family, encoding putative Wnt antagonists,

also showed altered expression during differentiation, figure 24. Both Frp-1 and SARP-1 were down-regulated following RA treatment, whilst FrpHE was absent in EC cells, but expressed at high levels in RA treated cultures.

Several members of the frizzled family were also detected, providing a candidate receptor system for Wnt-13, figure 24. Two of these, hFz-4 and hFz-6, showed developmental regulation. Transcripts corresponding to intracellular components of the Wnt pathway, including Dishevelled, GSK-3b, Axin, APC and TCF were present at equivalent levels in EC and differentiating cultures. CBP was also ubiquitously expressed.

15

REFERENCES

- 1. Andrews P.W. and Roberts D.B. (1974) The preparation and characterization of chromatin from third instar larvae of Drosophila melanogaster. Nucleic Acids Res. 1: 979-997.
- 20 2. Roberts D.B. and Andrews P.W. (1975) Drosophila chromatin: An immunological study. Nucleic Acids Res. 2:1291-1303.
 - 3. Andrews P.W. and Boyse E.A. (1978) Mapping of an H-2-linked gene that influences mating perference in mice. Immunogenetics <u>6</u>:265-268.
- Yamazaki K., Yamaguchi M., Andrews P.W., Peake B. and Boyse E.A. (1978)
 Mating preferences in F₂ segregants of crosses between MHC-congenic mouse strains. Immunogenetics 6: 253-259.
 - 5. Andrews P.W. and Wachtel S.S. (1979) Rejection of C57BL skin grafts by (C57Bl x *Mus musculus castaneus*) F₁ hybrids. Transplantation <u>27</u>: 43-44.
- 6. Andrews P.W. and Goodfellow P.N. (1980) Antigen expression by somatic cell hybrids of a murine embryonal carcinoma cell with thymocytes and L cells. Somat. Cell Genet. <u>6</u>: 271-284.

7. Bronson D.L., Andrews P.W., Solter D., Cervenka J., Lange P.H. and Fraley E.E. (1980) A cell line derived from a metastasis of a human testicular germ-cell tumor. Cancer Res. 40: 2500 - 2506.

- 8. *Andrews P.W., Bronson D.L., Benham F., Strickland S. and Knowles B.B. (1980)

 5 A comparative study of eight cell lines derived from human testicular teratocarcinoma. Int. J. Cancer <u>26</u>: 269-280.
 - 9. Andrews P.W., Knowles B.B. and Goodfellow P.N. (1981) A human cell surface antigen defined by a monoclonal antibody and controlled by a gene on chromosome 12. Somat. Cell Genet. 7: 435-443.
- 10 10. Andrews P.W., Bronson D.L., Wiles M.V. and Goodfellow P.N. (1981) The expression of major histocompatibility antigens by human teratocarcinoma derived cells lines. Tissue Antigens 17: 493-500.
- 11. Benham F.J., Andrews P.W., Bronson D.L., Knowles B.B. and Harris H. (1981)

 Alkaline phosphatase isozymes as possible markers of differentiation in human teratocarcinoma cell lines. Dev. Biol. 88: 279-287.
 - Andrews P.W., Goodfellow P.N., Shevinsky L., Bronson D. L. and Knowles B.B. (1982) Cell surface antigens of a clonal human embryonal carcinoma cell line: Morphological and antigenic differentiation in culture. Int. J. Cancer 29: 523-531.
- 13. Andrews P.W. (1982) Human embryonal carcinoma cells in culture do not synthesize fibronectin until they differentiate. Int. J. Cancer <u>30</u>: 567-571.
 - 14. Damjanov I. and Andrews P.W. (1983) Ultrastructural differentiation of a clonal human embryonal carcinoma cell line *in vitro*. Cancer Res. <u>43</u>: 2190-2198.
- Matthaei K., Andrews P.W. and Bronson D.L. (1983) Retinoic acid fails to induce differentiation in human teratocarcinoma cell lines that express high levels of cellular receptor protein. Exp. Cell Res. <u>143</u>: 471-474.
 - 16. Cossu G., Andrews P.W. and Warren L. (1983) Covalent binding of lactosaminoglycans and heparan sulphate to fibronectin synthesized by a human teratocarcinoma cell line. Biochem. Biophys. Res. Comm. 111: 952-957.
- Tunnacliffe A., Goodfellow P.N., Banting G., Solomon E., Knowles B.B. and Andrews P.W. (1983) Human chromosome 11 carries at least 4 genes controlling expression of cell surface antigens. Somat. Cell Genet. <u>9</u>: 629-642.

18. Kannagi R., Cochran N.A., Ishigami F., Hakomori S.-i., Andrews P.W., Knowles B.B. and Solter D. (1983a) Stage-specific embryonic antigens (SSEA-3 and -4) are epitopes of a unique globo-series ganglioside isolated from human teratocarcinoma cells. The EMBO J. <u>2</u>: 2355-2361.

- 5 19. *Andrews P.W., Damjanov I., Simon D., Banting G., Carlin C., Dracopoli N.C. and Fogh J. (1984b) Pluripotent embryonal carcinoma clones derived from the human teratocarcinoma cell line Tera-2: Differentiation *in vivo* and *in vitro*. Lab. Invest. 50: 147-162.
- 20. Andrews P.W., Meyer L.J., Bednarz K.L. and Harris H. (1984c) Two monoclonal antibodies recognizing determinants on human embryonal carcinoma cells react specifically with the liver isozyme of human alkaline phosphatase. Hybridoma 3: 33-39.
- *Gönczöl E., Andrews P.W. and Plotkin S.A. (1984) Cytomegalovirus replicates in differentiated but not undifferentiated human embryonal carcinoma cells. Science
 224: 159-161.
 - 22. *Andrews P.W. (1984) Retinoic acid induces neuronal differentiation of a cloned human embryonal carcinoma cell line *in vitro*. Dev. Biol. <u>103</u>: 285-293.
 - 23. Oosterhuis J.W., Andrews P.W., Knowles B.B. and Damjanov I. (1984) Effects of cisplatinum on embryonal carcinoma cell lines *in vitro*. Int. J. Cancer <u>34</u>: 133-139.
- 20 24. Blaineau C., Connan F., Arnaud D., Andrews P.W., Williams L., McIlhinney R.A.J. and Avner P. (1984) Definition of three species-specific monoclonal antibodies recognizing antigenic structures present on human EC cells which undergo modulation during *in vitro* differentition. Int. J. Cancer <u>34</u>: 487-494.
- 25. Andrews P.W., Banting G.S., Damjanov I., Arnaud D. and Avner P. (1984a) Three monoclonal antibodies defining distinct differentiation antigens associated with different high molecular weight polypeptides on the surface of human embryonal carcinoma cells. Hybridoma 3: 347-361.
 - 26. Damjanov I., Clark C.K. and Andrews P.W. (1984) Cytoskeleton of human embryonal carcinoma cells. Cell Differentiation 15: 133-139.
- Andrews P.W., Knowles B.B., Parkar M., Pym B., Stanley K. and Goodfellow P.N.
 (1985) A human cell-surface antigen defined by a monoclonal antibody and controlled by a gene on human chromosome 1. Ann. Human Genet. 49: 31-39.

28. Gönczöl E., Andrews P.W. and Plotkin S.A. (1985) The replication of human cytomegalovirus in human teratocarcinoma cell lines. J. Gen. Virol. <u>66</u>: 509-515.

29. Damjanov I., Damjanov A. and Andrews P.W. (1985) Trophectodermal carcinoma: Mouse teratocarcinoma-derived tumor stem cells differentiating into trophoblastic and yolk sac elements. J. Embryol. Exp. Morph. 86: 125-141.

- 30. Carlin C.R. and Andrews P.W. (1985) Human embryonal carcinoma cells express low levels of functional receptor for epidermal growth factor. Exp. Cell. Res. <u>159</u>: 17-26.
- Andrews P.W., Damjanov I., Simon D. and Dignazio M. (1985) A pluripotent human stem cell clone isolated from the TERA-2 teratocarcinoma line lacks antigens SSEA-3 and SSEA-4 *in vitro* but expresses these antigens when grown as a xenograft tumor. Differentiation <u>29</u>: 127-135.
- 32. Lee V.M-Y. and Andrews P.W. (1986) Differentiation of NTERA-2 clonal human embryonal carcinoma cells into neurons involves the induction of all three neurofilament proteins. J. Neurosci. <u>6</u>: 514-521.
 - 33. Andrews P.W., Gönczöl E., Plotkin S.A., Dignazio M. and Oosterhuis J.W. (1986)
 Differentiation of TERA-2 human embryonal carcinoma cells into neurons and
 HCMV permissive cells: Induction by agents other than retinoic acid.
 Differentiation 31: 119-126.
- 20 34. Tippett P., Andrews P.W., Knowles B.B. Solter D. and Goodfellow P.N. (1986)
 Red cell antigens P (globoside) and Luke: Identification by monoclonal antibodies
 defining the murine stage-specific embryonic antigens -3 and -4 (SSEA-3 and -4).
 Vox Sang. 51: 53-56.
- 35. Swallow D.M., Povey S., Parkar M., Andrews P.W., Harris H., Pym B. and Goodfellow P.N. (1986) Mapping of the gene coding for the human liver/bone/kidney isozyme of alkaline phosphatase to chromosome 1. Ann. Human Genet. 50: 229-235.
- 36. Andrews P.W., Trinchieri G., Perussia B. and Baglioni C. (1987) Induction of class 1 major histocompatibility complex antigens in human teratocarcinoma cells by interferon without induction of differentiation, growth inhibition or resistance to viral infection. Cancer Res. <u>47</u>: 740-746.

37. *Fenderson B.A., Andrews P.W., Nudelman E., Clausen H. and Hakomori S.-i. (1987) Glycolipid core structure switching from globo- to lacto- and ganglio-series during retinoic acid-induced differentiation of TERA-2-derived human embryonal carcinoma cells. Dev. Biol. 122: 21-34.

- 5 38. Zhang X.-Y., Loflin P.T., Gehrke C.W., Andrews P.W. and Ehrlich M. (1987) Hypermethylation of human DNA sequences in embryonal carcinoma cells and somatic tissues but not in sperm. Nucleic Acids Res. 15: 9429-9449.
 - 39. Mavilio F., Simeone A., Boncinelli E. and Andrews P.W. (1988) Activation of four homeobox gene clusters in human embryonal carcinoma cells induced to differentiate by retinoic acid. Differentiation <u>37</u>: 73-79.

- 40. Williams B.P., Daniels G.L., Pym B., Sheer D., Povey S., Okubo Y., Andrews P.W. and Goodfellow P.N. (1988) Biochemical and genetic analysis of the OKa blood group antigen. Immunogenetics <u>27</u>: 322-329.
- 41. Rendt J., Erulkar S. and Andrews P.W. (1989) Presumptive neurons derived by differentiation of a human embryonal carcinoma cell line exhibit tetrodotoxin-sensitive sodium currents and the capacity for regenerative responses. Exp. Cell Res. 180: 580-584.
- 42. Chen C., Fenderson B.A., Andrews P.W. and Hakomori S.-i. (1989) Glycolipid-glycosyltransferases in human embryonal carcinoma cells during retinoic acid-induced differentiation. Biochemistry <u>28</u>: 2229-2238.
 - 43. Andrews P.W., Gönczöl E., Fenderson B.A., Holmes E.H., O'Malley G., Hakomori S. -i and Plotkin S.A. (1989). Human cytomegalovirus induces stage-specific embryonic antigen-1 in differentiating human teratocarcinoma cells and fibroblasts. J. Exp. Med. 169: 1347-1359.
- Andrews P.A., Nudelman E., Hakomori S. -i. and Fenderson B.A. (1990). Different patterns of glycolipid antigens are expressed following differentiation of TERA-2 human embryonal carcinoma cells induced by retinoic acid, hexamtehylene bisacetamide (HMBA) or bromodeoxyuridine (BUdR). Differentiation 43: 131-138.
- *Simeone A., Acampora D., Arcioni L., Andrews P.W., Boncinelli E. and Mavilio F. (1990). Sequential activation of human HOX2 homeobox genes by retinoic acid in human embryonal carcinoma cells. Nature <u>346</u>: 763-766.

46. Hirka G., Prakesh K., Kawashima H., Plotkin S.A., Andrews P.W. and Gönczöl E. (1991). Differentiation of human embryonal carcinoma cells induces human immunodeficiency virus permissiveness which is stimulated by human cytomegalovirus coinfection. J. Virol. 65: 2732-2735.

- 5 47. Marrink J., Andrews P.W., van Brummen P.J., de Jong H.J., Sleijfer D., Schraffordt-Koops H. and Oosterhuis J.W. (1991). TRA-1-60: A new serum marker in patients with germ cell tumors. Int. J. Cancer <u>49</u>: 368-372.
 - 48. Zeichner S.L., Hirka G., Andrews P.W. and Alwine J.C. (1992). Differentiation-dependent HIV LTR regulatory elements active in human teratocarcinoma cells. J. Virol. 66: 2268-2273.

- 49. Fenderson B.A., Radin N. and Andrews P.W. (1993) Differentiation antigens of human germ cell tumors: distribution of carbohydrate epitopes on glycolipids and glycoproteins analysed using PDMP, an inhibitor of glycolipid synthesis. European Urology. 23: 30-37.
- 15 50. Giwercman, A., Andrews, P.W., Jørgensen, N., Muller, J., Graem, N., Skakkebaek, N.E. (1993) Immunochemical expression of embryonal marker TRA-1-60 in carcinoma in situ germ cells and in testicular germ cell tumours. Cancer, <u>72</u>: 1308-1314.
- P.W. and Gönczöl E. (1994) DNA binding proteins that interact with the 19-base pair (CRE-like) element from the HCMV immediate early promoter in differentiating human embryonal carcinoma cells. Differentiation, 56: 119-129.
- 52. Wenk, J., Andrews, P.W., Casper, J., Hata, J-I., Pera, M.F., von Keitz, A., Damjanov, I., Fenderson, B.A. 1994. Glycolipids of germ cell tumours: extended globo-series glycolipids are a hallmark of human embryonal carcinoma cells. Int. J. Cancer. <u>58</u>: 108-115.
 - 53. Ackerman S.L., Knowles B.B., Andrews P.W. (1994). Gene regulation during neuronal and non-neuronal differentiation of NTERA2 human teratocarcinomaderived stem cells. Mol. Brain Res. 25: 157-162.
- 30 54. *Andrews P.W., Damjanov I., Berends J., Kumpf S., Zappavingna V. Mavilio F. and Sampath K. (1994). Inhibition of proliferation and induction of differentiation

of pluripotent human embryonal carcinoma cells by osteogenic protein-1 (or bone morphogenetic protein-7). Laboratory Investigation <u>71</u>: 243-251.

55. Damjanov, I., Zhu, Z.M., Andrews, P.W., Fenderson, B.A. (1994). Embryonal carcinoma cells differentiate into parietal endoderm via an intermediate stage corresponding to primitive endoderm. *In Vivo* <u>8</u>: 967-974.

5

10

- 56. Squires, P.E., Wakeman, J.A., Chapman, H., Kumpf, S., Fiddock, M.D., Andrews, P.W. and Dunne, M.J. (1996). Regulation of intracellular Ca²⁺ in response to muscarinic and glutamate receptor agonists during the differentiation of NTERA2 human embryonal carcinoma cells into neurons. European Journal of Neuroscience 8: 783-793.
- 57. Andrews, P.W., Casper, J., Damjanov, I., Duggan-Keen, M., Giwercman, A., Hata, J.I., von Keitz, A., Looijenga, L.H.J., Millán, J.L., Oosterhuis, J.W., Pera, M., Sawada, M., Schmoll, H.J., Skakkaebaek, N.E., van Putten, W. and Stern, P. (1996). Comparative analysis of cell surface antigens expressed by cell lines derived from human germ cell tumours. Int. J. Cancer 66: 806-816.
- 58. Gels, M.E., Marrink J, Visser, P., Sleijfer, D.T., Droste J.H.J., Hoekstra, H.J., Andrews, P.W., Koops, H.S. (1997). Importance of a new tumour marker TRA-1-60 in the follow-up of patients with clinical state I nonseminomatous testicular germ cell tumours. Annals of Surgical Oncology 4; 321-327.
- 59. Wakeman, J.A., Heath, P.R., Pearson, R.C.A., Andrews, P.W. (1997) MAL mRNA is induced during the differentiation of human embryonal carcinoma cells into neurons, and is also localised within specific regions of the human brain. Differentiation 62:97-105.
- 60. *Wakeman, J.A., Walsh, J., Andrews, P.W., (1998). Human Wnt-13 is developmentally regulated during the differentiation of NTERA-2 pluripotent human embryonal carcinoma cells. Oncogene <u>17</u>:179-186
 - 61. Giesberts, A.N., Duran, C., Morton, I.E., Piggot, C., White, S.J., Andrews, P.W. (1999). The expression and function of cadherin-mediated cell-to-cell adhesion in human embryonal carcinoma cells. Mechanisms of Development <u>83</u> 115-125.
- 30 62. *Badcock, G., Pigott, C., Goepel, J., Andrews, P.W. (1999). The Human Embryonal Carcinoma Marker Antigen TRA-1-60 Is A Sialylated Keratan Sulphate Proteoglycan.

Cancer Research <u>59</u> 4715-4719.

63. Gokhale, P.J., Giesberts, A.N., Andrews, P.W. (2000). *Brachyury* is Expressed by Human Teratocarcinoma Cells in the Absence of Mesodermal Differentiation. Cell Growth and Differentiation <u>11</u> 157-162.

*Przyborski, S.A., Morton, I.E., Wood, A., Andrews, P.W. (2000) Developmental Regulation of Neurogenesis in the Pluripotent Human Embryonal Carcinoma Cell Line NTERA-2. Eur. J. Neurosci. 12: 3521 - 3528.

10

15

20

- 65. Andrews P.W. and Knowles B.B. (1982) Human teratocarcinoma: Tools for human embryology In: Teratocarcinoma and Embryonic Cell Interactions (T. Murumatsu, G. Gachelin, A.A. Moscona, and Y. Ikawa, eds). Japan Scientific Societies Press, Tokyo, pp 19-30.
- Andrews P.W., Knowles B.B., Cossu G. and Solter D. (1982) Teratocarcinoma and mouse embryo cell surface antigens: Characterization of the molecule(s) carrying the SSEA-1 antigenic determinant. In: Teratocarcinoma and embryonic Cell Interactions (T. Murumatsu, G. Gachelin, A.A. Moscona and Y. Ikawa eds). Japan Scientific Societies Press, Tokyo, pp 103-119.
- 67 Goodfellow P.N. and Andrews P.W. (1982) Sexual differentiation and H-Y antigen(s). Nature, News and Views <u>295</u>: 11-13.
- 68. Andrews P.W. and Goodfellow P.N. (1982) Analysing the mouse T/t complex. Nature, News and Views 299: 296-297.
- 25 69. Goodfellow P.N. and Andrews P.W. (1982) The biology of teratocarcinomas. (Meeting Report). Nature, News and Views 300: 107-108.
 - 70. Andrews P.W. (1983) The characteristics of cell lines derived from human germ cell tumors. In: The Human Teratomas: Experimental and Clinical Biology (I. Damjanov, B.B. Knowles and D. Solter eds). Humana Press, Clifton, NJ, pp 285-311.
- 30 71. Benham F.J., Wiles, M.V., Banting G., Andrews P.W. and Goodfellow P.N. (1983) Human-mouse teratocarcinoma hybrids: A tool for analysis of gene activity in early

- human development. In: Human Teratomas: Experimental and Clinical Biology (I. Damjanov, B.B. Knowles and D. Solter, eds.). Humana Press, Clifton, NJ, pp 313-314.
- 72. Andrews P.W., Goodfellow P.N. and Damjanov I. (1983) Human teratocarcinoma cells in culture. Cancer Surveys <u>2</u>: 41-73.
- 5 73. Goodfellow P.N. and Andrews P.W. (1983) Is there a human T/t locus? Nature, News and Views 302: 657-658.
 - 74. Andrews P.W., Goodfellow P.N. and Bronson D.L. (1983) Cell surface characteristics and other markers of differentiation of human teratocarcinomas in culture. In: Teratocarcinoma Stem Cells. Cold Spring Harbor Conferences on Cell Proliferation, Vol. 10 (L.M. Silver, G.R. Martin and S. Strickland, eds.) pp 579-590.

- 75. Goodfellow P.N., Benham F., Andrews P.W., Trowsdale J., Lee J. and Quintero M. (1983) Developmental genetics of MHC expression using human-mouse hybrid cell lines. In: Teratocarcinoma Stem Cells. Cold Spring Harbor Conferences on Cell Proliferation, Vol. 10 (L.M. Silver, G.R. Martin and S. Strickland, eds.), pp 439-449.
- 76. Bronson D.L., Andrews P.W., Vessella R.L. and Fraley E.E. (1983) In vitro differentiation of human embryonal carcinoma cells. In: Teratocarcinoma Stem Cells. Cold Spring Harbor Conferences on Cell Proliferation, Vol. 10 (L.M. Silver, G.R. Martin and S. Strickland, eds.), pp 597-605.
- 77. Andrews P.W. (1984) The male specific antigen (H-Y) and sexual differentiation. In:

 Genetic Analysis of the Cell Surface (P.N. Goodfellow, ed.). Chapman and Hall,
 London, pp 159-190.
 - 78. Andrews P.W. and Damjanov I. (1985) Immunochemistry of human teratocarcinoma stem cells. In: Monoclonal Antibodies in Cancer (S. Sell and R.A. Reisfeld, eds.). The Humana Press Inc., Clifton, NJ, pp 339-364.
- 79. Andrews P.W. (1985) Properties of cloned human embryonal carcinoma cells and their differentiation in vitro. In: Germ Cell Tumors II: Proceedings of the 2nd Germ Cell Tumor Conference, Leeds (W.G. Jones, A. Milford-Ward and C.K. Anderson, eds.). Pergamon Press, Oxford, pp 71-75.
- 80. Damjanov I., Clark R.K. and Andrews P.W. (1985) Expression of keratin polypeptides in human embryonal carcinoma cells. Ann. NY Acad. Sci. 455: 732-733.

81. Oosterhuis J.W., Andrews P.W. and de Jong, B. (1986) Mechanisms of therapy related differentiation in testicular germ cell tumors. In: Biochemical Mechanisms of the Platinum Anti-tumor Drugs (D.C.H. McBrien and T.F. Slater, eds.). Proceedings of an Association for International Cancer Research Symposium. IRL Press, Oxford, pp 65-90.

- 82. Andrews, P.W., Oosterhuis J.W. and Damjanov I. (1987) Cell lines from human germ cell lines. In: Teratocarcinomas and embryonic stem cells: A practical approach (E.J. Robertson, ed.). IRL Press, Oxford, pp 207-248.
- 83. Andrews P.W., Fenderson B.A. and Hakomori S.-i. (1987) Human embryonal carcinoma cells and their differntiation in culture. Int. J. Androl. <u>10</u>: 95-104.

5

15

- 84. Andrews P.W. (1987) Human teratocarcinoma stem cells: Glycolipid antigen expression and modulation during differentiation. J. Cell Biochem. <u>35</u>: 321-332.
- 85. Andrews P.W. (1988) The properties of human teratocarcinoma in vitro. In In Vitro Models for Cancer Research (M. Webber and L. Sekely, eds.). CRC Press, Boca Raton, FL, pp 191-213.
- 86. Andrews P.W. (1988) Induction of differentiation in neoplastic cells. Editorial commentary. In Oncology Overview: Selected Abstracts on Induction of Differentiation in Neoplastic Cells. CIDA-CCB Information Ventures, Inc., Philadelphia, PA.
- 87. Andrews P.W. (1988) Human teratocarcinoma. Biochim. Biophys. Acta 948: 17-36.
- 20 88. Andrews P.W. and Oliver R.T.D. (1990) (Editors) Germ Cell Tumours of the Testis: Cancer Surveys <u>9</u> [Editorial Commentary, pp 239-241].
 - 89. Andrews P.W., Marrink J., Hirka G., von Keitz A., Sleijfer D. and Gönczöl E. (1991)

 The surface antigen phenotype of human embryonal carcinoma cells: Modulation upon differentiation and viral infection. In: Recent Results in Cancer Research, Vol 123;
- Pathobiology of Human Germ Cell Neoplasia (J.W. Oosterhuis, H. Walt and I. Damjanov, eds.). Springer-Verlag, pp 63-83.
 - 90. Bottero L., Simeone A., Arcioni L., Acampora D., Andrews P.W., Boncinelli E. and Mavilio F. (1991) Differential activation of homeobox genes by retinoic acid in human embryonal carcinoma cells. In: Recent Results in Cancer Research, Vol 123; Pathobiology of Human Germ Cell Neoplasia (J.W. Oosterhuis, H. Walt and I. Damjanov, eds.). Springer-Verlag, pp 133-143.

91. McCarrick J. and Andrews P.W. (1992) Embryonal carcinoma cells and embryonic stem cells as models for neuronal development and function. In: Cell Lines in Neurobiology: A Practical Approach (J. Wood, ed.). IRC Press, Oxford pp 77-104.

- 92. Fenderson B.A. and Andrews P.W. (1992) Carbohydrate antigens of embryonal carcinoma cells; changes upon differentiation. Acta Path. Microbiol. Immunol. Scand. Vol. 100, Suppl. 27 "Carbohydrate Pathology". (Dabelsteen, E. & Clausen, H., eds), Munksgaard Copenhagen, pp 109-118.
 - 93. Andrews, P.W. (1993). Teratomas the cross roads of embryology and oncology. Oncology Newsletter (Journal of the Yorkshire Regional Cancer Organisation), No. 14 pp 16-17.
 - 94. Andrews P.W., Damjanov I. (1994) Cell lines from human germ cell tumors. In: Atlas of Human Tumor Cell Lines (R.J. Hay, J-G Park, A. Gazdar, eds.). Academic Press, pp 443-476.
- 95. Oosterhuis, J.W., Andrews, P.W. (1996). Differentiation in germ cell tumours. In:
 15 Testicular Cancer (2nd Edition) (A. Horwich, ed) Chapman & Hall, pp 61-72.
 - 96. Andrews, P.W., Wakeman, J. (1996). Cell differentiation in germ cell tumours. In: "Ares Serono Conference on Sex Differentiation" (I.A. Hughes, ed), Frontiers in Endocrinology vol. 20, pp 33-44
- 97. Andrews, P.W., (1998) Teratocarcinomas and human embryology: pluripotent human 20 EC cell lines. Acta Pathologica Microbiologica et Immunologica Scandinavica, 106:158-168.
 - 98. Gokhale, P.J., Eastwood, D., Walsh, J., Andrews, P.W. (1998). The possible role of Notch genes in Germ Cell Tumour Development and Progression. Germ Cell Tumours IV (W G Jones, I Appleyard, P Handen & J K Joffee, eds), John Libby, London, pp 69-71.
 - 99. Andrews, P.W. (2001) Life story inside a cell. Times Higher Education Supplement. Jan 19th 2001, p21.
 - 100. Andrews, P.W., Przyborski, S.A. and Thomson, J.A. (2000). Embryonal Carcinoma Cells as Embryonic Stem Cells. Cold Spring Harbor Laboratory Press. In press.

25

5

CLAIMS

1. A method to modulate the differentiation of an embryonic stem cell comprising:

- i) providing a culture of embryonic stem cells;
- ii) providing at least one ligand, or the active binding fragment thereof, capable of binding its cognate receptor polypeptide expressed by said embryonic stem cell;
- 10 iii) forming a culture comprising embryonic stem cells and said ligand; and
 - iv) growing said cell culture.
 - 2. A method according to Claim 1 wherein said ligand is encoded by a nucleic acid molecule selected from the group consisting of:
- i) a nucleic acid molecule as represented in Figure 22;
 - ii) a nucleic acid molecule which hybridises to the nucleic acid in (i) and which encodes a ligand capable of binding a Wnt receptor; and
 - iii) nucleic acid molecules which are degenerate as a result of the genetic code to the sequences defined in (i) and (ii) above.

20

3. A method according to Claim 2 wherein said ligand is encoded by a nucleic acid molecule selected from the nucleic acid sequences represented in: Fig 30; Fig 32; Fig 34; Fig 36; Fig 38; Fig 40; Fig 42; Fig 44; Fig 47; Fig 49; Fig 51; Fig 53; Fig 55.

25

4. A method according to Claim 2 or 3 wherein said ligand is encoded by a nucleic acid molecule as represented by the nucleic acid sequence in Fig 22.

5. A method according to Claim 1 wherein said ligand is encoded by a nucleic acid molecule selected from the group consisting of:

- i) a nucleic acid molecule as represented in Figures 2, 4, 5, 7, 10, 12, 14, 16, or 18.
- 5 ii) a nucleic acid molecule which hybridises to the nucleic acid in (i) and which encodes a ligand capable of modulating embryonic stem cell differentiation; and
 - iii) nucleic acid molecules which are degenerate as a result of the genetic code to the sequences defined in (i) and (ii) above.

- 6. A method according to Claim 5 wherein said ligand is selected from the group comprising the amino acid sequences in Figures 3, 6, 8, 9, 11, 13, 15, 17, 19, or polypeptide variants thereof.
- 7. A method according to any of Claims 1-6 wherein said cells are induced to differentiate by the addition of at least one agent selected from the group consisting of: retinoic acid; hexamethylene bisacetamide; bone morphogenetic proteins; bromodeoxyuridine; lithium; sonic hedgehog.
- 20 8. A method for modulating the differentiation of embryonic stem cells comprising:
 - i) providing a cell transfected with a nucleic acid molecule selected from the group consisting of:
 - a) a nucleic acid molecule as represented in Figures 2, 4, 5, 7, 10, 12, 14, 16, 18.
- 25 b) a nucleic acid molecule which hybridises to the nucleic acid in (ii) and which encodes a ligand capable of modulating embryonic stem cell differentiation; and
 - c) nucleic acid molecules which are degenerate as a result of the genetic code to the sequences defined in (a) and (b) above.
- 30 ii) forming a culture comprising the cell identified in (i) above with an embryonic stem cell; and

iii) growing said culture under conditions suitable for the maintenance and/or differentiation of said embryonic stem cell.

- 9. A method for modulating the differentiation of embryonic stem cells comprising:
 - i) providing a cell transfected with a nucleic acid molecule selected from the group consisting of:
 - a) a nucleic acid molecule as represented by the sequence in Figure 22;
 - b) a nucleic acid molecule which hybridises to the nucleic acid in (a) and which encodes a ligand capable of binding a Wnt receptor; and
 - c) nucleic acid molecules which are degenerate as a result of the genetic code to the sequences defined in (a) and (b) above.
 - ii) forming a culture comprising a cell identified in (i) above with an embryonic stem cell; and
- 15 iii) growing said culture under conditions suitable for the maintenance and/or differentiation of embryonic stem cells.

10

- 10. A method according to Claim 9 wherein said cell expresses Wnt-13 ligand.
- 20 11. A method according to any of Claims 9 or 10 wherein said cells are induced to differentiate by the addition of at least one agent selected from the group consisting of: retinoic acid; hexamethylene bisacetamide; bone morphogenetic proteins; bromodeoxyuridine; lithium; sonic hedgehog.
- 25 12. A method according to any of Claims 1-11 wherein said nucleic acid molecule encodes a ligand of human origin.
 - 13. A method according to any of Claims 1-12 wherein said embryonic stem cells are of human origin.
 - 14. A method according to any of Claims 8-13 wherein said transfected cell is a

mammalian cell.

15. A cell according to Claim 14 wherein said cell is selected from the group consisting of: a chinese hamster ovary cell; murine primary fibroblast cell; human primary fibroblast cell; transformed mouse fibroblast cell-line STO.

- 16. A method for inhibiting the differentiation of embryonic stem cells comprising the steps of:
- i) providing at least one polypeptide, or active fragment thereof, wherein said polypeptide is an inhibitor of the *Wnt* signalling pathway.
 - iii) forming a culture comprising the polypeptide identified in (i) above with an embryonic stem cell; and
 - iii) growing said culture under conditions suitable for the maintenance of embryonic stem cells in an undifferentiated state.

15

5

17. A method according to Claim 16 wherein said inhibitor is selected from the group consisting of the active binding fragments thereof of the following polypeptides: frizzled related polypeptides (FRP); Wnt Inhibitory Factors (WIF); Dickkopf; Cerebrus.

20

- 18. A method according to Claim 17 wherein said inhibitor is encoded by a nucleic acid molecule selected from the nucleic acid sequences represented by: Fig 57; Fig 59; Fig 61; Fig 63; Fig 65; Fig 67; Fig 69; Fig 71; Fig 73; Fig 75; Fig 77; Fig 79; Fig 81; Fig 83; Fig 85; Fig 87; Fig 89; Fig 91; Fig 93; Fig 95; Fig 97; Fig 99; Fig 101; or Fig 103.
 - 19. A method for inhibiting the differentiation of embryonic stem cells comprising the steps of:
- i) providing a cell transfected with a nucleic acid molecule selected from the
 group consisting of:
 - a) a nucleic acid molecule encoding a Wnt inhibitory polypeptide;

b) a nucleic acid molecule which hybridises to the nucleic acid in (a) and which encodes a polypeptide capable of inhibiting *Wnt* signalling; and

- c) nucleic acid molecules which are degenerate as a result of the genetic code to the sequences defined in (a) and (b) above.
- 5 ii) forming a culture of the cell identified in (i) above with an embryonic stem cell; and
 - iii) growing said culture under conditions suitable for the maintenance of embryonic stem cells in an undifferentiated state.
- 10 20. A method according to Claim 19 wherein said cells express at least one Wnt inhibitory polypeptide selected from the group consisting of the active binding fragments thereof of the following polypeptides: frizzled related polypeptides (FRP); Wnt Inhibitory Factors (WIF); Dickkopf; Cerebrus.
- 15 21. A method according to Claim 19 wherein said cells express at least one Wnt inhibitory polypeptide encoded by a nucleic acid molecule selected from the nucleic acid sequences represented by: Fig 57; Fig 59; Fig 61; Fig 63; Fig 65; Fig 67; Fig 69; Fig 71; Fig 73; Fig 75; Fig 77; Fig 79; Fig 81; Fig 83; Fig 85; Fig 87; Fig 89; Fig 91; Fig 93; Fig 95; Fig 97; Fig 99; Fig 101; Fig or 103.

20

- 22. A cell or cell culture obtainable by the method according to any of Claims 1-21.
- 23. A therapeutic cell composition obtainable by the method according to any of Claims 1-15.
 - 24. Use of a cell according to Claim 23 for the manufacture of a composition for use in the treatment of a disease selected from the group consisting of: Parkinson's disease; Huntington's disease; motor neurone disease; heart disease; diabetes; liver disease (eg cirrhosis); renal disease; AIDS.

25. A method of treatment of an animal, preferably a human, comprising administering a cell composition comprising embryonic stem cells which have been induced to differentiate into at least one cell-type by the method according to any of Claims 1-14.

26. Condition medium obtained by culturing embryonic stem cells according to the method of any of Claims 1-21.

. 10

5

15

20

25

D.melanogaster


Notch



Lin-12 Glp-1

Vertebrate

Notch 1, 2



Notch 4



Figure 1

Figure 2

GTCCAGCGGTACCATGGGCCGTCGGAGCGCGCTAGCCCTTGCCGTGGTCTCTGCCCTGC TGTGCCAGGTCTGGAGCTCCGGCGTATTTGAGCTGAAGCTGCAGGAGTTCGTCAACAA GAAGGGGCTGCTGGGGAACCGCAACTGCTGCCGGGGGGCTCTGGCCCGCCTTGCGCC TGCAGGACCTTCTTTCGCGTATGCCTCAAGCACTACCAGGCCAGCGTGTCACCGGAGCC ACCCTGCACCTACGGCAGTGCTGTCACGCCAGTGCTGGGTGTCGACTCCTTCAGCCTGC CTGATGGCGCAGGCATCGACCCCGCCTTCAGCAACCCCATCCGATTCCCCTTCGGCTTC ACCTGGCCAGGTACCTTCTCTGATCATTGAAGCCCTCCATACAGACTCTCCCGATGA CCTCGCAACAGAAAACCCAGAAAGACTCATCAGCCGCCTGACCACACAGAGGCACCTC ACTGTGGGAGAAGAATGGTCTCAGGACCTTCACAGTAGCGGCCGCACAGACCTCCGGT ACTCTTACCGGTTTGTGTGTGACGAGCACTACTACGGAGAAGGTTGCTCTGTGTTCTGC CGACCTCGGGATGACGCCTTTGGCCACTTCACCTGCGGGGACAGAGGGGAGAAGATGT GGCCGCTACTGCGATGAGTGCATCCGATACCCAGGTTGTCTCCATGGCACCTGCCAGC AACCCTGGCAGTGTAACTGCCAGGAAGGCTGGGGGGGCCTTTTCTGCAACCAAGACCT GAACTACTGTACTCACCATAAGCCGTGCAGGAATGGAGCCACCTGCACCAACACGGGC ${\tt CAGGGGAGCTACACATGTTCCTGCCGACCTGGGTATACAGGTGCCAACTGTGAGCTGG}$ GGACAGCTTCTCTTGCACCTGCCCTCCCGGCTTCTATGGCAAGGTCTGTGAGCTGAGCG CCATGACCTGTGCAGATGGCCCTTGCTTCAATGGAGGACGATGTTCAGATAACCCTGAC GGAGGCTACACCTGCCATTGCCCCTTGGGCTTCTCTGGCTTCAACTGTGAGAAGAAGAT GGATCTCTGCGGCTCTTCCCCTTGTTCTAACGGTGCCAAGTGTGTGGACCTCGGCAACT CTTACCTGTGCCGGTGCCAGGCTGGCTTCTCCGGGAGGTACTGCGAGGACAATGTGGA TGACTGTGCCTCCCCGTGTGCAAATGGGGGCACCTGCCGGGACAGTGTGAACGAC TTCTCCTGTACCTGCCCACCTGGCTACACGGCCAAGAACTGCAGCGCCCCTGTCAGCAG GTGTGAGCATGCACCCTGCCATAATGGGGCCACCTGCCACCAGAGGGGCCAGCGCTAC ATGTGTGAGTGCGCCCAGGGCTATGGCGGCCCCAACTGCCAGTTTCTGCTCCCTGAGCC ACCACCAGGGCCCATGGTGGTGGACCTCAGTGAGAGGCATATGGAGAGCCAGGGCGG GCTGTGCTGCTGGTGGTCTGCGTCCGGCTGAAGCTACAGAAACACCAGCCTCCACCT GAACCCTGTGGGGGAGAGACAGAAACCATGAACAACCTAGCCAATTGCCAGCGCGAG AAGGACGTTTCTGTTAGCATCATTGGGGCTACCCAGATCAAGAACACCAACAAGAAGG CGGACTTTCACGGGGACCATGGAGCCAAGAAGAGCAGCTTTAAGGTCCGATACCCCAC TGTGGACTATAACCTCGTTCGAGACCTCAAGGGAGATGAAGCCACGGTCAGGGATACA CACAGCAAACGTGACACCAAGTGCCAGTCACAGAGCTCTGCAGGAGAAGAGAAGATC GTGTGTTATAGCGACTGAGGTGTAAGATGGAAGCGATGTGGCAAAATTCCCATTTCTCT CAAATAAAATTCCAAGGATATAGCCCCGATGAATGCTGCTGAGAGAGGAAGGGAGAG GAAACCCAGGGACTGCTGCTGAGAACCAGGTTCAGGCGAAGCTGGTTCTCAGAGTT TTGTTCCCATTGCACTATGGACAGTTGCTTTGAAGAGTATATATTTAAATGGACGAGTG ACTTGATTCATATAGGAAGCACGCACTGCCCACACGTCTATCTTGGATTACTATGAGCC AGTCTTTCCTTGAACTAGAAACACAACTGCCTTTATTGTCCTTTTTGATACTGAGATGTG TTTTTTTTTTCCTAGACGGGAAAAAGAAAACGTGTGTTATTTTTTTGGGATTTGTAAAA ATATTTTCATGATATCTGTAAAGCTTGAGTATTTTGTGACGTTCATTTTTTATAATTT ATAAATGTATTTATGGAATATTGTGCAAATGTTATTTGAGTTTTTTACTGTTTTGTTAAT GAAGAAATTCATTTTAAAAATATTTTTCCAAAATAAATATAATGAACTACA

Figure 3

MGRRSALALAVVSALLCQVWSSGVFELKLQEFVNKKGLLGNRNCCRGGSGPPCACRTFFR VCLKHYQASVSPEPPCTYGSAVTPVLGVDSFSLPDGAGIDPAFSNPIRFPFGFT,WPGTFSLIIE ALHTDSPDDLATENPERLISRLTTQRHLTVGEEWSQDLHSSGRTDLRYSYRFVCDEHYYGE GCSVFCRPRDDAFGHFTCGDRGEKMCDPGWKGQYCTDPICLPGCDDQHGYCDKPGECKC RVGWQGRYCDECIRYPGCLHGTCQQPWQCNCQEGWGGLFCNQDLNYCTHHKPCRNGAT CTNTGQGSYTCSCRPGYTGANCELEVDECAPSPCKNGASCTDLEDSFSCTCPPGFYGKVCE LSAMTCADGPCFNGGRCSDNPDGGYTCHCPLGFSGFNCEKKMDLCGSSPCSNGAKCVDL GNSYLCRCQAGFSGRYCEDNVDDCASSPCANGGTCRDSVNDFSCTCPPGYTGKNCSAPVS RCEHAPCHNGATCHQRGQRYMCECAQGYGGPNCQFLLPEPPPGPMVVDLSERHMESQGG PFPWVAVCAGVVLVLLLLLGCAAVVVCVRLKLQKHQPPPEPCGGETETMNNLANCQREK DVSVSIIGATQIKNTNKKADFHGDHGAKKSSFKVRYPTVDYNLVRDLKGDEATVRDTHSK RDTKCQSQSSAGEEKIAPTLRGGEIPDRKRPESVYSTSKDTKYQSVYVLSAEKDECVIATEV

Figure 4

CGGGCAGAGGTGGAAGAGGGGGGGGGCCTCAAAGAAGCGATCAGAATAATAAAAGG AGGCCGGGCTCTTTGCCTTCTGGAACGCGCGGCTCTTGAAAGGGCTTTTGAAAAGTAGT GTTGTTTCCAGTCGTGCATGCTCCAATCCACGGAGTATATTAGAGCCGGGACGCGGCG GCCGCGGGGCAGCGACGACGCCTCGGCGGAGCACCAGCGCTAGCAGCGCG GCGCCGTCCGGAGTGCCCGTGGCGCGCGCGCGCGATGCGGTCCCCACGGACGCGCG GCCGGCCCGGGCCCCCTGAGTCTTCTGCTCGCCCTGCTCTGTGCCCTGCGAGCCAAG GTGTGCGGGGCCTCGGGTCAGTTTGAGCTGGAGATCCTGTCCATGCAGAACGTGAATG GAGAGCTACAGAATGGGAACTGTTGTGGTGGAGTCCGGAACCCTGGCGACCGCAAGTG CACCCGCGACGAGTGTGATACGTACTTCAAAGTGTGCCTCAAGGAGTATCAGTCCCGC GTCACTGCCGGGGACCCTGCAGCTTCGGCTCAGGGTCTACGCCTGTCATCGGGGGTA ACACCTTCAATCTCAAGGCCAGCCGTGGCAACGACCGTAATCGCATCGTACTGCCTTTC AGTTTCGCCTGGCCGAGGTCCTACACTTTGCTGGTGGAGGCCTGGGATTCCAGTAATGA GCCGGCAATGGCAGACACTGAAACAAAACACAGGGATTGCCCACTTCGAGTATCAGAT CCGAGTGACCTGTGATGACCACTACTATGGCTTTGGCTGCAATAAGTTCTGTCGTCCCA GAGATGACTTCTTTGGACATTATGCCTGTGACCAGAACGGCAACAAAACTTGCATGGA AGGCTGGATGGGTCCTGATTGCAACAAGCTATCTGCCGACAGGGCTGCAGTCCCAAG CATGGGTCTTGTAAACTTCCAGGTGACTGCAGGTGCCAGTACGGTTGGCAGGGCCTGT ACTGCGACAAGTGCATCCCGCACCCAGGATGTCCACGGCACCTGCAATGAACCCTG GCAGTGCCTCTGTGAGACCAACTGGGGTGGACAGCTCTGTGACAAAGATCTGAATTAC TGTGGGACTCATCAGCCCTGTCTCAACCGGGGAACATGTAGCAACACTGGGCCTGACA AATACCAGTGCTCCTGCCCAGAGGGCTACTCGGGCCCCAACTGTGAAATTGCTGAGCA TGCTTGTCTCTGACCCCTGCCATAACCGAGGCAGCTGCAAGGAGACCTCCTCAGGCT TTGAGTGTGAGTGTTCTCCAGGCTGGACTGGCCCCACGTGTTCCACAAACATCGATGAC TGTTCTCCAAATAACTGTTCCCATGGGGGCACCTGCCAGGATCTGGTGAATGGATTCAA GTGTGTGCCCGCCCCAGTGGACTGGCAAGACTTGTCAGTTAGATGCAAATGAGTGC GAGGCCAAACCTTGTGTAAATGCCAGATCCTGTAAGAATCTGATTGCCAGCTACTACTG TGATTGCCTTCCTGGCTGGATGGGTCAGAACTGTGACATAAATATCAATGACTGCCTTG GCCAGTGTCAGAATGACGCCTCCTGTCGGGATTTGGTTAATGGTTATCGCTGTATCTGT CCACCTGGCTATGCAGGCGATCACTGTGAGAGAGACATCGATGAGTGTGCTAGCAACC CCTGCTTGAATGGGGGTCACTGTCAGAATGAAATCAACAGATTCCAGTGTCTCTGTCCC

ACTGGTTTCTCTGGAAACCTCTGTCAGCTGGACATCGATTACTGCGAGCCCAACCCTTG CCAGAATGGCGCCCAGTGCTACAATCGTGCCAGTGACTATTTCTGCAAGTGCCCCGAG GACTATGAGGGCAAGAACTGCTCACACCTGAAAGACCACTGCCGTACCACCACCTGCG AAGTGATTGACAGCTGCACTGTGGCCATGGCCTCCAACGACACGCCTGAAGGGGTGCG GTATATCTCTTCTAACGTCTGTGGTCCCCATGGGAAGTGCAAGAGCCAGTCGGGAGGC AAATTCACCTGTGACTGTAACAAAGGCTTCACCGGCACCTACTGCCATGAAAATATCA ACGACTGCGAGAGCAACCCCTGTAAAAACGGTGGCACCTGCATCGATGGCGTTAACTC CTACAAGTGTATCTGTAGTGACGGCTGGGAGGGAGCGCACTGTGAGAACAACATAAAT GACTGTAGCCAGAACCCTTGTCACTACGGGGGTACATGTCGAGACCTGGTCAATGACT TTTACTGTGACTGCAAAAATGGCTGGAAAGGAAAGACTTGCCATTCCCGTGACAGCCA GTGTGACGAAGCCACGTGTAATAATGGTGGTACCTGCTATGATGAAGTGGACACGTTT AAGTGCATGTCCCGGTGGCTGGGAAGGAACAACTTGTAATATAGCTAGAAACAGTA GCTGCCTGCCGAACCCCTGTCATAATGGAGGTACCTGCGTGGTCAATGGAGACTCCTTC ACCTGTGTCTGCAAAGAAGGCTGGGAGGGGCCTATTTGTACTCAAAATACCAACGACT GCAGTCCCCATCCTTGTTACAATAGCGGGACCTGTGTGGACGGAGACAACTGGTATCG GTGCGAATGTGCCCCGGGTTTTGCTGGGCCAGACTGCAGGATAAACATCAATGAGTGC CAGTCTTCCCCTTGTGCCTTTGGGGCCACCTGTGTGGATGAGATCAATGGCTACCAGTG TATCTGCCCTCCAGGACATAGTGGTGCCAAGTGCCATGAAGTTTCAGGGCGATCTTGCA TCACCATGGGGAGAGTGATACTTGATGGGGCCAAGTGGGATGATGACTGTAACACCTG CCAGTGCCTGAATGGACGGGTGGCCTGCTCCAAGGTCTGGTGTGGCCCGAGACCTTGC AGGCTCCACAAAAGCCACAATGAGTGCCCCAGTGGGCAGAGCTGCATCCCGGTCCTGG ATGACCAGTGTTTCGTGCGCCCCTGCACTGGTGTTGGCGAATGTCGGTCCTCCAGCCTC CAGCCAGTGAAGACCAAGTGCACATCTGACTCCTATTACCAGGATAACTGTGCAAACA TCACTTTCACCTTTAACAAAGAGATGATGTCTCCAGGTCTTACCACCGAACACATTTGC AGCGAATTGAGGAATTTGAATATCCTGAAGAATGTTTCTGCTGAATATTCGATCTACAT AGCCTGTGAGCCTTCCCTGTCAGCAAACAATGAAATACACGTGGCCATCTCTGCAGAA GACATCCGGGATGATGGGAACCCTGTCAAGGAAATTACCGATAAAATAATAGATCTCG TTAGTAAACGGGATGGAAACAGCTCACTTATTGCTGCGGTTGCAGAAGTCAGAGTTCA GAGGCGTCCTCTGAAAAACAGAACAGATTTCCTGGTTCCTCTGCTGAGCTCTGTCTTAA CAGTGGCTTGGGTCTGTTGCTTGGTGACAGCCTTCTACTGGTGTACGGAAGCGGCGG AAGCCCAGCAGCCACACTCACTCCGCCCCGAGGACAACACCACCAACAATGTGCGGG AGCAGCTGAACCAAATCAAAAACCCCATCGAGAAACACGGAGCCAACACGGTCCCCA TTAAGGATTACGAGAACAAAACTCCAAAATGTCAAAAATCAGGACACACAACTCGG AAGTGGAGGAGGATGACATGGATAAACACCAGCAGAAAGTCCGCTTTGCCAAACAGC CAGTGTATACGCTGGTAGACAGAGAGGGGAAAGGCCCCCAGCGGCACGCCGACAAAAC ACCCGAACTGGACAAATAAACAGGACAACAGAGACTTGGAAAGTGCCCAGAGCTTGA ACCGGATGGAATACATCGTATAGCAGACAGTGGGCTGCCGCCATAGGTAGAGTTTGAG GGCACCGCGGGCCG

Figure 5

PCT/GB02/01195

GCCCGGAACCCGGGAGACCGCAAGTGCACCCGCGACGAGTGTGAACATACTTCAAAGT GTGCCTCAAGGAGTATCAGTCCCGCGTCACGGCCGGGGGGCCCTGCAGCTTCGGCTC AGGGTCCACGCCTGTCATCGGGGGCAACACCTTCAACCTCAAGGCCAGCCGCGCAAC GACCGCAACCCATCGTGCTGCCTTTCAGTTTCGCCTGGCCGAGGTCCTATACGTTGCTT GTGGAGGCGTGGGATTCCAGTAATGACACCGTTCAACCTGACAGTATTATTGAAAAGG CTTCTCACTCGGGCATGATCAACCCCAGCCGGCAGTGGCAGACGCTGAAGCAGAACAC GGGCGTTGCCCACTTTGAGTATCAGATCCGCGTGACCTGTGATGACTACTATGGCT TTGGCTGCAATAAGTTCTGCCGCCCCAGAGATGACTTCTTTGGACACTATGCCTGTG ACCAGAATGGCAACAAAACTTGCATGGAAGGCTGGATGGGCCCCGAATGTAACAGAG CTATTTGCCGAAAGGCTGCAGTCCTAAGCATGGGTCTTGCAAACTCCCAGGTGACTGCA GGTGCCAGTATGGCTGGCAAGGCCTGTACTGTGATAAGTGCATCCCACACCCGGGATG CGTCCACGGCATCTGTAATGAGCCCTGGCAGTGCCTCTGTGAGACCAACTGGGGCGGC CAGCTCTGTGACAAAGATCTCAATTACTGTGGGACTCATCAGCCGTGTCTCAACGGGG GAACTTGTAGCAACACAGGCCCTGACAAATATCAGTGTTCCTGCCCTGAGGGGTATTC AGGACCCAACTGTGAAATTGCTGAGCACGCCTGCCTCTGTGATCCCTGTCACAACAGA GGCAGCTGTAAGGAGACCTCCCTGGGCTTTGAGTGTGAGTGTTCCCCAGGCTGGACCG GCCCACATGCTCTACAAACATTGATGACTGTTCTCCTAATAACTGTTCCCACGGGGGC ACCTGCCAGGACCTGGTTAACGGATTTAAGTGTGTGTGCCCCCCACAGTGGACTGGGA AAACGTGCCAGTTAGATGCAAATGAATGTGAGGCCAAACCTTGTGTAAACGCCAAATC CTGTAAGAATCTCATTGCCAGCTACTACTGCGACTGTCTTCCCGGCTGGATGGGTCAGA ATTGTGACATAAATATTAATGACTGCCTTGGCCAGTGTCAGAATGACGCCTCCTGTCGG GATTTGGTTAATGGTTATCGCTGTATCTGTCCACCTGGCTATGCAGGCGATCACTGTGA GAGAGACATCGATGAATGTGCCAGCAACCCCTGTTTGAATGGGGGTCACTGTCAGAAT GAAATCAACAGATTCCAGTGTCTGTGTCCCACTGGTTTCTCTGGAAACCTCTGTCAGCT GGACATCGATTATTGTGAGCCTAATCCCTGCCAGAACGGTGCCCAGTGCTACAACCGT GCCAGTGACTATTTCTGCAAGTGCCCCGAGGACTATGAGGGCAAGAACTGCTCACACC TGAAAGACCACTGCCGCACGACCCCCTGTGAAGTGATTGACAGCTGCACAGTGGCCAT GGCTTCCAACGACACCTGAAGGGGTGCGGTATATTTCCTCCAACGTCTGTGGTCCTC ACGGGAAGTGCAAGAGTCAGTCGGGAGGCAAATTCACCTGTGACTGTAACAAAGGCTT CACGGGAACATACTGCCATGAAAATATTAATGACTGTGAGAGCAACCCTTGTAGAAAC GGTGGCACTTGCATCGATGGTGTCAACTCCTACAAGTGCATCTGTAGTGACGGCTGGG AGGGGCCTACTGTGAAACCAATATTAATGACTGCAGCCAGAACCCCTGCCACAATGG GGCACGTGTCGCGACCTGGTCAATGACTTCTACTGTGACTGTAAAAATGGGTGGAAAG GAAAGACCTGCCACTCACGTGACAGTCAGTGTGATGAGGCCACGTGCAACAACGGTGG CAACCTGTAACATAGCCCGAAACAGTAGCTGCCTGCCCAACCCCTGCCATAATGGGGG CCCATCTGTGCTCAGAATACCAATGACTGCAGCCCTCATCCCTGTTACAACAGCGGCAC CTGTGTGGATGGAGACAACTGGTACCGGTGCGAATGTGCCCCGGGTTTTGCTGGGCCC GACTGCAGAATAAACATCAATGAATGCCAGTCTTCACCTTGTGCCTTTGGAGCGACCTG TGTGGATGAGATCAATGGCTACCGGTGTGTCTGCCCTCCAGGGCACAGTGGTGCCAAG TGCCAGGAAGTTTCAGGGAGACCTTGCATCACCATGGGGAGTGTGATACCAGATGGGG CCAAATGGGATGACTGTAATACCTGCCAGTGCCTGAATGGACGATCGCCTGCTCA AAGGTCTGGTGTGGCCCTCGACCTTGCCTCCACAAAGGGCACAGCGAGTGCCCCA GCGGGCAGAGCTGCATCCCATCCTGGACGACCAGTGCTTCGTCCACCCCTGCACTGGT GTGGGCGAGTGTCGGTCTTCCAGTCTCCAGCCGGTGAAGACAAAGTGCACCTCTGACT CCTATTACCAGGATAACTGTGCGAACATCACATTTACCTTTAACAAGGAGATGATGTCA CCAGGTCTTACTACGGAGCACATTTGCAGTGAATTGAGGAATTTGAATATTTTGAAGAA TGTTTCCGCTGAATATTCAATCTACATCGCTTGCGAGCCTTCCCCTTCAGCGAACAATG AAATACATGTGGCCATTTCTGCTGAAGATATACGGGATGATGGGAACCCGATCAAG GAAATCACTGACAAAATAATCGATCTTGTTAGTAAACGTGATGGAAACAGCTCGCTGA TTGCTGCCGTTGCAGAAGTAAGAGTTCAGAGGCGGCCTCTGAAGAACAGAACAGATTT

CCTTGTTCCCTTGCTGAGCTCTGTCTTAACTGTGGCTTGGATCTGTTGCTTGGTGACGGC GAGGACAACACCACCAACAACGTGCGGGAGCAGCTGAACCAGATAAAAACCCCATTG AGAAACATGGGGCCAACACGGTCCCCATCAAGGATTACGAGAACAAGAACTCCAAAT GTCTAAAATAAGGACACACAATTCTGAAGTAGAAGAGGACGACATGGACAAACACCA GCAGAAAGCCCGGTTTGCCAAGCAGCCGGCGTATACGCTGGTAGACAGAGAAGAAA GCCCCCAACGCCACACACACCCAAACTGGACAAACAACAGGACAACAGAG ACTTGGAAAGTGCCCAGAGCTTAAACCGAATGGAGACATCGTATAGCAGACCGCGGGC ACTGCCGCCGCTAGGTAGAGTCTGAGGGCTTGTAGTTCTTTAAACTGTCGTGTCATACT CGAGTCTGAGGCCGTTGCTGACTTAGAATCCCTGTGTTAATTTAAGTTTTGACAAGCTG GCTTACACTGGCAATGGTAGTTTCTGTGGTTGGCTGGGAAATCGAGTGCCGCATCTCAC AGCTATGCAAAAAGCTAGTCAACAGTACCCTGGTTGTGTGTCCCCTTGCAGCCGACAC GGTCTCGGATCAGGCTCCCAGGAGCCTGCCCAGCCCCTGGTCTTTGAGCTCCCACTTC CTTGAGTTGTTTTTGTATATTGGTTTTATGATGACGTACAAGTAGTTCTGTATTTGAAAG ATTGTATTTTTGTTGGGGGGGGGGGGGGGGGTTGCTCAGCAGTTGCTGGTAAAATG AAGAATTTAAAGAAAAAATGTCAAAAGTAGAACTTTGTATAGTTATGTAAATAATTC TTTTTTATTAATCACTGTGTATATTTGATTTATTAACTTAATAATCAAGAGCCTTAAAAC ATCATTCCTTTTTATTTATATGTATGTGTTTAGAATTGAAGGTTTTTGATAGCATTGTAA GCGTATGGCTTTATTTTTTGAACTCTTCTCATTACTTGTTGCCTATAAGCCAAAATTAA GGTGTTTGAAAATAGTTTATTTTAAAACAATAGGATGGGCTTCTGTGCCCAGAATACTG ATGGAATTTTTTTTGTACGACGTCAGATGTTTAAAACACCTTCTATAGCATCACTTAA AACACGTTTTAAGGACTGACTGAGGCAGTTTGAGGATTAGTTTAGAACAGGTTTTTTTG CAGAGCAGTAAGGGAACAAGTTGAGCTATGACTTAACATAGCCAAAATGTGAGTGGTT GAATATGATTAAAAATATCAAATTAATTGTGTGAACTTGGAAGCACACCAATCTGACTT TGTAAATTCTGATTTCTTTTCACCATTCGTACATAATACTGAACCACTTGTAGATTTGAT TTTTTTTTTAATCTACTGCATTTAGGGAGTATTCTAATAAGCTAGTTGAATACTTGAACC GTGAGGAAATCAAAGTGCTATTACGAAGTTCAAGATCAAAAAGGCTTATAAAACAGAG TAATCTTGTTGGTTCACCATTGAGACCGTGAAGATACTTTGTATTGTCCTATTAGTGTTA TATGAACATACAAATGCATCTTTGATGTGTTGTTCTTGGCAATAAATTTTGAAAAGTAA TATTTATTAAATTTTTTTGTATGAAAACATGGAACAGTGTGGCTCTTCTGAGCTTACGTA GTTCTACCGGCTTTGCCGTGTGCTTCTGCCACCCTGCTGAGTCTGTTCTGGTAATCGGGG TATAATAGGCTCTGCCTGACAGAGGGATGGAGGAAGAACTGAAAGGCTTTTCAACCC AAAACTCATCTGGAGTTCTCAAAGACCTGGGGCTGCTGTGAAGCTGGAACTGCGGGAG ${\tt CCCCATCTAGGGGAGCCTTGATTCCCTTGTTATTCAACAGCAAGTGTGAATACTGCTTG}$

Figure 6

MRSPRTRGRSGRPLSLLLALLCALRAKVCGASGQFELEILSMQNVNGELQNGNCCGGARN PGDRKCTRDECDTYFKVCLKEYQSRVTAGGPCSFGSGSTPVIGGNTFNLKASRGNDRNRIV LPFSFAWPRSYTLLVEAWDSSNDTVQPDSIIEKASHSGMINPSRQWQTLKQNTGVAHFEYQ IRVTCDDYYYGFGCNKFCRPRDDFFGHYACDQNGNKTCMEGWMGPECNRAICRQGCSPK HGSCKLPGDCRCQYGWQGLYCDKCIPHPGCVHGICNEPWQCLCETNWGGQLCDKDLNYC GTHQPCLNGGTCSNTGPDKYQCSCPEGYSGPNCEIAEHACLSDPCHNRGSCKETSLGFECE CSPGWTGPTCSTNIDDCSPNNCSHGGTCQDLVNGFKCVCPPQWTGKTCQLDANECEAKP CVNAKSCKNLIASYYCDCLPGWMGQNCDININDCLGQCQNDASCRDLVNGYRCICPPGYA GDHCERDIDECASNPCLNGGHCQNEINRFQCLCPTGFSGNLCQLDIDYCEPNPCQNGAQCY

NRASDYFCKCPEDYEGKNCSHLKDHCRTTPCEVIDSCTVAMASNDTPEGVRYISSNVCGPH
GKCKSQSGKFTCDCNKGFTGTYCHENINDCESNPCRNGGTCIDGVNSYKCICSDGWEGA
YCETNINDCSQNPCHNGGTCRDLVNDFYCDCKNGWKGKTCHSRDSQCDEATCNNGGTCY
DEGDAFKCMCPGGWEGTTCNIARNSSCLPNPCHNGGTCVVNGESFTCVCKEGWEGPICAQ
NTNDCSPHPCYNSGTCVDGDNWYRCECAPGFAGPDCRININECQSSPCAFGATCVDEIN
GYRCVCPPGHSGAKCQEVSGRPCITMGSVIPDGAKWDDDCNTCQCLNGRIACSKVWCGPR
PCLLHKGHSECPSGQSCIPILDDQCFVHPCTGVGECRSSSLQPVKTKCTSDSYYQDNCANIT
FTFNKEMMSPGLTTEHICSELRNLNILKNVSAEYSIYIACEPSPSANNEIHVAISAEDIRDDGN
PIKEITDKIIDLVSKRDGNSSLIAAVAEVRVQRRPLKNRTDFLVPLLSSVLTVAWICCLVTAF
YWCLRKRRKPGSHTHSASEDNTTNNVREQLNQIKNPIEKHGANTVPIKDYENKNSKMSKIR
THNSEVEEDDMDKHQQKARFAKQPAYTLVDREEKPPNGTPTKHPNWTNKQDNRDLESAQ
SLNRMEYIV

GCGCAGGGCCGGGCCTTCCCCCCGGCGCTGCTGCTGCTGCTGCGCTCTGGGTGCAG GCGCGCGCCCATGGGCTATTTCGAGCTGCAGCTGAGCGCGCTGCGGAACGTGAACG CTGCGGCCACGACGAGTGCGACACGTACGTGCGCGTGTGCCTTAAGAGTACCAGGCCA AGGTGACGCCACGGGGCCTGCAGCTACGGCCACGCCCACGCCCGTGCTGGGCG CGGGCCGCCGACCAGGACCCGGGCTTCGTCGTCATCCCCTTCCAGTTCGCCTGGCCG CGCTCCTTTACCCTCATCGTGGAGGCCTGGGACTGGGACAACGATACCACCCCGAATG AGGAGCTGCTGATCGAGCGAGTGTCGCATGCCGCATGATCAACCCGGAGGACCGCTGG AAGAGCCTGCACTTCAGCGGCCACGTGGCGCACCTGGAGCTGCGATCCGCGTGCGCTG CGACGAGAACTACTACAGCGCCACTTGCAACAAGTTCTGCCGGCCCCGCAACGACT TTTTCGGCCACTACACCTGCGACCAGTACGGCAACAAGGCCTGCATGGACGGCTGGAT GGGCAAGGAGTGCAAGGAAGCTGTGTAAACAAGGGTGTAATTTGCTCCACGGGGG ATGCACCGTGCCTGGGGAGTGCAGTGCAGCTACGGCTGGCAAGGGAGGTTCTGCGATG AGTGTGTCCCCTACCCCGGCTGCGTGCATGGCAGTTGTGTGGAGCCCTGGCAGTGCAA CTGTGAGACCAACTGGGGCGGCCTGCTCTGTGACAAAGACCTGAACTACTGTGGCAGC CACCACCCTGCACCAACGGAGGCACGTGCATCAACGCCGAGCCTGACCAGTACCGCT GCACCTGCCCTGACGGCTACTCGGGCAGGAACTGTGAGAAGGCTGAGCACGCCTGCAC CTCCAACCGTGTGCCAACGGGGGCTCTTGCCATGAGGTGCCGTCCGGCTTCGAATGCC ACTGCCCATCGGGCTGGAGCGGGCCCACCTGTGCCCTTGACATCGATGAGTGTGCTTCG AACCCGTGTGCGGCCGGTGGCACCTGTGTGGACCAGGTGGACGGCTTTGAGTGCATCT GCCCGAGCAGTGGGTGGGGCCACCTGCCAGCTGGACGTCAACGACTGTGAAGGGA AGCCATGCCTTAACGCTTTTTCTTGCAAAAACCTGATTGGCGGCTATTACTGTGATTGC ATCCCGGGCTGGAAGGGCATCAACTGCCATATCAACGTCAACGACTGTCGCGGGCAGT GGCTTCGGAGGCCGGCATTGCGAGCTGGAACGAGACAAGTGTGCCAGCAGCCCCTGCC ACAGCGGCGCCTCTGCGAGGACCTGGCCGACGGCTCCACTGCCACTGCCCAGGGC TTCTCCGGGCCTCTCTGTGAGGTGGATGTCGACCTTTGTGAGCCAAGCCCCTGCCGGAA CGGCGCTCGCTGTATAACCTGGAGGGTGACTATTACTGCGCCTGCCCTGATGACTTTG GTGGCAAGAACTGCTCCGTGCCCGCGAGCCGTGCCCTGGCGGGGCCTGCAGAGTGAT CGATGGCTGCGGGTCAGACGCGGGGCCTGGGATGCCTGGCACAGCAGCCTCCGGCGTG TGTGGCCCCCATGGACGCTGCGTCAGCCAGCCAGGGGGCAACTTTTCCTGCATCTGTGA CAGTGGCTTTACTGGCACCTACTGCCATGAGAACATTGACGACTGCCTGGGCCAGCCCT GCCGCAATGGGGCACATGCATCGATGAGGTGGACGCCTTCCGCTGCTTCTGCCCCAG CGGCTGGGAGGCGAGCTCTGCGACACCAATCCCAACGACTGCCTTCCCGATCCCTGC

GCTGGAAGGCCAAGACCTGCCACTCACGCGAGTTCCAGTGCGATGCCTACACCTGCAG CAACGGTGGCACCTGCTACGACAGCGGCGACACCTTCCGCTGCGCCTGCCCCCCGGC TGAATGGTGGCACCTGCGTGGGCAGCGGGCCTCCTTCTCCTGCATCTGCCGGGACGG CTGGGAGGGTCGTACTTGCACTCACAATACCAACGACTGCAACCCTCTGCCTTGCTACA ATGGTGGCATCTGTTGACGGCGTCAACTGGTTCCGCTGCGAGTGTGCACCTGGCTTC GCGGGGCCTGACTGCCGCATCAACATCGACGAGTGCCAGTCCTCGCCCTGTGCCTACG GGGCCACGTGTGGGATGAGATCAACGGGTATCGCTGTAGCTGCCCACCCGGCCGAGC CGGCCCCGGTGCCAGGAAGTGATCGGGTTCGGGAGATCCTGCTGGTCCCGGGGCACT CCGTTCCCACACGGAAGCTCCTGGGTGGAAGACTGCAACAGCTGCCGCTGCCTGGATG GCCCGAGGCCCTGAGCGCCAGTGCCCACTGGGGCAAAGGTGCCTGGAGAAGGCCCC AGGCCAGTGTCTGGACCACCCTGTGAGGCCTGGGGGGAGTGCGGCGCAGAAGAGCCA CCGAGCACCCCTGCCTGCCACGCTCGGCCACCTGGACAATAACTGTGCCCGCCTCACC TTGCATTTCAACCGTGACCACGTGCCCCAGGGCACCACGGTGGGCGCCATTTGCTCCGG GATCCGCTCCCTGCCAGCCACAAGGGCTGTGGCACGGGACCGCCTGCTGGTGTTGCTTT GCGACCGGCCTCCTCGGGGGCCAGTGCCGTGGAGGTGGCCGTGTCCTTCAGCCCTGC CAGGGACCTGCCTGACAGCAGCCTGATCCAGGGCGCGCCCACGCCATCGTGGCCGCC ATCACCCAGCGGGGAACAGCTCACTGCTCCTGGCTGTCACCGAGGTCAAGGTGGAGAC GGTTGTTACGGGCGGCTCTTCCACAGGTCTGCTGGTGCCTGTGCTGTGGTGCCTTCA GCGTGCTGTGGCTGCGTGCGTGCTCCTGTGCGTGGGGACACGCAAGCGCAGGAA AGAGCGGGAGAGGCCGGCTGCCGCGGGAGGAGAGCGCCAACACAGTGGGCCCCGC TCAACCCCATCGCAACCCCATCGAGCGGCCGGGGGCCACAAGGACGTGCTCTACCA GTGCAAGAACTTCACGCCGCCGCGCGCAGGGCGGACGAGGCGCTGCCCGGGCCGGC CGGCCACGCGCGTCAGGGAGGATGAGGAGGACGAGGATCTGGGCCGCGGTGAGGAG GACTCCCTGGAGGCGGAGAAGTTCTCTCACACAAATTCACCAAAGATCCTGGCCGCTC GCCGGGGAGGCCGGCCCACTGGGCCTCAGGCCCCAAAGTGGACAACCGCGCGGTCAG GAGCATCAATGAGGCCCGCTACGCCGGCAAGGAGTAGGGGCGGCTGCGCTGGGCCGG GACCCAGGCCCTCGGTGGGAGCCATGCCGTCTGCCGGACCCGGAGCCGAGGCATGTG CTAGTTTCTTTATTTTGTGTAAAAAAACCACCAAAAACAAAAACCAAATGTTTATTTTC TACGTTTCTTTAACCTTGTATAAATTATTCAGTAACTGTCAGGCTGAAAACAATGGAGT GAGAGAGCAAAGGGTGTCTGCGTCGTCACCAAATCGTAGCGTTTGTTACCAGAGGTTG TGCACTGTTTACAGAATCTTCCTTTTATTCCTCACTCGGGTTTCTCTGTGGCTCCAGGCC AAAGTGCCGGTGAGACCCATGGCTGTTGTTGGTGGCCCATGGCTGTTGGTGGACC CGTGGCTGATGGTGTGGCCTGTGGCTGTGGGACTCGTGGCTGTCAATGGGACCTG TGGCTGTCGGTGGGACCTACGGTGGTCGGTGGGACCCTGGTTATTGATGTGGCCCTGGC TGCCGGCACGGCCCGTGGCTGTTGACGCACCTGTGGTTGTTAGTGGGGCCTGAGGTCAT CCGTCTGTGCTTCCTCCCGGAAACGCCCGCTCCAGCGATCTCTCCACTGTGCTTTCA GAAGTGCCCTTCCTGCGCAGTTCTCCCATCCTGGGACGGCGGCAGTATTGAAGCTC GTGACAAGTGCCTTCACACAGACCCCTCGCAACTGTCCACGCGTGCCGTGGCACCAGG CGCTGCCCACCTGCCGGCCCGCCCCCCCCCCTCGTGAAAGTGCATTTTTGTAAATGT

Figure 8

AAAAAAAAAATTCCTGCCC

 $MRAQGRGAFPPALLLLLALWVQAARPMGYFELQLSALRNVNGELLSGACCDGDGRTTRA\\GGCGHDECDTYVRVCLKEYQAKVTPTGPCSYGHGATPVLGGNSFYLPPAGAAGDRARAR$

PRAGGDQDPGFVVIPFQFAWPRSFTLIVEAWDWDNDTTPNEELLIERVSHAGMINPEDRWK SLHFSGHVAHLELQIRVRCDENYYSATCNKFCRPRNDFFGHYTCDQYGNKACMDGWMG KECKEAVCKQGCNLLHGGCTVPGECRCSYGWQGRFCDECVPPGCVHGSCVEPWQCNCET NWGGLLCDKDLNYCGSHHPCTNGGTCINAEPDQYRCTCPDGYSGRNCEKAEHACTSNPC ANGGSCHEVPSGFECHCPSGWSGPTCALDIDECASNPCAAGGTCVDQVDGFECICPEQWV GATCQLDVNDCEGKPCLNAFSCKNLIGGYYCDCIPGWKGINCHINVNDCRGQCQHGGTCK DLVNGYQCVCPRGFGGRHCELERDKCASSPCHSGGLCEDLADGFHCHCPQGFSGPLCEVD VDLCEPSPCRNGARCYNLEGDYYCACPDDFGGKNCSVPREPCPGGACRVIDGCGSDAGPG MPGTAASGVCGPHGRCVSQPGGNFSCICDSGFTGTYCHENIDDCLGQPCRNGGTCIDEVDA FRCFCPSGWEGELCDTNPNDCLPDPCHSRGRCYDLVNDFYCACDDGWKGKTCHSREFQC DAYTCSNGGTCYDSGDTFRCACPPGWKGSTCAVAKNSSCLPNPCVNGGTCVGSGASFSCI CRDGWEGRTCTHNTNDCNPLPCYNGGICVDGVNWFRCECAPGFAGPDCRINIDECQSSPC AYGATCVDEINGYRCSCPPGRAGPRCQEVIGFGRSCWSRGTPFPHGSSWVEDCNSCRCLDG RRDCSKVWCGWKPCLLAGQPEALSAQCPLGQRCLEKAPGQCLRPPCEAWGECGAEEPPST PCLPRSGHLDNNCARLTLHFNRDHVPQGTTVGAICSGIRSLPATRAVARDRLLVLLCDRAS SGASAVEVAVSFSPARDLPDSSLIQGAAHAIVAAITQRGNSSLLLAVTEVKVETVVTGGSST GLLVPVLCGAFSVLWLACVVLCVWWTRKRRKERERSRLPREESANNQWAPLNPIRNPIER PGGHKDVLYQCKNFTPPPRRADEALPGPAGHAAVREDEEDEDLGRGEEDSLEAEKFLSHK FTKDPGRSPGRPAHWASGPKVDNRAVRSINEARYAGKE

Figure 9

MRSPRTRGRPGRPLSLLLALLCALRAKVCGASGQFELEILSMQNVNGELQNGNCCGGVRN PGDRKCTRDECDTYFKVCLKEYQSRVTAGGPCSFGSGSTPVIGGNTFNLKASRGNDRNRIV LPFSFAWPRSYTLLVEAWDSSNDTIQPDSIIEKASHSGMINPSRQWQTLKQNTGIAHFEYQIR VTCDDHYYGFGCNKFCRPRDDFFGHYACDQNGNKTCMEGWMGPDCNKAICRQGCSPKH GSCKLPGDCRCQYGWQGLYCDKCIPHPGCVHGTCNEPWQCLCETNWGGQLCDKDLNYC GTHQPCLNRGTCSNTGPDKYQCSCPEGYSGPNCEIAEHACLSDPCHNRGSCKETSSGFECE CSPGWTGPTCSTNIDDCSPNNCSHGGTCQDLVNGFKCVCPPQWTGKTCQLDANECEAKPC VNARSCKNLIASYYCDCLPGWMGQNCDININDCLGQCQNDASCRDLVNGYRCICPPGYAG DHCERDIDECASNPCLNGGHCQNEINRFQCLCPTGFSGNLCQLDIDYCEPNPCQNGAQCYN RASDYFCKCPEDYEGKNCSHLKDHCRTTTCEVIDSCTVAMASNDTPEGVRYISSNVCGPHG KCKSOSGGKFTCDCNKGFTGTYCHENINDCESNPCKNGGTCIDGVNSYKCICSDGWEGAH CENNINDCSQNPCHYGGTCRDLVNDFYCDCKNGWKGKTCHSRDSQCDEATCNNGGTCY DEVDTFKCMCPGGWEGTTCNIARNSSCLPNPCHNGGTCVVNGDSFTCVCKEGWEGPICTQ NTNDCSPHPCYNSGTCVDGDNWYRCECAPGFAGPDCRININECOSSPCAFGATCVDEINGY QCICPPGHSGAKCHEVSGRSCITMGRVILDGAKWDDDCNTCQCLNGRVACSKVWCGPRPC RLHKSHNECPSGQSCIPVLDDQCFVRPCTGVGECRSSSLQPVKTKCTSDSYYQDNCANITFT FNKEMMSPGLTTEHICSELRNLNILKNVSAEYSIYIACEPSLSANNEIHVAISAEDIRDDGNP VKEITDKIIDLVSKRDGNSSLIAAVAEVRVQRRPLKNRTDFLVPLLSSVLTVAWVCCLVTAF YWCVRKRRKPSSHTHSAPEDNTTNNVREQLNQIKNPIEKHGANTVPIKDYENKNSKMSKIR THNSEVEEDDMDKHQQKVRFAKQPVYTLVDREEKAPSGTPTKHPNWTNKQDNRDLESAQ SLNRMEYIV

Figure 10

TCGAGGCGCGATGCGGCACGCGGCTGGGGACGCCTGCCTCGGCGGCTGCTGCT ACTGGTTCTGCGTGCAGGCGACGCGGCCCATGGGCTATTTCGAGCTGCAGCTGAGC

GCGCTGCGGAACGTGAACGGGGAGCTGCTGAGCGGCGCCTGCTGACGGCGACGGC TGCCTTAAGGAGTACCAGGCCAAGGTGACGCCCACGGGGCCCTGCAGCTACGGCTACG GGACCGAGCGCGCGCGGTCTCGGACCGGCGGCCACCAGGACCCGGGCCTCGTCGTC ATTCCCTTTCAGTTCGCCTGGCCGCGTTCTTTCACCCTCATCGTGGAGGCCTGGGACTG GGACAATGACACCACTCCAGATGAGGAGCTGCTGATTGAGCGGGTGTCGCACGCTGGC ATGATCAACCCCGAGGACCGCTGGAAGAGCCTGCACTTCAGCGGCCACGTGGCACACC TGGAGCTGCAGATCCGAGTGCGCTGTGATGAGAACTACTACAGTGCCACCTGCAACAA GTTCTGCCGGCCCCGCAACGACTTCTTTGGCCACTATACCTGCGACCAGTACGGCAACA AGGCCTGCATGGATGGCTGGATGGCCAAAGAATGCAAAGAAGCCGTGTGTAAACAAG GATGTAATTTGCTCCACGGGGGATGCACTGTGCCTGGGGAGTGCAGGTGCAGCTACGG CTGGCAGGCAAGTTCTGTGACGAGTGTGCCCCTACCCTGGCTGCGTGCATGGCAGCT GTGTGGAGCCCTGCACTGTGACTGTGAGACCAACTGGGGTGGCCTGCTCTGCGACAA AGACCTGAACTACTGTGGCAGCCACCACCCTGTGTCAACGGGGGTACCTGCATCAAT GCTGAGCCTGACCAATACCTCTGCGCCTGCCCAGATGGCTACTTGGGCAAGAACTGTG AGCGGGCTGAGCACGCCTGTGCCCAACCCGTGTGCCAATGGGGGCTCTTGCCACGA AGTGCCATCTGGCTTTGAATGCCACTGTCCGTCAGGATGGAGCGGACCCACCTGTGCG CTCGACATTGATGAGTGTGCCTCTAACCCATGTGCAGCGGGTGGTACCTGCGTGGATCA GACGCCAATGAGTGTGAAGGGAAGCCGTGCCTTAATGCTTTTCTTGCAAAAACCTGAT TGGCGGCTATTACTGTGATTGCCTCCCGGGCTGGAAGGGCATCAACTGCCAAATCAAC ATCAACGATTGTCATGGGCAGTGTCAGCATGGGGGCACCTGCAAGGACCTGGTCAATG GGTACCAGTGTGTGCCCGCGGGGCTTTGGAGGTCGCCATTGCGAACTAGAGTACGA CAAGTGTGCCAGCAGCCCCTGCCGCCGGGGTGGCATCTGCGAGGACCTGGTGGATGGC TTCCGCTGCCACTGCCCACGGGCCTCTCTGGGCTGCACTGTGAGGTGGACATGGATCT CTGTGAACCAAGCCCCTGCCTCAACGGTGCTCGCTGCTACAACCTTGAGGGTGACTACT ACTGCGCCTGCCCAGAAGACTTTGGTGGCAAGAACTGCTCAGTGCCCAGGGACACATG CCCTGGCGGGCATGTAGAGTGATCGATGGCTGCGGGTTCGAGGCAGGGTCCAGGGCA GGGAAACTTCTCCTGCATCTGTGACAGCGGCTTCACAGGCACCTACTGCCATGAAAAC ATTGACGACTGCATGGGCCAGCCCTGCCGCAACGGGGGCACGTGCATTGACGAAGTGG ACTCCTTCCGCTGCTTCTGCCCCAGTGGCTGGGAAGGAGAACTCTGTGACATCAATCCC AACGACTGCCTCCCGACCCCTGCCACAGCCGCGGCCGCTGCTATGACCTGGTCAATG ACTTCTACTGTGCCTGTGACGATGGCTGGAAGGGCAAGACCTGCCACTCACGCGAGTT CCAGTGTGACGCCTACACCTGCAGCAACGGTGGCACATGCTATGACAGCGGCGACACC TTCCGCTGCGCGTGCCCTCCGGGCTGGAAGGGCACCTGCACCATCGCCAAGAACA GCAGCTGTGTGCCCAATCCCTGTGTGAATGGAGGCACCTGCGTGGGTAGCGGAGACTC TTTCTCCTGCATCTGCCGGGATGGCTGGGAGGGCCGCACCTGCACACATAACACCAAT GACTGCAACCCTCTGCCCTGCTATAACGGAGGCATCTGTGTTGATGGCGTCAACTGGTT CCGCTGCGAGTGTGCGCCTGGCTTTGCGGGTCCTGACTGCCGTATCAACATTGATGAGT GCCAGTCCTCGCCCTGTGCCTACGGAGCCACGTGTGTGGATGAGATCAACGGGTACCG CTGCAGCTGCCCACGGTCGTTCTGGCCCCAGGTGCCAGGAAGTGGTCATATTCACG GCAACAGCTGCCGCTGCCTGGATGGCCACCGGGATTGTAGCAAGGTATGGTGCGGATG GAAGCCTTGCCTGCTCTGGTCAGCCCAGCGATCCGAGTGCCCAGTGCCCCCAGGG CAGCAATGTCAGGAGAAGGCCGTGGGTCAGTGCTTGCAGCCACCCTGTGAGAACTGGG GGGAGTGTACÁGCGGAGGAGCCTCTGCCACCCAGCACCCCTGTCAGCCACGGAGCAG TCATTTGGACAACAACTGTGCCCGACTCACACTGCGCTTCAACCGTGATCAAGTGCCTC GGCGCACACGACCGCCTCCTCCTGCTTTTTGTGATCGAGCATCCTCGGGGGCCAGTG

Figure 11

CAGGGCGTGTGTATGTGTGTGTGTGTGTCCTCACC

MLCDKDLNYCGSHHPCVNGGTCINAEPDQYLCACPDGYLGKNCERAEHACASNPCANGG SCHEVPSGFECHCPSGWSGPTCALDIDECASNPCAAGGTCVDQVDGFECICPEQWVGATC QLDANECEGKPCLNAFSCKNLIGGYYCDCLPGWKGINCQITINDCHGQVSAWGHLQGPVN GYQCVCPRGFGVRHCELEYDKCASSPCRRGGICEDLVDGFRCHCPRGLSGLHCEVDMDLC EPSPCFNGVRCYNLEGDYYCACPEDFGGKNCSVPRDTCPGGACRVIDGCGFEAGSRARGV APSGICGPHGHCVSLPGGNFSCICDSGFTGTYCHENIDDCMGQPCRNGGTCIDEVDSFRCFC PSGWEGELCDINPNDCLPDPCHSRGRCYDLVNDFYCACDDGWKGKTCHSREFQCDAYTC SNGGTCYDSGDTFRCACPPGWKGSTCTIAKNSSCVPNPCVNGGTCVGSGDSFSCICRDGWE GRTCTHNTNDCNPLPCYNGGICVDGVHWFACECAPGF

Figure 12

GAAGGCCATGGTCTCCCCACGGATGTCCGGGCTCCTCTCCCAGACTGTGATCCTAGCGC TCATTTTCCTCCCCAGACACGGCCCGCTGGCGTCTTCGAGCTGCAGATCCACTCTTTC GGGCCGGGTCCAGGCCCTGGGGCCCCGCGGTCCCCCTGCAGCGCCCCGGCTCCCCTGCC GCCTCTTCTTCAGAGTCTGCCTGAAGCCTGGGCTCTCAGAGGAGGCCGCCGAGTCCCCG TGCGCCCTGGGCGCGCTGAGTGCGCGCGGACCGGTCTACACCGAGCAGCCCGGAG CGCCCGCGCCTGATCTCCCACTGCCCGACGGGCTCTTGCAGGTGCCCTTCCGGGACG CCTGGCCTGGCACCTTCTCTTTCATCATCGAAACCTGGAGAGAGGAGTTAGGAGACCA GCCGGAGGCCCGTGGGCCCGGGCATTCAGCGCGCAGGCGCCTGGGAGCTGCGCTTCTC GTACCGCGCGCGCTGCGAGCCGCCTGCCGTCGGGACCGCGTGCACGCGCCTCTGCCGT CCGCGCAGCGCCCCTCGCGGTGCGGTCCGGGACTGCGCCCCTGCGCACCGCTCGAGG ACGAATGTGAGGCGCCGCTGGTGTGCCGAGCAGGCTGCAGCCCTGAGCATGGCTTCTG TGAACAGCCGGTGAATGCCGATGCCTAGAGGGCTGGACTGGACCCCTCTGCACGGTC CCTGTCTCCACCAGCAGCTGCCTCAGCCCCAGGGGCCCGTCCTCTGCTACCACCGGATG CCTTGTCCCTGGGCCTGGGCCCTGTGACGGGAACCCGTGTGCCAATGGAGGCAGCTGT AGTGAGACACCCAGGTCCTTTGAATGCACCTGCCCGCGTGGGTTCTACGGGCTGCGGT GTGAGGTGAGCGGGGTGACATGTGCAGATGGACCCTGCTTCAACGGCG

12/66

GCTTGTGTCGGGGGTGCAGACCCTGACTCTGCCTACATCTGCCACTGCCCACCTGGT TTCCAAGGCTCCAACTGTGAGAAGAGGGTGGACCGGTGCAGCCTGCAGCCATGCCGCA ATGGCGGACTCTGCCTGGACCGGGCCACGCCCTGCGCTGCCGCTGCCGCCGCCTTC GCGGGTCCTCGCTGCGACCACCTGGACGACTGCGCGGGCCGCCCTGCGCTAACG GCGGCACGTGTGTGGAGGGCGCGCGCGCGCCCCCTGCTCCTGCCGCTGGGCTTCGGC GGCCGCGACTGCCGCGAGCGCGCGGACCCGTGCGCCCCCCGCGCCCCTGTGCTCACGGC GGCCGCTGCTACGCCCACTTCTCCGGCCTCGTCTGCGCTTGCGCTCCCGGCTACATGGG AGCGCGGTGTGAGTTCCCAGTGCACCCCGACGCGCAAGCGCCTTGCCCGCGGCCCCG CCGGGCCTCAGGCCCGGGACCCTCAGCGCTACCTTTTGCCTCCGGCTCTGGGACTGCT CGTGGCCGCGGGCGTGGCCGCGCTCTTGCTGGTCCACGTGCGCCGCCGTGGC CACTCCCAGGATGCTGGGTCTCGCTTGCTGGCTGGGACCCCGGAGCCGTCAGTCCACG CACTCCCGGATGCACTCAACAACCTAAGGACGCAGGAGGGTTCCGGGGATGGTCCGG CTCGTCCGTAGATTGGAATCGCCCTGAAGATGTAGACCCTCAAGGGATTTATGTCATAT ${\tt CTGCTCCTTCCATCTACGCTCGGGAGGTAGCGACGCCCCTTTTCCCCCCGCTACACACT}$ GGGCGCGCTGGGCAGAGGCACCTGCTTTTTCCCTACCCTTCCTCGATTCTGTCCGT GAAATGAATTGGGTAGAGTCTCTGGAAGGTTTTAAGCCCCATTTTCAGTTCTAACTTACT TTCATCCTATTTTGCATCCCTCTTATCGTTTTGAGCTACCTGCCATCTTCTCTTT

Figure 13

MVSPRMSGLLSQTVILALIFLPQTRPAGVFELQIHSFGPGPGPGAPRSPCSARLPCRLFFRVC LKPGLSEEAAESPCALGAALSARGPVYTEQPGAPAPDLPLPDGLLQVPFRDAWPGTFSFIIE TWREELGDQIGGPAWSLLARVAGRRRLAAGGPWARDIQRAGAWELRFSYRARCEPPAVG TACTRLCRPRSAPSRCGPGLRPCAPLEDECEAPLVCRAGCSPEHGFCEQPGECRCLEGWTG PLCTVPVSTSSCLSPRGPSSATTGCLVPGPGPCDGNPCANGGSCSETPRSFECTCPRGFYGLR CEVSGVTCADGPCFNGGLCVGGADPDSAYICHCPPGFQGSNCEKRVDRCSLQPCRNGGLC LDLGHALRCRCRAGFAGPRCEHDLDDCAGRACANGGTCVEGGGAHRCSCALGFGGRDCR ERADPCAARPCAHGGRCYAHFSGLVCACAPGYMGARCEFPVHPDGASALPAAPPGLRPG DPQRYLLPPALGLLVAAGVAGAALLLVHVRRRGHSQDAGSRLLAGTPEPSVHALPDALNN LRTQEGSGDGPSSSVDWNRPEDVDPQGIYVISAPSIYAREVATPLFPPLHTGRAGQRQHLLF PYPSSILSVK

Figure 14

AAACCGGAACGGGCCCAACTTCTGGGGCCTGGAGAAGGGAAACGAAGTCCCCCCG GTTTCCCGAGGTGCCTTTCCTCGGGCATCCTTGGTTTCGGCGGGACTTCGCAGGGCGGA GTCCTGCGGCTTGGGCGAGGCAAGGGCGAGGCAGGCGCTTTCTGCCGACGCTCCCCG TGGCCCTACGATCCCCCGCGCGTCCGCCGCTGTTCTAAGGAGAGAAGTGGGGGCCCCC CAGGCTCGCGCGTGGAGCGAAGCAGCATGGGCAGTCGGTGCGCGCTGGCCT GCTCTCGGCCTTGCTGTCAGGTCTGGAGCTCTGGGGTGTTCGAACTGAAGCTGCAGG AGTTCGTCAACAAGAAGGGGCTGCTGGGGAACCGCAACTGCTGCCGCGGGGGCGCGG GGCCACCGCCGTGCCGCCTGCCGACCTTCTTCCGCGTGTGCCTCAAGCACTACCAGGCCA GCGTGTCCCCCGAGCCGCCCTGCACCTACGGCAGCGCCGTCACCCCCGTGCTGGGCGT CGACTCCTTCAGTCTGCCCGACGGCGGGGGCCCGACTCCGCGTTCAGCAACCCCATC CGCTTCCCCTTCGGCTTCACCTGGCCGGGCACCTTCTCTCTGATTATTGAAGCTCTCC ACACAGATTCTCCTGATGACCTCGCAACAGAAAACCCAGAAAGACTCATCAGCCGCCT GGCCACCCAGAGGCACCTGACGGTGGGCGAGGAGTGGTCCCAGGACCTGCACAGCAG CGGCCGCACGGACCTCAAGTACTCTACCGCTTCGTGTGACGAACACTACTACGGAG AGGGCTGCTCCGTTTTCTGCCGTCCCCGGGACGATGCCTTCGGCCACTTCACCTGTGGG GAGCGTGGGAGAAAGTGTGCAACCCTGGCTGGAAAGGGCCCTACTGCACAGAGCCG

ATCTGCCTGCCTGGATGTGATGAGCAGCATGGATTTTGTGACAAACCAGGGGAATGCA AGTGCAGAGTGGGCTGGCAGGGCCGGTACTGTGACGAGTGTATCCGCTATCCAGGCTG TCTCCATGGCACCTGCCAGCAGCCCTGGCAGTGCAACTGCCAGGAAGGCTGGGGGGGC CTTTTCTGCAACCAGGACCTGAACTACTGCACACACCATAAGCCCTGCAAGAATGGAG CCACCTGCACCAACACGGGCCAGGGGAGCTACACTTCTCTTGCCGGCCTGGGTACACA GGTGCCACCTGCGAGCTGGGGATTGACGAGTGTGACCCCAGCCCTTGTAAGAACGGAG GGAGCTGCACGGATCTCGAGAACAGCTACTCCTGTACCTGCCCACCCGGCTTCTACGG CAAAATCTGTGAATTGAGTGCCATGACCTGTGCGGACGGCCCTTGCTTTAACGGGGGTC GGTGCTCAGACAGCCCGATGGAGGGTACAGCTGCCGCTGCCCCGTGGGCTACTCCGG CTTCAACTGTGAGAAGAAAATTGACTACTGCAGCTCTTCACCCTGTTCTAATGGTGCCA AGTGTGTGGACCTCGGTGATGCCTACCTGTGCCGCTGCCAGGCCGGCTTCTCGGGGAG GCACTGTGACGACAACGTGGACGACTGCGCCTCCCCGTGCGCCAACGGGGGCACC TGCCGGGATGGCGTGAACGACTTCTCCTGCACCTGCCCGCCTGGCTACACGGGCAGGA ACTGCAGTGCCCCGTCAGCAGGTGCGAGCACGCACCCTGCCACAATGGGGCCACCTG CCACCAGAGGGCCCCATGTGTGCGAATGTGCCCGAAGCTACGGGGGTCCCAACT GCCAGTTCCTGCTCCCGAGCTGCCCCCGGGCCCAGCGGTGGTGGACCTCACTGAGAA GCTAGAGGGCCAGGGCCATTCCCCTGGGTGGCGTGTGCGCCGGGGTCATCCTTG TCCTCATGCTGCTGGGCTGTGCCGCTGTGGTGGTCTGCGTCCGGCTGAGGCTGCAG AAGCACCGGCCCCAGCCGACCCCTGCCGGGGGGAGACGGAGACCATGAACAACCTG GCAACTGCCAGCGTGAGAAGGACATCTCAGTCAGCATCATCGGGGCCACGCAGATCAA GAACACCAACAAAAGGCGGACTTCCACGGGGACCACAGCGCCGACAAGAATGGCTTC AAGGCCCGCTACCCAGCGGTGGACATAACCTCGTGCAGGACCTCAAGGGTGACGACAC CGCCGTCAGGGACGCGCACAGCAAGCGTGACACCAGTGCCAGGCCCCAGGGCTCCTCAG GGCCGGACTCGGGCTGTTCAACTTCAAAAGACACCAAGTACCAGTCGGTGTACGTCAT ATCCGAGGAGAAGGATGAGTGCGTCATAGCAACTGAGGTGTAAAATGGAAGTGAGAT GGCAAGACTCCCGTTCTCTTAAAATAAGTAAAATTCCAAGGATATATGCCCCAACGAA TGCTGCTGAAGAGGGGGGGGCCTCGTGGACTGCTGAGAAACCGAGTTCAGACCG AGCAGGTTCTCCTCGAGGTCCTCGACGCCTGCCGACAGCCTGTCGCGGCCCGGCCGC CTGCGGCACTGCCTTCCGTGACGTCGCCGTTGCACTATGGACAGTTGCTCTTAAGAGAA TATATATTTAAATGGGTGAACTGAATTACGCCTAAGAAGCATGCACTGCCTGAGTGTAT ATTTTGGATTCTTATGAGCCAGTCTTTTCTTGAATTAGAAACACAAACACTGCCTTTATT GTCCTTTTTGATACGAAGATGTGCTTTTTCTAGATGGAAAAGATGTGTGTTATTTTTTGG ATTTGTAAAAATATTTTCATGATATCTGTAAAGCTTGAGTATTTTGTGATGTTCGTTTT TTATAATTTAAATTTTGGTAAATATGTACAAAGGCACTTCGGGTCTATGTGACTATATT TTTTTGTATATAAATGTATTTATGGAATATTGTGCCAATGTTATTTGAGTTTTTTACTGT C

Figure 15

MGSRCALALAVLSALLCQVWSSGVFELKLQEFVNKKGLLGNRNCCRGGAGPPPCACRTFF RVCLKHYQASVSPEPPCTYGSAVTPVLGVDSFSLPDGGGADSAFSNPIRFPFGFTWPGTFSLI IEALHTDSPDDLATENPERLISRLATQRHLTVGEEWSQDLHSSGRTDLKYSYRFVCDEHYY GEGCSVFCRPRDDAFGHFTCGERGEKVCNPGWKGPYCTEPICLPGCDEQHGFCDKPGECK CRVGWQGRYCDECIRYPGCLHGTCQQPWQCNCQEGWGGLFCNQDLNYCTHHKPCKNGA TCTNTGQGSYTCSCRPGYTGATCELGIDECDPSPCKNGGSCTDLENSYSCTCPPGFYGKICE LSAMTCADGPCFNGGRCSDSPDGGYSCRCPVGYSGFNCEKKIDYCSSSPCSNGAKCVDLG DAYLCRCQAGFSGRHCDDNVDDCASSPCANGGTCRDGVNDFSCTCPPGYTGRNCSAPVSR CEHAPCHNGATCHQRGHGYVCECARSYGGPNCQFLLPELPPGPAVVDLTEKLEGQGGFFP WVAVCAGVILVLMLLLGCAAVVVCVRLRLQKHRPPADPCRGETETMNNLANCQREKDIS

VSIIGATQIKNTNKKADFHGDHSADKNGFKARYPAVDYNLVQDLKGDDTAVRDAHSKRD TKCQPQGSSGEEKGTPTTLRGGEASERKRPDSGCSTSKDTKYQSVYVISEEKDECVIATEV

Figure 16

ATGCCGCAGCGTCCCGGAGCGCCTCTGGCTGGCGCGCTACTGCTGCTGGTGGCACTTT GGCAGCAGCGCGCCGGCTCCGGCGTCTTCCAGCTGCAGCTGCAGGAGTTCATCAA CGAGCGCGCGTACTGGCCAGTGGGCGCCTTGCGAGCCCGGCTGCCGGACTTTCTTC CGCGTCTGCCTTAAGCACTTCCAGGCGGTCGTCTCGCCCGGACCCTGCACCTTCGGGAC GTCTCCACGCCGGTATTGGGCACCAACTCCTTCGCTGTCCGGGACGACAGTAGCGGCG GGGGGCGCAACCCTCTCCAACTGCCCTTCAATTTCACCTGGCCGGGTACCTTCTCGCT CATCATCGAAGCTTGGCACGCCCAGGAGACGACCTGCGGCCAGAGGCCTTGCCACCA GATGCACTCATCAGCAAGATCGCCATCCAGGGCTCCCTAGCTGTGGGTCAGAACTGGT TATTGGATGAGCAACCAGCACCCTCACAAGGCTGCGCTACTCTTACCGGGTCATCTGC AGTGACAACTACTATGGAGACAACTGCTCCCGCCTGTGCAAGAAGCGCAATGACCACT GAATATTGCCAACAGCCTATCTGTCTTTCGGGCTGTCATGAACAGAATGGCTACTGCA GCAAGCCAGCAGAGTGCCTCTGCCGCCCAGGCTGGCAGGCCGGCTGTGTAACGAATG CATCCCCACAATGGCTGTCGCCACGGCACCTGCAGCACTCCCTGGCAATGTACTTGTG CCCATGCAAGAATGGGGCAACGTGCTCCAACAGTGGGCAGCGAAGCTACACCTGCACC TGTCGCCCAGGCTACACTGGTGTGGACTGTGAGCTGGAGCTCAGCGAGTGTGACAGCA ACCCCTGTCGCAATGGAGGCAGCTGTAAGGACCAGGAGGATGGCTACCACTGCCTGTG TCCTCCGGGCTACTATGGCCTGCATTGTGAACACAGCACCTTGAGCTGCGCCGACTCCC CCTGCTTCAATGGGGGCTCCTGCCGGGAGCGCAACCAGGGGGCCAACTATGCTTGTGA ATGTCCCCCAACTTCACCGGCTCCAACTGCGAGAAGAAGTGGACAGGTGCACCAGC AACCCCTGTGCCAACGGGGACAGTGCCTGAACCAGGTCCAAGCCGCATGTGCCGCTG CCGTCCTGGATTCACGGGCACCTACTGTGAACTCCACGTCAGCGACTGTGCCCGTAACC CTTGCGCCCACGGTGGCACTTGCCATGACCTGGAGAATGGGCTCATGTGCACCTGCCC GTCCCTGCTTCAACAGGGCCACCTGCTACACCGACCTCTCCACAGACACCTTTGTGTGC AACTGCCCTTATGGCTTTGTGGGCAGCCGCTGCGAGTTCCCCGTGGGCTTGCCGCCCAG CTTCCCCTGGGTGGCCGTCTCGCTGGGTGTGGGGCTGGCAGTGCTGCTGGTACTGCTGG GCATGGTGGCAGTGGCTGTGCGGCAGCTGCGGCTTCGACGGCCGGACGACGCAGCAG GGAAGCCATGAACAACTTGTCGGACTTCCAGAAGGACAACCTGATTCCTGCCGCCAGC TTAAAAACACAAACCAGAAGAAGGAGCTGGAAGTGGACTGTGGCCTGGACAAGTCCA ACTGTGGCAACAGCAAAACCACACATTGGACTATAATCTGGCCCCAGGGCCCCTGGGG CACTGCGGTTACACAGTGAAAAGCCAGAGTGCGGATATCAGCGATATGCTCCCCCAGG CACGGAGGTATAA

Figure 17

MAAASRSASGWALLLLVALWQQRAAGSGVFQLQLQEFINERGVLASGRPCEPGCRTFFRV CLKHFQAVVSPGPCTFGTVSTPVLGTNSFAVRDDSSGGGRNPLQLPFNFTWPGTFSLIEAW HAPGDDLRPEALPPDALISKIAIQGSLAVGQNWLLDEQTSTLTRLRYSYRVICSDNYYGDN CSRLCKKRNDHFGHYVCQPDGNLSCLPGWTGEYCQQPICLSGCHEQNGYCSKPAECLCRP GWQGRLCNECIPHNGCRHGTCSTPWQCTCDEGWGGLFCDQDLNYCTHHSPCKNGATCSN SGQRSYTCTCRPGYTGVDCELELSECDSNPCRNGGSCKDQEDGYHCLCPPGYYGLHCEHS TLSCADSPCFNGGSCRERNQGANYACECPPNFTGSNCEKKVDRCTSNPCANGGQCLNR

GPSRMCRCRPGFTGTYCELHVSDCARNPCAHGGTCHDLENGLMCTCPAGFSGRRCEVRTS IDACASSPCFNRATCYTDLSTDTFVCNCPYGFVGSRCEFPVGLPPSFPWVAVSLGVGLAVLL VLLGMVAVAVRQLRLRRPDDGSREAMNNLSDFQKDNLIPAAQLKNTNQKKELEVDCGLD KSNCGKQQNHTLDYNLAPGPLGRGTMPGKFPHSDKSLGEKAPLRLHSEKPECRISAICSPR DSMYQSVCLISEERNECVIATEV


Figure 18

CTCGCAGGCTAGGAACCCGAGGCCAAGAGCTGCAGCCAAAGTCACTTGGGTGCAGTGT ACTCCCTCACTAGCCCGCTCGAGACCCTAGGATTTGCTCCAGGACACGTACTTAGAGCA GCCACCGCCCAGTCGCCCTCACCTGGATTACCTACCGAGGCATCGAGCAGCGGAGTTT TTGAGAAGGCGACAAGGGAGCAGCGTCCCGAGGGAATCAGCTTTTCAGGAACTCGGCT GGCAGACGGGACTTGCGGGAGAGCGACATCCCTAACAAGCAGATTCGGAGTCCCGGA GTGGAGAGGACACCCCAAGGGATGACGCCTGCGTCCCGGAGCGCCTGTCGCTGGGCGT ACTGCTGCTGGCGGTACTGTGGCCGCAGCAGCGCGCTGCGGGCTCCGGCATCTTCCAG CTGCGGCTGCAGGAGTTCGTCAACCAGCGCGGTATGCTGGCCAATGGGCAGTCCTGCG AACCGGGCTGCCGGACTTTCTTCCGCATTTGCCTTAAGCACTTCCAGGCAACCTTCTCC GAGGGACCTGCACCTTTGGCAATGTCTCCACGCCGGTATTGGGCACCAACTCCTTCGT CGTCAGGGACAAGAATAGCGGCAGTGGTCGCAACCCTCTGCAGTTGCCCTTCAATTTC ACCTGGCCGGGAACCTTCTCACTCAACATCCAAGCTTGGCACACACCGGGAGACGACC TGCGGCCAGAGACTTCGCCAGGAAACTCTCTCATCAGCCAAATCATCATCCAAGGCTC TCTTGCTGTGGGTAAGATTTGGCGAACAGACGAGCAAAATGACACCCTCACCAGACTG AGCTACTCTTACCGGGTCATCTGCAGTGACAACTACTATGGAGAGAGCTGTTCTCGCCT TCCTGCCTGCCGGGCTGGACTGGGAAGTACTGTGACCAGCCTATATGTCTTTCTGGCTG TCATGAGCAGAATGGTTACTGCAGCAAGCCAGATGAGTGCATCTGCCGTCCAGGTTGG CAGGGTCGCCTGTGCAATGAATGTATCCCCCACAATGGCTGTCGTCATGGCACCTGCA GCATCCCCTGGCAGTGTGCCTGCGATGAGGGATGGGGAGGTCTGTTTTGTGACCAAGA TCTCAACTACTGTACTCACCACTCTCCGTGCAAGAATGGATCAACGTGTTCCAACAGTG GGCCAAAGGGTTATACCTGCACCTGTCTCCCAGGCTACACTGGTGAGCACTGTGAGCT GGGACTCAGCAAGTGTGCCAGCAACCCCTGTCGAAATGGTGGCAGCTGTAAGGACCAG GAGAATAGCTACCACTGCCTGTGTCCCCCAGGCTACTATGGCCAGCACTGTGAGCATA GTACCTTGACCTGTGCGGACTCACCCTGCTTCAATGGGGGCTCTTGCCGGGAGCGCAAC CAGGGGTCCAGTTATGCCTGCGAATGCCCCCCAACTTTACCGGCTCTAACTGTGAGAA GAAAGTAGACAGGTGTACCAGCAACCCGTGTGCCAATGGAGGCCAGTGCCTGAACAG AGGTCCAAGCCGAACCTGCCGCTGCCGGCCTGGATTCACAGGCACCCACTGTGAACTG CACATCAGCGATTGTGCCCGAAGTCCCTGTGCCCACGGGGGCACTTGCCACGATCTGG AGAATGGGCCTGTGTGCACCTGCCCCGCTGGCTTCTCTGGCAGGCGCTGCGAGGTGCG GATAACCCACGATGCCTGTGCCTCCGGACCCTGCTTCAATGGGGCCACCTGCTACACTG GCCTCTCCCCAAACAACTTCGTCTGCAACTGTCCTTATGGCTTTGTGGGCAGCCGCTGC GAGTTTCCCGTGGGCTTGCCACCCAGCTTCCCCTGGGTAGCTGTCTCGCTGGGCGTGGG GCTAGTGGTACTGCTGGTGCTGGTCATGGTGGTAGTGGCTGCGGCAGCTGCGGC TTCGGAGGCCCGATGACGAGAGCAGGGAAGCCATGAACAATCTGCAGACTTCCAGAA GGACAACCTAATCCCTGCCGCCCAGCTCAAAAACACAAACCAGAAGAAGAAGGAGCTGGA GTGGACTGTGGTCTGGACAAGTCCAATTGTGGCAAACTGCAGAACCACACATTGGACT ACAATCTAGCCCCGGGACTCCTAGGACGGGCAGCATGCCTGGGAAGTATCCTCACAG TGACAAGAGCTTAGGAGAGAAGTGCCACTTCGGTTACACAGTGAGAAGCCAGAGTGTC GAATATCAGCCATTTGCTCTCCCAGGGACTCTATGTACCAATCAGTGTGTTTGATATCA GAAGAGAGGAACGAGTGTGTGATTGCCACAGAGGTATAAGGCAGAGCCTACTCAGAC ACCCAGCTCCGGCCCAGCAGCTGGGCCTTCCTTCTGCATTGTTTACATTGCATCCTGT ATGGGACATCTTTAGTATGCACAGTGCTGCTCTGCGGAGGAGGAGGAATGGCATGAA CTGAACAGACGTGAACCCGCCAAGAGTTGCACCGGCTCTGCACACCTCCAGGAGTCTG

Figure 19


MTPASRSACRWALLLLAVLWPQQRAAGSGIFQLRLQEFVNQRGMLANGQSCEPGCRTFFR ICLKHFQATFSEGPCTFGNVSTPVLGTNSFVVRDKNSGSGRNPLQLPFNFTWPGTFSLNIQA WHTPGDDLRPETSPGNSLISQIIIQGSLAVGKIWRTDEQNDTLTRLSYSYRVICSDNYYGESC SRLCKKRDDHFGHYECQPDGSLSCLPGWTGKYCDQPICLSGCHEQNGYCSKPDECICRPG WQGRLCNECIPHNGCRHGTCSIPWQCACDEGWGGLFCDQDLNYCTHHSPCKNGSTCSNS GPKGYTCTCLPGYTGEHCELGLSKCASNPCRNGGSCKDQENSYHCLCPPGYYGQHCEHST LTCADSPCFNGGSCRERNQGSSYACECPPNFTGSNCEKKVDRCTSNPCANGGQCLNRGPSR TCRCRPGFTGTHCELHISDCARSPCAHGGTCHDLENGPVCTCPAGFSGRRCEVRITHDACA SGPCFNGATCYTGLSPNNFVCNCPYGFVGSRCEFPVGLPPSFPWVAVSLGVGLVVLLVLV MVVVAVRQLRLRRPDDESREAMNNLSDFQKDNLIPAAQLKNTNQKKELEVDCGLDKSNC GKLQNHTLDYNLAPGLLGRGSMPGKYPHSDKSLGEKVPLRLHSEKPECRISAICSPRDSMY QSVCLISEERNECVIATEV

Figure 20



Western blot analysis of Notch 2 expression in human germ cell tumour derived cell lines.

Western blot probed with antibody specific for the intracellular portion of human NOTCH2 and visualised using chemilumenesence. Lanes from left to right 1: BeWo, 2: TERA-1, 3: 833KE, 4: 2102 Ep 2A6, 5: 2102 Ep 4D3, 6: NTERA2/D1 8 days exposure to retinoic acid, 7: NTERA2/D1 EC cells. Molecular weight markers are indicated on the right in kDa. Notch2 protein product is visualized at apprx 100 kDa






Figure 21

Figure 22

AAACCACTCCACCTTACTACCAGACAACCTTAGCCAAACCATTTACCCAAATAAAGT ATAGGCGATAGAAATTGAAACCTGGCGCAATAGATATAGTACCGCAAGGGAAAGATG AAAAATTATAACCAAGCATAATATAGCAAGGACTAACCCCTATACCTTCTGCATAATG AATTAACTAGAAATAACTTTGCAAGGAGAGTCAAAGCTAAGGCCCCCGAAACCAGGCG AGCTACCTAAGAACAGCTAAAAGAGCACACCCGTCTATGTAGCAAAATAGTGGGAAG ATTTATAGGTAGAGGCGACAAACCTACCGAGCCTGGTGATAGCTGGTTGTCCAAGATA GAATCTTAGTTCAACTTTAAATTTGCCCACAGAACCCTCTAAATCCCCTTGTAAATTTA ACTGTTAGTCCAAAGAGGAACAGCTCTTTGGACACTAGGAAAAAACCTTGTAGAGAGA GTGTCAGCCCAATTCCACACTTTTCCACATGTTGGATGGCCTTGGAGTGGTAGCCATAA GCATTTTTGGAATTCAACTAAAAACTGAAGGATCCTTGAGGACGGCAGTACCTGGCAT ACCTACACAGTCAGCGTTCAACAAGTGTTTGCAAAGGTACATTGGGGCACTGGGGGCA CGAGTGATCTGTGACAATATCCCTGGTTTGGTGAGCCGGCAGCGGCAGCTGTGCCAGC GTTACCCAGACATCATGCGTTCAGTGGGCGAGGGTGCCCGAGAATGGATCCGAGAGTG TCAGCACCAATTCCGCCACCACCGCTGGAACTGTACCACCCTGGACCGGGACCACACC GTCTTTGGCCGTGTCATGCTCAGAAGTAGCCGAGAGGCAGCTTTTGTATATGCCATCTC ATCAGCAGGGTGATCCACGCTATTACTCGCGCCTGTAGCCAGGGTGAACTGAGTGTG TGCAGCTGTGACCCCTACACCCGTGGCCGACACCATGACCAGCGTGGGACTTTTGACT GGGGTGGCTGCAGTGACAACATCCACTACGGTGTCCGTTTTGCCAAGGCCTTCGTGGAT GCCAAGGAGAAGAGGCTTAAGGATGCCCGGGCCCTCATGAACTTACATAATAACCGCT GTGGTCGCACGGCTGTGCGGCGGTTTGTCAAGCTGGAGTGTAAGTGCCATGGCGTGAG TGGTTCCTGTACTCTGCGCACCTGCTGCGTGCACTCTCAGATTTCCGCCGCACAGGTG ATTACCTGCGGCGACGCTATGATGGGGCTGTGCAGGTGATGGCCACCCAAGATGGTGC CAACTTCACCGCAGCCCGCCAAGGCTATCGCCGTGCCACCCGGAGTGATCTTGTCTACT TTGACAACTCTCCAGATTACTGTGTCTTGGACAAGGCTGCAGGTTCCCTAGGCACTGCA GGCCGTGTCTGCAGCAAGACATCAAAAGGAACAGACGGTTGTGAAATCATGTGCTGTG GCCGAGGGTACGACACACTCGAGTCACCCGTGTTACCCAGTGTGAGTGCAAATTCCA CTGGTGCTGTGCGGTGCAAGGAATGCAGAAATACTGTGGACGTCCATACTTGC AAAGCCCCCAAGAAGGCAGAGTGGCTGGACCAGACCTGAACACACAGATACCTCACT CTCCACCCTCCACCCTGGGCTGCTACCGCTTCTATTTAAGGATGTAGAGAGTAATCCAT AGGGACCATGGTGTCCTGGCTGCTTAGCCCTGGGAAGGAGTTGTCAGGGGATAT AAGAAACTGTGCAAGCTCCCTGATTTCCCGCTCTGGAGATTTGAAGGGAGAGTAGAAG AGATAGGGGGTCTTTAGAGTGAAATGAGTTGCACTAAAGTACGTAGTTGAGGCTCCTT TTTTCTTTCCTTTGCACCAGCTTCCCGACACTTCTTGGTGTGCAAGAGGAAGGGTACCT GTAGAGAGCTTCTTTTTGTTTCTACCTGGCCAAAGTTAGATGGGACAAAGATGAATGGC TAGGCTACCACATTCTATTATTGAGAGCCTGAGATGTTAGCCATAGTGGACAAGGTTCC ATTCACATGCTCATATGTTTATAAACTGTGTTTTGTAGAAGAAAAAGAATCATAACAAT ACAAACACACATTCATTCTCTTTTTCTCTCTACCATTCTCAACCTGTATTGGACAGCA CTGCCTCTTTTGCTTACTTGCTGCCTGTTCAAACTGAGGTGGAATGCAGTGGTTCCCATG CTTAACAGATCATTAAAACACCCTAGAACACTCCTAGGATAGATTAATGT

Fig 23 FRP WIF Wnt DSL ligands Extracellular Dickkopf Cerberus Dally Notch Frizzled CBF-1 Dishevelled Intracellular Activation - Inhibition GSK-3β Transcription Axin | β-catenin APC Transcription of Notch target genes TLE TCF CBP Transcription or repression of Wnt target genes Nucleus






Figure 24

Dishevelled



GSK-3β,Axin,APC



-3.5Kb — TCF1

Figure 25

Figure 26

ACCGCAGGGGCTCCCGGACCCTGACTCTGCAGCCGAACCGGCACGGTTTCGTGGGGA CCCAGGCTTGCAAAGTGACGGTCATTTTCTCTTTCTTCTCCCTCTTGAGTCCTTCTGAG ATGATGGCTCTGGGCGCAGCGGGAGCTACCCGGGTCTTTGTCGCGATGGTAGCGGCGG CTCTCGGCGGCCACCTCTGCTGGGAGTGAGCGCCACCTTGAACTCGGTTCTCAATTCC AACGCTATCAAGAACCTGCCCCCACCGCTGGGCGCGCTGCGGGGCACCCAGGCTCTG CAGTCAGCGCCGCGCGGAATCCTGTACCCGGGCGGGAATAAGTACCAGACCATTGA CAACTACCAGCCGTACCCGTGCGCAGAGGACGAGGAGTGCGGCACTGATGAGTACTGC GCTAGTCCCACCCGCGGAGGGGACGCAGGCGTGCAAATCTGTCTCGCCTGCAGGAAGC GCCGAAAACGCTGCATGCGTCACGCTATGTGCTGCCCCGGGAATTACTGCAAAAATGG AATATGTGTGTCTTCTGATCAAAATCATTTCCGAGGAGAAATTGAGGAAACCATCACTG AAAGCTTTGGTAATGATCATAGCACCTTGGATGGGTATTCCAGAAGAACCACCTTGTCT TCAAAAATGTATCACACCAAAGGACAAGAAGGTTCTGTTTGTCTCCGGTCATCAGACT GTGCCTCAGGATTGTGTTGTGCTAGACACTTCTGGTCCAAGATCTGTAAACCTGTCCTG AAAGAAGGTCAAGTGTGTACCAAGCATAGGAGAAAAGGCTCTCATGGACTAGAAATA TTCCAGCGTTGTTACTGTGGAGAAGGTCTGTCTTGCCGGATACAGAAAGATCACCATCA AGCCAGTAATTCTTCTAGGCTTCACACTTGTCAGAGACACTAAACCAGCTATCCAAATG CAGTGAACTCCTTTTATATAATAGATGCTATGAAAACCTTTTATGACCTTCATCAACTC AATCCTAAGGATATACAAGTTCTGTGGTTTCAGTTAAGCATTCCAATAACACCTTCCAA AAACCTGGAGTGTAAGAGCTTTGTTTCTTTATGGAACTCCCCTGTGATTGCAGTAAATT ACTGTATTGTAAATTCTCAGTGTGGCACTTACCTGTAAATGCAATGAAACTTTTAATTA TTTTTCTAAAGGTGCTGCACTGCCTATTTTTCCTCTTGTTATGTAAATTTTTGTACACATT GATTGTTATCTTGACTGACAAATATTCTATATTGAACTGAAGTAAATCATTTCAGCTTA TAGTTCTTAAAAGCATAACCCTTTACCCCATTTAATTCTAGAGTCTAGAACGCAAGGAT CTCTTGGAATGACAAATGATAGGTACCTAAAATGTAACATGAAAATACTAGCTTATTTT CTGAAATGTACTATCTTAATGCTTAAATTATATTTCCCTTTAGGCTGTGATAGTTTTTGA AATAAAATTTAACATTTAATATCATGAAATGTTATAA

Figure 27

AGAAAGCGGAGCCCGCGCGAGCGTAGCGCAAGTCCGCTCCCTAGGCATCGCTGCGC TGGCAGCGATTCGCTGTCTTGTGAGTCAGGGGACAACGCTTCGGGGCAACTGTGAG TGCGCGTGTGGGGGACCTCGATTCTCTTCAGATCTCGAGGATTCGGTCCGGGGACGTCT CCTGATCCCCTACTAAAGCGCCTGCTAACTTTGAAAAGGAGCACTGTGTCCTGCAAAGT TTGACACATAAAGGATAGGAAAAGAGAGAGAGAAAAGCAACTGAGTTGAAGGAGAA GGAGCTGATGCGGGCCTCCTGATCAATTAAGAGGAGAGTTAAACCGCCGAGATCCCGG CGGGACCAAGGAGGTGCGGGCAAGAAGGAACGGAAGCGGTGCGATCCACAGGGCTG GGTTTTCTTGCACCTTGGGTCACGCCTCCTTGGCGAGAAAGCGCCTCGCATTTGATTGC TTCCAGTTATTGCAGAACTTCCTGTCCTGGTGGAGAAGCGGGTCTCGCTTGGGTTCCGC TAATTTCTGTCCTGAGGCGTGAGACTGAGTTCATAGGGTCCTGGGTCCCCGAACCAGGA AGGGTTGAGGGAACACAATCTGCAAGCCCCCGCGACCCAAGTGAGGGGCCCCGTGTTG GGGTCCTCCCTTTGCATTCCCACCCCTCCGGGCTTTGCGTCTTCCTGGGGACCCCC TCGCCGGGAGATGGCCGCGTTGATGCGGAGCAAGGATTCGTCCTGCTGCTGCTCCTA CTGGCCGCGGTGCTGATGGTGGAGAGCTCACAGATCGGCAGTTCGCGGGCCAAACTCA ACTCCATCAAGTCCTCTCTGGGCGGGGAGACGCCTGGTCAGGCCGCCAATCGATCTGC GGGCATGTACCAAGGACTGGCATTCGGCGGCAGTAAGAAGGGCAAAAACCTGGGGCA GGCCTACCCTTGTAGCAGTGATAAGGAGTGTGAAGTTGGGAGGTATTGCCACAGTCCC CACCAAGGATCATCGGCCTGCATGGTGTCGGAGAAAAAAGAAGCGCTGCCACCGA GATGGCATGTGCCCCAGTACCCGCTGCAATAATGGCATCTGTATCCCAGTTACTGA AAGCATCTTAACCCCTCACATCCCGGCTCTGGATGGTACTCGGCACAGAGATCGAAAC CACGGTCATTACTCAAACCATGACTTGGGATGGCAGAATCTAGGAAGACCACACACTA AGATGTCACATATAAAAGGGCATGAAGGAGACCCCTGCCTACGATCATCAGACTGCAT TGAAGGGTTTTGCTGTCCTCATTTCTGGACCAAAATCTGCAAACCAGTGCTCCATC AGGGGGAAGTCTGTACCAAACAACGCAAGAAGGGTTCTCATGGGCTGGAAATTTTCCA GCGTTGCGACTGTGCGAAGGGCCTGTCTTGCAAAGTATGGAAAGATGCCACCTACTCC TCCAAAGCCAGACTCCATGTGTGTCAGAAAATTTGATCACCATTGAGGAACATCATCA ATTGCAGACTGTGAAGTTGTGTATTTAATGCATTATAGCATGGTGGAAAATAAGGTTCA GATGCAGAAGAATGGCTAAAATAAGAAACGTGATAAGAATATAGATGATCACAAAAA GGGAGAAAGAAACATGAACTGAATAGATTAGAATGGGTGACAAATGCAGTGCAGCC AGTGTTTCCATTATGCAACTTGTCTATGTAAATAATGTACACATTTGTGGAAAATGCTA TTATTAAGAGAACAAGCACAGTGGAAATTACTGATGAGTAGCATGTGACTTTCCAA GAGTTTAGGTTGTGCTGGAGGAGGGTTTCCTTCAGATTGCTGATTGCTTATACAAATA ACCTACATGCCAGATTTCTATTCAACGTTAGAGTTTAACAAAATACTCCTAGAATAACT TGTTATACAATAGGTTCTAAAAATAAAATTGCTAAACAAGAAATGAAAACATGGAGCA TTGTTAATTTACAACAGAAAATTACCTTTTGATTTGTAACACTACTTCTGCTGTTCAATC AAGAGTCTTGGTAGATAAGAAAAAAATCAGTCAATATTTCCAAATAATTGCAAAATAA AAAAACAGTTCCTTCAGATTCTACGGAATGACAGTATATCTCTCTTTATCCTATGTGAT TCCTGCTCTGAATGCATTATATTTTCCAAACTATACCCATAAATTGTGACTAGTAAAAT ACTTACACAGAGCAGAATTTTCACAGATGGCAAAAAAATTTAAAGATGTCCAATATAT GTGGGAAAAGAGCTAACAGAGAGATCATTATTTCTTAAAGATTGGCCATAACCTGTAT TTGAGCTGGATCTGTACTGCACTGGAGTAAGCAAGAAAATTGGGAAAACTTTTTCGTTT GTTCAGGTTTTGGCAACACATAGATCATATGTCTGAGGCACAAGTTGGCTGTTCATCTT TGAAACCAGGGGATGCACAGTCTAAATGAATATCTGCATGGGATTTGCTATCATAATA TTTACTATGCAGATGAATTCAGTGTGAGGTCCTGTGTCCGTACTATCCTCAAATTATTTA TTTTATAGTGCTGAGATCCTCAAATAATCTCAATTTCAGGAGGTTTCACAAAATGGACT

Figure 28

ACCTCGGCTCCAGTCAAGCCCGGCCCGGCTCTCAGCTACCCGCAGGAGGAGGCCACCC TCAATGAGATGTTCCGCGAGGTTGAGGAACTGATGGAGGACACGCAGCACAAATTGCG CAGCGCGGTGGAAGAGATGGAGGCAGAAGAAGCTGCTGCTAAAGCATCATCAGAAGT GAACCTGGCAAACTTACCTCCCAGCTATCACAATGAGACCAACACAGACACGAAGGTT GGAAATAATACCATCCATGTGCACCGAGAAATTCACAAGATAACCAACAACCAGACTG GACAAATGGTCTTTTCAGAGACAGTTATCACATCTGTGGGAGACGAAGAAGGCAGAAG GAGCCACGAGTGCATCATCGACGAGGACTGTGGGCCCAGCATGTACTGCCAGTTTGCC AGCTTCCAGTACACCTGCCAGCCATGCCGGGGCCAGAGGATGCTCTGCACCCGGGACA GTGAGTGCTGTGGAGACCAGCTGTGTGTCTGGGGTCACTGCACCAAAATGGCCACCAG GGGCAGCAATGGGACCATCTGTGACAACCAGAGGGACTGCCAGCCGGGGCTGTGCTGT GCCTTCCAGAGAGGCCTGCTGTTCCCTGTGTGCACACCCCTGCCCGTGGAGGGCGAGCT TTGCCATGACCCCGCCAGCCGCTTCTGGACCTCATCACCTGGGAGCTAGAGCCTGATG GAGCCTTGGACCGATGCCCTTGTGCCAGTGGCCTCCTCTGCCAGCCCCACAGCCACAGC CTGGTGTATGTGTGCAAGCCGACCTTCGTGGGGAGCCGTGACCAAGATGGGGAGATCC TGCTGCCCAGAGAGGTCCCCGATGAGTATGAAGTTGGCAGCTTCATGGAGGAGGTGCG CCAGGAGCTGGAGGACCTGAGGAGCCTGACTGAAGAGATGGCGCTGGGGGAGCC TGCGGCTGCCGCCGCTGCACTGCTGGGAGGGGAAGAGATTTAGATCTGGACCAGGCTG TGGGTAGATGTGCAATAGAAATAGCTAATTTATTTCCCCAGGTGTGTGCTTTAGGCGTG GGCTGACCAGGCTTCTTCCTACATCTTCTTCCCAGTAAGTTTCCCCTCTGGCTTGACAGC ATGAGGTGTTGTGCATTTGTTCAGCTCCCCCAGGCTGTTCTCCAGGCTTCACAGTCTGG TGCTTGGGAGAGTCAGGCAGGGTTAAACTGCAGGAGCAGTTTGCCACCCCTGTCCAGA TTATTGGCTGCTTTGCCTCTACCAGTTGGCAGACAGCCGTTTGTTCTACATGGCTTTGAT AATTGTTTGAGGGGAGGAGATGGAAACAATGTGGAGTCTCCCTCTGATTGGTTTTGGG GAAATGTGGAGAAGAGTGCCCTGCTTTGCAAACATCAACCTGGCAAAAATGCAACAA TGAATTTTCCACGCAGTTCTTTCCATGGGCATAGGTAAGCTGTGCCTTCAGCTGTTGCA GATGAAATGTTCTGTTCACCCTGCATTACATGTGTTTATTCATCCAGCAGTGTTGCTCAG 26/66

Figure 29

GACAAACAGACGTGCTGAGCTGCCAGCTTAGTGGAAGCTCTGCTCTGGGTGGAGA
GCAGCCTCGCTTTGGTGACGCACAGTGCTGGGACCCTCCAGGAGCCCCGGGATTGAAG
GATGGTGGCGGCCGTCCTGCTGGGGCTGAGCTGGCTCTGCTCTCCCCTGGGAGCTCTGG
TCCTGGACTTCAACAACATCAGGAGCTCTGCTGACCTGCATGGGGCCCGGAAGGGCTC
ACAGTGCCTGTCTGACACGGACTGCAATACCAGAAAGTTCTGCCTCCAGCCCCGCGAT
GAGAAGCCGTTCTGTGCTACATGTCGTGGGTTGCGGAGGAGGTGCCAGCGAGATGCCA
TGTGCTGCCCTGGGACACTCTGTGTGAACGATGTTTGTACTACGATGGAAGATGCAACC
CCAATATTAGAAAGGCAGCTTGATGAGCAAGATGGCACACATGCAGAAGGAACACT
GGGCACCCAGTCCAGGAAAACCAACCCAAAAGGAAGCCAAGTATTAAGAAATCACAA
GGCAGGAAGGGACAAGAGGGAGAAAAGTTGTCTGAGAACTTTTGACTGTGGCCCTGGAC
TTTGCTGTGCTCGTCATTTTTGGACGAAAATTTGTAAGCCAGTCCTTTTGGAGGGACAG
GTCTGCTCCAGAAGAGGGCATAAAGACACTGCTCAAGCTCCAGAAATCTTCCAGCGTT
GCGACTGTGGCCCTGGACTACTGTTGTCGAAGCCAATTGACCAGCAATCGGCAGCATGC
TCGATTAAGAGTATGCCAAAAAAATAGAAAAAGCTATAAAATATTTCAAAAATAAAAGAAAA
TCCACATTGCATTTGAG

Figure 30

Figure 31

MGLWALLPGWVSATLLLALAALPAALAANSSGRWWGIVNVASSTNLLTDSKSLQLVLEPS LQLLSRKQRRLIRQNPGILHSVSGGLQSAVRECKWQFRNRRWNCPTAPGPHLFGKIVNRGC RETAFIFAITSAGVTHSVARSCSEGSIESCTCDYRRRGPGGPDWHWGGCSDNIDFGRLFGRE FVDSGEKGRDLRFLMNLHNNEAGRTTVFSEMRQECKCHGMSGSCTVRTCWMRLPTLRAV GDVLRDRFDGASRVLYGNRGSNRASRAELLRLEPEDPAHKPPSPHDLVYFEKSPNFCTYSG RLGTAGTAGRACNSSSPALDGCELLCCGRGHRTRTQRVTERCNCTFHWCCHVSCRNCTHT RVLHECL

Figure 32

AGCAGAGCGGACGGCGCGCGGGAGGCGCAGAGCTTTCGGGCTGCAGGCGCTCGC GGGCCCATCGTTTGAAACTTTATCAGCGAGTCGCCACTCGTCGCAGGACCGAGCGGG GGCGGGGGCGCGAGGCGCGGCGTGACGAGGCGCTCCCGGAGCTGAGCGCTTC TGCTCTGGGCACGCATGGCGCCCGCACACGGAGTCTGACCTGATGCAGACGCAAGGGG GTTAATATGAACGCCCCTCTCGGTGGAATCTGGCTCTGGCTCCCTCTGCTCTTGACCTG GCTCACCCCGAGGTCAACTCTTCATGGTGGTACATGAGAGCTACAGGTGGCTCCTCCA ACATCCAGATGTGATGCGTGCCATTAGCCAGGGCGTGGCCGAGTGGACAGCAGAATGC CAGCACCAGTTCCGCCAGCACCGCTGGAATTGCAACACCCTGGACAGGGATCACAGCC TTTTTGGCAGGGTCCTACTCCGAAGTAGTCGGGAATCTGCCTTTGTTTATGCCATCTCCT CAGCTGGAGTTGTATTTGCCATCACCAGGGCCTGTAGCCAAGGAGAAGTAAAATCCTG TTCCTGTGATCCAAAGAAGATGGGAAGCGCCAAGGACAGCAAAGGCATTTTTGATTGG GGTGGCTGCAGTGATAACATTGACTATGGGATCAAATTTGCCCGCGCATTTGTGGATGC AAAGGAAAGGAAAGGATGCCAGAGCCCTGATGAATCTTCACAACAACAGAGC TGGCAGGAAGGCTGTAAAGCGGTTCTTGAAACAAGAGTGCCAAGTGCCACGGGGTGAG CGGCTCATGTACTCTCAGGACATGCTGGCTGGCCATGGCCGACTTCAGGAAAACGGGC GATTATCTCTGGAGGAAGTACAATGGGGCCATCCAGGTGGTCATGAACCAGGATGGCA CAGGTTTCACTGTGGCTAACGAGAGGTTTAAGAAGCCAACGAAAAATGACCTCGTGTA GCAGGCCGTGTGTGCAACCTGACTTCCCGGGGCATGGACAGCTGTGAAGTCATGTGCT GTGGGAGAGGCTACGACACCTCCCATGTCACCCGGATGACCAAGTGTGGGTGTAAGTT CCACTGGTGCTGCGCCGTGCGCTGTCAGGACTGCCTGGAAGCTCTGGATGTGCACACA TGCAAGGCCCCAAGAACGCTGACTGGACAACCGCTACATGACCCCAGCAGGCGTCAC CATCACCTTCCCTTCTACAAGGACTCCATTGGATCTGCAAGAACACTGGACCTTTGGG TTCTTTCTGGGGGGATATTTCCTAAGGCATGTGGCCTTTATCTCAACGGAAGCCCCCTC TTCCTCCTGGGGGCCCCAGGATGGGGGGCCACACGCTGCACCTAAAGCCTACCCTAT

Figure 33

MNAPLGGIWLWLPLLLTWLTPEVNSSWWYMRATGGSSRVMCDNVPGLVSSQRQLCHRH PDVMRAISQGVAEWTAECQHQFRQHRWNCNTLDRDHSLFGRVLLRSSRESAFVYAISSAG VVFAITRACSQGEVKSCSCDPKKMGSAKDSKGIFDWGGCSDNIDYGIKFARAFVDAKERK GKDARALMNLHNNRAGRKAVKRFLKQECKCHGVSGSCTLRTCWLAMADFRKTGDYLW RKYNGAIQVVMNQDGTGFTVANERFKKPTKNDLVYFENSPDYCIRDREAGSLGTAGRVC NLTSRGMDSCEVMCCGRGYDTSHVTRMTKCGCKFHWCCAVRCQDCLEALDVHTCKAPK NADWTTAT

Figure 34

CGGGAGTCTTCGGGGAGCTATGCTGAGACCGGGTGGTGCGGAGGAAGCTGCGCAGCTC CCGCTTCGGCGCCCAGCGCCCCGGTCCCTGTGCCGTCGCCCGCGCCCCCGACGGCTC CCGGGCTTCGGCCCGCCTAGGTCTTGCCTGCCTTCTGCTCCTGCTGCTGCTGACGCTGC CGGCCCGCGTAGACACGTCCTGGTGGTACATTGGGGCACTGGGGGCACGAGTGATCTG TGACAATATCCCTGGTTTGGTGAGCCGGCAGCGCAGCTGTGCCAGCGTTACCCAGAC ATCATGCGTTCAGTGGGCGAGGGTGCCCGAGAATGGATCCGAGAGTGTCAGCACCAAT TCCGCCACCACCGCTGGAACTGTACCACCCTGGACCGGACCACACCGTCTTTGGCCGT GTCATGCTCAGAAGTAGCCGAGAGGCAGCTTTTGTATATGCCATCTCATCAGCAGGGG TAGTCCACGCTATTACTCGCGCCTGTAGCCAGGGTGAACTGAGTGTGTGCAGCTGTGAC CCCTACACCCGTGGCCGACACCATGACCAGCGTGGGGACTTTGACTGGGGTGGCTGCA GTGACAACATCCACTACGGTGTCCGTTTTGCCAAGGCCTTCGTGGATGCCAAGGAGAA GAGGCTTAAGGATGCCCGGGCCCTCATGAACTTACATAATAACCGCTGTGGTCGCACG GCTGTGCGGCGGTTTCTGAAGCTGGAGTGTAAGTGCCATGGCGTGAGTGGTTCCTGTAC TCTGCGCACCTGCTGGCGTGCACTCTCAGATTTCCGCCGCACAGGTGATTACCTGCGGC GACGCTATGATGGGGCTGTGCAGGTGATGGCCACCCAAGATGGTGCCAACTTCACCGC AGCCCGCCAAGGCTATCGCCGTGCCACCCGGACTGATCTTGTCTACTTTGACAACTCTC CAGATTACTGTGTCTTGGACAAGGCTGCAGGTTCCCTAGGCACTGCAGGCCGTGTCTGC AGCAAGACATCAAAAGGAACAGACGGTTGTGAAATCATGTGCTGTGGCCGAGGGTAC GACACAACTCGAGTCACCCGTGTTACCCAGTGTGAGTGCAAATTCCACTGGTGCTGTGC TGTACGGTGCAAGGAATGCAGAAATACTGTGGACGTCCATACTTGCAAAGCCCCCAAG CAAGCCTCTCAACTCAAAAGCACAAGATCCTTGCATGCACACCTTCCTCCACCCTCCAC CCTGGGCTGCTACCGCTTCTATTTAAGGATGTAGAGAGTAATCCATAGGGACCATGGTG TCCTGGCTGGTTCCTTAGCCCTGGGAAGGAGTTGTCAGGGGATATAAGAAACTGTGCA AGCTCCCTGATTTCCCGCTCTGGAGATTTGAAGGGAGAGTAGAAGAGATAGGGGGTCT 29/66

ACCAGCTTCCCGACACTTCTTGGTGTGCAAGAGGAAGGGTACCTGTAGAGAGCTTCTTT
TTGTTTCTACCTGGCCAAAGTTAGATGGGACAAAGATGAATGGCATGTCCCTTCTCTGA
AGTCCGTTTGAGCAGAACTACCTGGTACCCCGAAAGAAAAATCTTAGGCTACCACATT
CTATTATTGAGAGCCTGAGATGTTAGCCATAGTGGACAAGGTTCCATTCACATGCTCAT
ATGTTTATAAACTGTGTTTTGTAGAAGAAAAAAGAATCATAACAATACAAACACACATT
CATTCTCTCTTTTTCTCTCTACCATTCTCAACCTGTATTGGACAGCACTGCCTCTTTTGCT
TACTTGCTGCCTGTTCAAACTGAGGTGGAATGCAGTGGTTCCCATGCTTAACAGATCAT
TAAAACACCCTAGAACACTCCTAGGATAGATTAATGT

Figure 35

MLDGLGVVAISIFGIQLKTEGSLRTAVPGIPTQSAFNKCLQRYIGALGARVICDNIPGLVSRQ RQLCQRYPDIMRSVGEGAREWIRECQHQFRHHRWNCTTLDRDHTVFGRVMLRSSREAAF VYAISSAGVIHAITRACSQGELSVCSCDPYTRGRHHDQRGTFDWGGCSDNIHYGVRFAKAF VDAKEKRLKDARALMNLHNNRCGRTAVRRFVKLECKCHGVSGSCTLRTCWRALSDFRRT GDYLRRRYDGAVQVMATQDGANFTAARQGYRRATRSDLVYFDNSPDYCVLDKAAGSLG TAGRVCSKTSKGTDGCEIMCCGRGYDTTRVTRVTQCECKFHWCCAVRCKECRNTVDVHT CKAPKKAEWLDQT

Figure 36

GCGCTTCTGACAAGCCCGAAAGTCATTTCCAATCTCAAGTGGACTTTGTTCCAACTATT GGGGCGTCGCTCCCCTCYTCATGGTCGCGGGCAAACTTCCTCCTCGGCGCCTCTTCT AATGGAGCCCACCTGCTCGGGCTGCTCCTCGGCCTCCTGGTGGCACCAGGGTCC TCGCTGGCTACCCAATTTGGTGGTCCCTGGCCCTGGGCCAGCAGTACACATCTCTGGGC TCACAGCCCCTGCTCTGCGGCTCCATCCCAGGCCTGGTCCCCAAGCAACTGCGCTTCTG CCGCAATTACATCGAGATCATGCCCAGCGTGGCCGAGGGCGTGAAGCTGGGCATCCAG GAGTGCCAGCACCAGTTCCGGGGCCGCCGCTGGAACTGCACCACCATAGATGACAGCC TGGCCATCTTTGGGCCCGTCCTCGACAAAGCCACCGCGAGTCGGCCTTCGTTCACGCC ATCGCCTCGGCCGGCGTGGCCTTCGCCGTCACCCGCTCCTGCGCCGAGGGCACCTCCAC CATTTGCGGCTGTGACTCGCATCATAAGGGGCCGCCTGGCGAAGGCTGGAAGTGGGGC GGCTGCAGCGAGGACGCTGACTTCGGCGTGTTAGTGTCCAGGGAGTTCGCGGATGCGC GCGAGAACAGGCCGGACGCGCCCCGGCCATGAACAAGCACAACAACGAGGCGGGCC GCACGACTATCCTGGACCACATGCACCTCAAATGCAAGTGCCACGGGCTGTCGGGCAG CTGTGAGGTGAAGACCTGCTGGTGGGCGCAGCCTGACTTCCGTGCCATCGGTGACTTCC TCAAGGACAAGTATGACAGCGCCTCGGAGATGGTAGTAGAGAAGCACCGTGAGTCCCG GACCTGGTCTACTACGAGAACTCCCCCAACTTTTGTGAGCCCAACCCAGAGACGGGTT CCTTTGGCACAAGGGACCGGACTTGCAATGTCACCTCCCACGGCATCGATGGCTGCGA CCACTGCATCTTCCACTGGTGCTACGTCAGCTGCCAGGAGTGTATTCGCATCTACG ACGTGCACACCTGCAAGTAGGGCACCAG

MEPHLLGLLLGGTRVLAGYPIWWSLALGQQYTSLGSQPLLCGSIPGLVPKQLRFCRN YIEIMPSVAEGVKLGIQECQHQFRGRRWNCTTIDDSLAIFGPVLDKATRESAFVHAIASAGV AFAVTRSCAEGTSTICGCDSHHKGPPGEGWKWGGCSEDADFGVLVSREFADARENRPDAR SAMNKHNNEAGRTTILDHMHLKCKCHGLSGSCEVKTCWWAQPDFRAIGDFLKDKYDSAS EMVVEKHRESRGWVETLRAKYSLFKPPTERDLVYYENSPNFCEPNPETGSFGTRDRTCNVT SHGIDGCDLLCCGRGHNTRTEKRKEKCHCI

Figure 38

GCCGCGAGCAACTGGCTGTACCTGGCCAAGCTGTCGTCGGTGGGGAGCATCTCAGAGG AGGAGACGTGCGAGAAACTCAAGGGCCTGATCCAGAGGCAGGTGCAGATGTGCAAGC GGAACCTGGAAGTCATGGACTCGGTGCGCGGGTGCCCAGCTGGCCATTGAGGAGTG CCAGTACCAGTTCCGGAACCGGCGCTGGAACTGCTCCACACTCGACTCCTTGCCCGTCT TCGGCAAGGTGGTGACGCAAGGGATTCGGGAGGCGGCCTTGGTGTACGCCATCTCTTC GGCAGGTGTGGCCTTTGCAGTGACGCGGGCGTGCAGCAGTGGGGAGCTGGAGAAGTGC GGCTGTGACAGGACAGTGCATGGGGTCAGCCCACAGGGCTTCCAGTGGTCAGGATGCT CTGACAACATCGCCTACGGTGTGGCCTTCTCACAGTCGTTTGTGGATGTGCGGGAGAGA AGCAAGGGGCCTCGTCCAGCAGAGCCCTCATGAACCTCCACAACAATGAGGCCGGCA GGAAGGCCATCCTGACACACATGCGGGTGGAATGCAAGTGCCACGGGGTGTCAGGCTC CTGTGAGGTAAAGACGTGCTGCCGAGCCGTGCCGCCCTTCCGCCAGGTGGGTCACGCA CTGAAGGAGAAGTTTGATGGTGCCACTGAGGTGGAGCCACGCCGCGTGGGCTCCTCCA GGGCACTGGTGCCACGCACGCACAGTTCAAGCCGCACACAGATGAGGACTTGGTGTA CTTGGAGCCTAGCCCCGACTTCTGTGAGCAGGACATGCGCAGCGCGTGCTGGGCACG AGGGGCCGCACATGCAACAAGACGTCCAAGGCCATCGACGGCTGTGAGCTGCTGTGCT GTGGCCGCGCTTCCACACGCCCAGGTGGAGCTGCAACGCTGCAGCTGCAAATT CCACTGGTGCTCGTCAAGTGCCGGCAGTGCCAGCGGCTCGTGGAGTTGCACACG TGCCGATGA

Figure39

MSPRSCLRSLRLLVFAVFSAAASNWLYLAKLSSVGSISEEETCEKLKGLIQRQVQMCKRNL EVMDSVRRGAQLAIEECQYQFRNRRWNCSTLDSLPVFGKVVTQGIREAALVYAISSAGVA FAVTRACSSGELEKCGCDRTVHGVSPQGFQWSGCSDNIAYGVAFSQSFVDVRERSKGASSS RALMNLHNNEAGRKAILTHMRVECKCHGVSGSCEVKTCWRAVPPFRQVGHALKEKFDG ATEVEPRRVGSSRALVPRNAQFKPHTDEDLVYLEPSPDFCEQDMRSGVLGTRGRTCNKTS KAIDGCELLCCGRGFHTAQVELAERCSCKFHWCCFVKCRQCQRLVELHTCR

Figure 40

CTTTGGCCATATTTTCTCCTTCGCCCAGGTTGTAATTGAAGCCAATTCTTGGTGGTCGC TAGGTATGAATAACCCTGTTCAGATGTCAGAAGTATATATTATAGGAGCACAGCCTCTC TGCAGCCAACTGGCAGGACTTTCTCAAGGACAGAAGAAACTGTGCCACTTGTATCAGG ACCACATGCAGTACATCGGAGAAGGCGCGAAGACAGGCATCAAAGAATGCCAGTATC AATTCCGACATCGACGGTGGAACTGCAGCACTGTGGATAACACCTCTGTTTTTGGCAGG GTGATGCAGATAGGCAGCCGCGAGACGGCCTTCACATACGCCGTGAGCGCAGCAGGG GTGGTGAACGCCATGAGCCGGGCGTGCCGCGAGGGCGAGCTGTCCACCTGCGGCTGCA GCCGCGCGCGCCCCAAGGACCTGCCGCGGGACTGGCTCTGGGGCGCTGCGGCGA CAACATCGACTATGGCTACCGCTTTGCCAAGGAGTTCGTGGACGCCCGCGAGCGGGAG CGCATCCACGCCAAGGGCTCCTACGAGAGTGCTCGCATCCTCATGAACCTGCACAACA ACGAGGCCGCCGCAGGACGGTGTACAACCTGGCTGATGTGGCCTGCAAGTGCCATGG GGTGTCCGCTCATGTAGCCTGAAGACATGCTGGCTGCAGCTGCCAGACTTCCGCAAG GTGGGTGATGCCCTGAAGGAGAAGTACGACAGCGCGGCGGCCATGCGGCTCAACAGC CGGGGCAAGTTGGTACAGGTCAACAGCCGCTTCAACTCGCCCACCACACAAGACCTGG TCTACATCGACCCCAGCCCTGACTACTGCGTGCGCAATGAGAGCACCGGCTCGCTGGG TGCTGCGGCCGTGGGTACGACCAGTTCAAGACCGTGCAGACGGAGCGCTGCCACTGCA AGTTCCACTGGTGCTACGTCAAGTGCAAGAAGTGCACGGAGATCGTGGACCAGTT TGTGTGCAAGTAGTGGGTGCCACCCAGCACTCAGCCCCGCTCCCAGGACCCGCTTATTT AATTGCAACCGGAACCATTTTTTTCCTGTTACCATCTAAGAACTCTGTGGTTTATTATT GTGGATCTTTGAAAAGGTAATACAAGACTTCTTTTGGATAGTATAGAATGAAGGGGGA AATAACACATACCCTAACTTAGCTGTGTGGGACATGGTACACATCCAGAAGGTAAAGA AATACATTTCTCTCAAATATGCCATCATATGGGATGGGTAGGTTCCAGTTGAAA GAGGGTGGTAGAAATCTATTCACAATTCAGCTTCTATGACCAAAATGAGTTGTAAATTC CCCAGCAGGGCTGCTAGCTTCTTCTGCATTTTCAAAATGATAATTTACAATGGAAGG ACAAGAATGTCATATTCTCAAGGAAAAAAGGTATATCACATGTCTCATTCTCCTCAAAT ATTCCATTTGCAGACAGACCGTCATATTCTAATAGCTCATGAAATTTGGGCAGCAGGGA GGAAAGTCCCCAGAAATTAAAAAATTTAAAACTCTTATGTCAAGATGTTGATTTGAAG CTGTTATAAGAATTGGGATTCCAGATTTGTAAAAAGACCCCCAATGATTCTGGACACTA GATTTTTGTTTGGGGAGGTTGGCTTGAACATAAATGAAATATCCTGTATTTTCTTAGG GATACTTGGTTAGTAAATTATAATAGTAGAAATAATACATGAATCCCATTCACAGGTTT CTCAGCCCAAGCAACAAGGTAATTGCGTGCCATTCAGCACTGCACCAGAGCAGACAAC CTATTTGAGGAAAAACAGTGAAATCCACCTTCCTCTTCACACTGAGCCCTCTCTGATTC CTCCGTGTTGTGATGTGATGCTGGCCACGTTTCCAAACGGCAGCTCCACTGGGTCCCCT TTGGTTGTAGGACAGGAAATGAAACATTAGGAGCTCTGCTTGGAAAACAGTTCACTAC TTAGGGATTTTTGTTTCCTAAAACTTTTATTTTGAGGAGCAGTAGTTTTCTATGTTTTAA TGACAGAACTTGGCTAATGGAATTCACAGAGGTGTTGCAGCGTATCACTGTTATGATCC TGTGTTTAGATTATCCACTCATGCTTCTCCTATTGTACTGCAGGTGTACCTTAAAACTGT TCCCAGTGTACTTGAACAGTTGCATTTATAAGGGGGGAAATGTGGTTTAATGGTGCCTG TATAAATATCTCATTGCAGCCAGTGATTTAGATTTACAGCTTACTCTGGGGTTATCTC TCTGTCTAGAGCATTGTTGTCCTTCACTGCAGTCCAGTTGGGATTATTCCAAAAGTTTTT TGAGTCTTGAGCTTGGGCCCCGCTGTGATCATACCCTGAGCACGACGAAGCA ACCTCGTTTCTGAGGAAGAAGCTTGAGTTCTGACTCACTGAAATGCGTGTTGGGTTGAA GATATCTTTTTCTTTCTGCCTCACCCCTTTGTCTCCAACCTCCATTTCTGTTCACTTT GTGGAGAGGCATTACTTGTTCGTTATAGACATGGACGTTAAGAGATATTCAAAACTC AGAAGCATCAGCAATGTTTCTTTTTTTTAGTTCATTCTGCAGAATGGAAACCCATGCC TATTAGAAATGACAGTACTTATTAATTGAGTCCCTAAGGAATATTCAGCCCACTACATA GATAGCTTTTTTTTTTTTTTTTTTTAATAAGGACACCTCTTTCCAAACAGGCCATCA

AATATGTTCTTATCTCAGACTTACGTTGTTTTAAAAAGTTTGGAAAGATACACATCTTTTC
ATACCCCCCCTTAGGAGGTTGGGCTTTCATATCACCTCAGCCAACTGTGGCTCTTAATT
TATTGCATAATGATATCCACATCAGCCAACTGTGGCTCTTTAATTTATTGCATAATGAT
ATTCACATCCCCTCAGTTGCAGTGAATTGTGAGCAAAAAGATCTTGAAAGCAAAAAGCA
CTAATTAGTTTAAAAATGTCACTTTTTTGGTTTTTATTATACAAAAAACCATGAAGTACTTT
TTTTATTTGCTAAATCAGATTGTTCCTTTTTAGTGACTCATGTTTATGAAGAGAGTTGAG
TTTAACAATCCTAGCTTTTAAAAAGAAACTATTTAATGTAAAAATATTCTACATGTCATTC
AGATATTATGTATATCTTCTAGCCTTTATTCTGTACTTTTAATGTACATATTTCTGTCTTG
CGTGATTTGTATATTTCACTGGTTTAAAAAAAACAAACATCGAAAGGCTTATTCCAAATGG
AAG

Figure 41

MAGSAMSSKFFLVALAIFFSFAQVVIEANSWWSLGMNNPVQMSEVYIIGAQPLCSQLAGLS QGQKKLCHLYQDHMQYIGEGAKTGIKECQYQFRHRRWNCSTVDNTSVFGRVMQIGSRET AFTYAVSAAGVVNAMSRACREGELSTCGCSRAARPKDLPRDWLWGGCGDNIDYGYRFA KEFVDARERERIHAKGSYESARILMNLHNNEAGRRTVYNLADVACKCHGVSGSCSLKTC WLQLADFRKVGDALKEKYDSAAAMRLNSRGKLVQVNSRFNSPTTQDLVYIDPSPDYCVR NESTGSLGTQGRLCNKTSEGMDGCELMCCGRGYDQFKTVQTERCHCKFHWCCYVKCKK CTEIVDQFVCK

Figure 42

GGCACGAGCGCAGGAGACACAGGCGCTGGCTGCCCGTCCGCTCCCGCCTCCGCCGC GCCTCCTCGCCGGGATGGGCCCCCCGCGCCGCCGATCCCTCGCCTCCCGGCCGC CCCGCAGCCTCGCCCCTGCCCACCCGGGCGGCCGTAGGGCGGTCACGATGCTGCCGC CCTTACCCTCCGGCCTGGTGCTGCTGCTGCTGCTGCCGGCGCACGTCGGC GGACTGTGGTGGGCTGTGGCCCCTTGGTTATGGACCCTACCAGCATCTGCAGGA AGGCACGGCGGCTGGCCGGCCGGCCGAGTTGTGCCAGGCTGAGCCGGAAGTGG TGGCAGAGCTAGCTCGGGGCGCCCGGCTCGGGGTGCGAGAGTGCCAGTTCCAGTTCCG CTTCCGCCGCTGGAATTGCTCCAGCCACAGCAAGGCCTTTGGACGCATCCTGCAACAG TCACGCAGGCCTGTTCTATGGGCGAGCTGCTGCAGTGCGGCTGCCAGGCGCCCGCGG GCGGCCCCCCCGGCCTCCGGCCTGCCCGGCACCCCGGACCCCTGGCCCCGCG GGCTCCCGGAAGGCAGCGCCGCCTGGGAGTGGGGAGGCTGCGGCGACGACGTGGAC TTCGGGGACGAGAAGTCGAGGCTCTTTATGGACGCGCGCACAAGCGGGGACGCGGA GACATCCGCGCGTTGGTGCAACTGCACAACAACGAGGCGGGCAGGCTGGCCGTGCGG AGCCACACGCGCACCGAGTGCAAATGCCACGGGCTGTCGGGATCATGCGCGCTGCGCA CCTGCTGGCAGAAGCTGCCTCCATTTCGCGAGGTGGGCGCGCGGCTGCTGGAGCGCTT CCACGCGCCTCACGCGTCATGGGCACCAACGACGCCAAGGCCCTGCTGCCCGCCGTC CGCACGCTCAAGCCGCCGGGCCGAGCGGACCTCCTCTACGCCGCCGATTCGCCCGACT TTTGCGCCCCAACCGACGCACCGGCTCCCCGGCACGCGCGCTCGCCAATAG CAGCGCCCGGACCTCAGCGGCTGCGACCTGTGTGCTGCGGCCGCGGGCACCGCCAG

Figure 43

MLPPLPSRLGLLLLLLCPAHVGGLWWAVGSPLVMDPTSICRKARRLAGRQAELCQAEPE VVAELARGARLGVRECQFQFRFRRWNCSSHSKAFGRILQQDIRETAFVFAITAAGASHAVT QACSMGELLQCGCQAPRGRAPPRPSGLPGTPGPPGPAGSPEGSAAWEWGGCGDDVDFGD EKSRLFMDARHKRGRGDIRALVQLHNNEAGRLAVRSHTRTECKCHGLSGSCALRTCWQK LPPFREVGARLLERFHGASRVMGTNDGKALLPAVRTLKPPGRADLLYAADSPDFCAPNRR TGSPGTRGRACNSSAPDLSGCDLLCCGRGHRQESVQLEENCLCRFHWCCVVQCHRCRVRK ELSLCL

Figure 44

CACGCGTCCGGGCCAATCGGGACTATGAACCGGÁAAGCGCTGCGTGCCTGGGCCACC TCTTTCTCAGCCTGGGCATGGTCTGCCTCCGGATCGGTGGCTTCTCCTCAGTGGTAGCTC TGGGCGCAACGATCATCTGTAACAAGATCCCAGGCCTGGCTCCCAGACAGCGGGCGAT CTGCCAGAGCCGGCCGACGCCATCATCGTCATAGGAGAAGGCTCACAAATGGGCCTG GACGAGTGTCAGTTCCGCAATGGCCGCTGGAACTGCTCTGCACTGGGAGAGC GCACCGTCTTCGGGAAGGAGCTCAAAGTGGGGAGCCGGGACGGTGCGTTCACCTACGC CATCATTGCCGCCGGCGTGGCCCACGCCATCACAGCTGCCTGTACCCATGGCAACCTG AGCGACTGTGGCTGCGACAAAGAGAAGCAAGGCCAGTACCACCGGGACGAGGGCTGG AAGTGGGGTGGCTGCCGACATCCGCTACGGCATCGGCTTCGCCAAGGTCTTTGT GGATGCCCGGGAGATCAAGCAGAATGCCCGGACTCTCATGAACTTGCACAACAACGAG GCAGGCCGAAAGATCCTGGAGGAGAACATGAAGCTGGAATGTAAGTGCCACGGCGTG TCAGGCTCGTGCACCACCAAGACGTGCTGGACCACACTGCCACAGTTTCGGGAGCTGG CCGCAACAAGCGGCCCACCTTCCTGAAGATCAAGAAGCCACTGTCGTACCGCAAGCCC ATGGACACGGACCTGGTGTACATCGAGAAGTCGCCCAACTACTGCGAGGAGGACCCGG TGACCGGCAGTGTGGGCACCCAGGGCCGCCTGCAACAAGACGGCTCCCCAGGCCAG TGGCAGTGCAACTGTAAGTTCCACTGGTGCTGCTATGTCAAGTGCAACACGTGCAGCG AGCGCACGGAGATGTACACGTGCAAGTGAGCCCCGTGTGCACACCACCCTCCCGCTGC AAGTCAGATTGCTGGGAGGACTGGACCGTTTCCAAGCTGCGGGCTCCCTGGCAGGATG CTGAGCTTGTCTTTCTGCTGAGGAAGGTACTTTTCCTGGGTTTCCTGCAGGCATCCGTG GGGGAAAAAAATCTCTCAGAACCCTCAACTATTCTGTTCCACACCCAATGCTGCTCCA CCCTCCCCAGACACAGCCCAAGTCCCTCCGCGGCTGGAGCGAAGCCTTCTGCAGCAG GAACTCTGGACCCCTGGGCCTCATCACAGCAATATTTAACAATTTATTCTGATAAAAAT AAAAAAAGGGGGG

Figure 45

MNRKARRCLGHLFLSLGMVYLRIGGFSSVVALGASIICNKIPGLAPRQRAICQSRPDAIIVIG EGSQMGLDECQFQFRNGRWNCSALGERTVFGKELKVGSREAAFTYAIIAAGVAHAITAAC TQGNLSDCGCDKEKQGQYHRDEGWKWGGCSADIRYGIGFAKVFVDAREIKQNARTLMNL HNNEAGRKILEENMKLECKCHGVSGSCTTKTCWTTLPQFRELGYVLKDKYNEAVHVEPV RASRNKRPTFLKIKKPLSYRKPMDTDLVYIEKSPNYCEEDPVTGSVGTQGRACNKTAPQAS GCDLMCCGRGYNTHQYARVWQCNCKFHWCCYVKCNTCSERTEMYTCK

Figure 46

MHRNFRKWIFYVFLCFGVLYVKLGALSSVVALGANIICNKIPGLAPRQRAICQSRPDAIIVIG EGAQMGINECQYQFRFGRWNCSALGEKTVFGQELRVGSREAAFTYAITAAGVAHAVTAA CSQGNLSNCGCDREKQGYYNQAEGWKWGGCSADVRYGIDFSRRFVDAREIKKNARRLM NLHNNEAGRKVLEDRMQLECKCHGVSGSCTTKTCWTTLPKFREVGHLLKEKYNAAVQVE VVRASRLRQPTFLRIKQLRSYQKPMETDLVYIEKSPNYCEEDAATGSVGTQGRLCNRTSPG ADGCDTMCCGRGYNTHQYTKVWQCNCKFHWCCFVKCNTCSERTEVFTCK

Figure 47

TCCGCTTACACACCAAGGAAAGTTGGGCTTTGAAGAATTCCATCCCCATGGCCACTGG AGGAAGAATATTTCNCCCGTCTTGCTTACCCATCTCCCCAGTTTTTTTGGAATTTTCTCTA GCTGTTACTCCAGAGGATTATGTTTCTTTCAAAGCCTTCTGTGTACATCTGTCTTTTCAC CTGTGTCCTCCAACTCAGCCACAGCTGGTCGGTGAACAATTTCCTGATGACTGGTCCAA AGGCTTACCTGATTTACTCCAGCAGTGTGGCAGCTGGTGCCCAGAGTGGTATTGAAGA ATGCAAGTATCAGTTTGCCTGGGACCGCTGGAACTGCCCTGAGAGAGCCCTGCAGCTG TCCAGCCATGGTGGGCTTCGCAGTGCCAATCGGGAGACAGCATTTGTGCATGCCATCA GTTCTGCTGGAGTCATGTACACCCTGACTAGAAACTGCAGCCTTGGAGATTTTGATAAC GCTGCAGTGACAATGTGGGCTTCGGAGAGGCGATTTCCAAGCAGTTTGTCGATGCCCT GGAAACAGGACAGGATGCACGGGCAGCCATGAACCTGCACAACAACGAGGCTGGCCG CAAGGCGTGAAGGCACCATGAAACGCACGTGTAAGTGCCATGGCGTGTCTGGCAGC TGCACCACGCAGACCTGTTGGCTGCAGCTGCCCGAGTTCCGCGAGGTGGGCGCACC TGAAGGAGAAGTACCACGCAGCACTCAAGGTGGACCTGCTGCAGGGTGCTGGCAACA GCGCGCCCCCCGCGCCCATCGCCGACACCTTTCGCTCCATCTCTACCCGGGAGCTG GTGCACCTGGAGGACTCCCCGGACTACTGCCTGGAGAACAAAACGCTAGGGCTGCTGG GCACCGAAGGCCGAGAGTGCCTAAGGCGCGGGCGGCCCTGGGTCGCTGGGAACTCC GCAGCTGCCGCCGGCTCTGCGGGGACTGCGGGCTGGAGGAGCGCCGGGCCG AGACCGTGTCCAGCTGCAACTGCAAGTTCCACTGGTGCTGTGCAGTCCGCTGCGAGCA GTGCCGCCGGAGGGTCACCAAGTACTTCTGTAGCCGCGCAGAGCGGCCGCGGGGGGGC GCTGCGCACAAACCCGGGAGAAAACCCTAAGGGTTTCCTCTGCCCCCTCCTTTTCCCAC TGGTTCTTGGCTTCCTTTAGAGACCCCGGTAATTGTGGAACCTAGGGAATGGGGAACCC GCTCTCCCAGACCTAGGGATCCTGAAAGGGAAAAACTGCAATTTCTCCAAAGCTTGCC CAGCCACACCTAGGTCTGAAAACTCAGGCTTTGAGTTACTGATCTTCCTTGGATTAGGA AAACAGGTGTTCCTCCTCCCCTCTCCTATCAGCCCTAATCTCTGACCTAGCCTATCAAC CCTTAGGCGCTGGAAAAACCTTCTCATACACGCAGGACCCAGGTTAACTCAAAGCTTT

Figure 48

MFLSKPSVYICLFTCVLQLSHSWSVNNFLMTGPKAYLIYSSSVAAGAQSGIEECKYQFAWD RWNCPERALQLSSHGGLRSANRETAFVHAISSAGVMYTLTRNCSLGDFDNCGCDDSRNGQ LGGQGWLWGGCSDNVGFGEAISKQFVDALETGQDARAAMNLHNNEAGRKAVKGTMKR TCKCHGVSGSCTTQTCWLQLPEFREVGAHLKEKYHAALKVDLLQGAGNSAAARGAIADT FRSISTRELVHLEDSPDYCLENKTLGLLGTEGRECLRRGRALGRWELRSCRRLCGDCGLAV EERRAETVSSCNCKFHWCCAVRCEQCRRVTKYFCSRAERPRGGAAHKPGRKP

Figure 49

GCGCCGCGTCGACGGAGGGGCTGCAGCTCCGTCAGCCCGGCAGAGCCACCCTGAGCT GTGAAGAGGGGTGGCCCGGCCCTGGAAGAATGCGGCTCTGACAAGGGGACAGAACCC AGCGCAGTCTCCCCACGGTTTAAGCAGCACTAGTGAAGCCCAGGCAACCCAACCGTGC CTCCGGGCTTCGACATGCTGGAGGAGCCCCGGCCGCGCCTCCGCCCTCGGGCCTCGC GGGTCTCCTGTTCCTGGCGTTGTGCAGTCGGGCTCTAAGCAATGAGATTCTGGGCCTGA AGTTGCCTGGCGAGCCGCCGCTGACGCCAACACCGTGTGCTTGACGCTGTCCGGCCT GAGCAAGCGGCAGCTAGACCTGTGCCTGCGCAACCCCGACGTGACGGCGTCCGCGCTT CAGGGTCTGCACATCGCGGTCCACGAGTGTCAGCACCAGCTGCGCGACCAGCGCTGGA ACTGCTCCGCGCTTGAGGGCGGCGGCCGCCTGCCGCACCACAGCGCCATCCTCAAGCG TAGCCACGGCCTGCAGCCTGGGCAAGCTGGTGAGCTGTGGCTGGGAAGGGCAG TGGTGAGCAGGATCGGCTGAGGGCCAAACTGCTGCAGCTGCAGGCACTGTCCCGAGGC AAGAGTTTCCCCCACTCTGCCCAGCCCTGGCCCTGGCTCAAGCCCCAGCCCTGGCCC CCAGGACACATGGGAATGGGGTGGCTGTAACCATGACATGGACTTTGGAGAGAAGTTC TCTCGGGATTTCTTGGATTCCAGGGAAGCTCCCCGGGACATCCAGGCACGAATGCGAA TCCACAACAACAGGGTGGGCCCAGGTGGTAACTGAAAACCTGAAGCGGAAATGCA AGTGTCATGGCACATCAGGCAGCTGCCAGTTCAAGACATGCTGGAGGGCGGCCCCAGA ACCCACAACCGCAATTCTGGAGCCTTCCAGCCCCGTCTGCGTCCCCGTCGCCTCTCAGG AGAGCTGGTCTACTTTGAGAAGTCTCCTGACTTCTGTGAGCGAGACCCCACTATGGGCT CCCCAGGGACAAGGGCCGGGCCTGCAACAAGACCAGCCGCCTGTTGGATGGCTGTGG CAGCCTGTGCTGTGGCCGTGGGCACACGTGCTCCGGCAGACACGAGTTGAGCGCTGC CATTGCCGCTTCCACTGGTGCTGCTATGTGCTGTGTGATGAGTGCAAGGTTACAGAGTG GGTGAATGTGTAAGTGAGGGTCAGCCTTACCTTGGGGCTGGGGAAGAGGACTGTGT GAGAGGGGCCCTTTCAGCCCTTTGCTCTGATTTCCTTCCAAGGTCACTCTTGGTCCCT

Figure 50

MLEEPRPRPPPSGLAGLLFLALCSRALSNEILGLKLPGEPPLTANTVCLTLSGLSKRQLDLCL RNPDVTASALQGLHIAVHECQHQLRDQRWNCSALEGGGRLPHHSAILKRGFRESAFSFSM LAAGVMHAVATACSLGKLVSCGCGWKGSGEQDRLRAKLLQLQALSRGKSFPHSLPSPGP GSSPSPGPQDTWEWGGCNHDMDFGEKFSRDFLDSREAPRDIQARMRIHNNRVGRQVVTEN LKRKCKCHGTSGSCQFKTCWRAAPEFRAVGAALRERLGRAIFIDTHNRNSGAFQPRLRPRR LSGELVYFEKSPDFCERDPTMGSPGTRGRACNKTSRLLDGCGSLCCGRGHNVLRQTRVER CHCRFHWCCYVLCDECKVTEWVNVCK

Figure 51

TAACCCGCCGCCTCCCCCGGCTGCAGGCGGCGTGCAGGACCAGCGGCGGCCG TGCAGGCGAGGACTTCGGCGCGCTCCTCCTGGGTGTGACCCCGGGCGCGCCCCG CGCGACGATGAGGGCGCGGCCGCAGGTCTGCGAGGCGCTGCTCTTCGCCCTGGCGCTCCAGACCGGCGTGTGCTATGGCATCAAGTGGCTGGCGCTGTCCAAGACACCATCGGCCC TGGCACTGAACCAGACGCAACACTGCAAGCAGCTGGAGGGTCTGGTGTCTGCACAGGT GCAGCTGTGCCGCAGCAACCTGGAGCTCATGCACACGGTGGTGCACGCCGCCGCGAG GTCATGAAGGCCTGTCGCCGGGCCTTTGCCGACATGCGCTGGAACTGCTCCTCCATTGA GCTCGCCCCAACTATTTGCTTGACCTGGAGAGAGGGACCCGGGAGTCGGCCTTCGTG TATGCGCTGTCGGCCGCCACCATCAGCCACGCCATCGCCCGGGCCTGCACCTCCGGCG ACCTGCCCGGCTGCTCCTGCGGCCCCGTCCCAGGTGAGCCACCCGGGCCCGGGAACCG CTGGGGAAGATGTGCGGACAACCTCAGCTACGGGCTCCTCATGGGGGCCAAGTTTTCC GATGCTCCTATGAAGGTGAAAAAAAACAGGATCCCAAGCCAATAAACTGATGCGTCTAC ACAACAGTGAAGTGGGGAGACAGGCTCTGCGCGCCTCTCTGGAAATGAAGTGTAAGTG CCATGGGGTGTCTGGCTCCTGCTCCATCCGCACCTGCTGGAAGGGGCTGCAGGAGCTG CAGGATGTGGCTGCTGACCTCAAGACCCGATACCTGTCGGCCACCAAGGTAGTGCACC GACCCATGGGCACCCGCAAGCACCTGGTGCCCAAGGACCTGGATATCCGGCCTGTGAA GGACTGGGAACTTGTTTATTTGCAGAGCTCACCTGACTTTTGCATGAAGAATGAGAAG GTGGGCTCCCACGGGACACAAGACAGGCAGTGCAACAAGACTTCCAACGGAAGCGAC AGCTGCGACCTTATGTGCTGCGGGCGTGGCTACAACCCCTACACAGACCGCGTGGTCG AGCGGTGCCACTGTAAGTACCACTGGTGTTGCTACGTCACCTGCCGCAGGTGTGAGCGT ACCGTGGAGCGCTATGTCTGCAAGTGAGGCCCTGCCCTCCGCCCCACGCAGGAGCGAG GACTTTGCTCAAGGACCCTCAGCAACTGGGGCCGGGGGCCTGGAGACACTCCATGGAG CTCTGCTTGTGAATTCCAGATGCCAGGCATGGGAGGCGGCTTGTGCTTTGCCTTCACTT GGAAGCCACCAGGAACAGAAGGTCTGGCCACCCTGGAAGGAGNGCAGGACATCAAAG GAAACCGACAAGATTAAAAATAACTTGGCAGCCTGAGNTCTGGAGTGCCCACAGNNTG

Figure 52

MRARPQVCEALLFALALQTGVCYGIKWLALSKTPSALALNQTQHCKQLEGLVSAQVQLCR SNLELMHTVVHAAREVMKACRRAFADMRWNCSSIELAPNYLLDLERGTRESAFVYALSA ATISHAIARACTSGDLPGCSCGPVPGEPPGPGNRWGRCADNLSYGLLMGAKFSDAPMKVK KTGSQANKLMRLHNSEVGRQALRASLEMKCKCHGVSGSCSIRTCWKGLQELQDVAADLK TRYLSATKVVHRPMGTRKHLVPKDLDIRPVKDWELVYLQSSPDFCMKNEKVGSHGTQDR QCNKTSNGSDSCDLMCCGRGYNPYTDRVVERCHCKYHWCCYVTCRRCERTVERYVCK

Figure 53

GCTGACGCTGCTCGCCGCGCTGCGCCCTTCGGCCGCCTACTTCGGGCTGACGGGCA GCGAGCCCTGACCATCCTCCCGCTGACCCTGGAGCCAGAGGCGGCCCCCAGGCGCA CTACAAGGCCTGCGACCGGCTGAAGCTGGAGCGGAAGCAGCGGCGCATGTGCCGCCG GGACCCGGGCGTGGCAGAGACGCTGGTGGAGCCGTGAGCATGAGTGCGCTCGAGTG CCAGTTCCAGTTCCGCTTTGAGCGCTGGAACTGCACGCTGGAGGGCCGCTACCGGGCC AGCCTGCTCAAGCGAGGCTTCAAGGAGACTGCCTTCCTCTATGCCATCTCCTCGGCTGG CCTGACGCACGCACTGGCCAAGGCGTGCAGCGCGGGCCGCATGGAGCGCTGTACCTGC GATGAGGCACCCGACCTGGAGAACCGTGAGGCCTGGCAGTGGGGGGGCTGCGGAGAC ATCTGCGAGCCCGTGTGGACTTCCACAACACCTCGTGGGTGTGAAGGTGATCAAGGC TGGGGTGGAGACCACCTGCAAGTGCCACGGCGTGTCAGGCTCATGCACGGTGCGGACC TGCTGGCGGCAGTTGGCGCCTTTCCATGAGGTGGGCAAGCATCTGAAGCACAAGTATG AGACGGCACTCAAGGTGGGCAGCACCACCAATGAAGCTGCCGGCGAGGCAGGTGCCA TCTCCCCACCACGGGCCGTGCCTCGGGGGCAGGTGGCAGCGACCCGCTGCCCGCAC CGGGCACCGCTGGCCGTAGGTGCCACCGTGAGAACTGCGAGAGCATCTGCTGTGG CCGCGGCCATAACACACAGAGCCGGGTGGTGACAAGGCCCTGCCAGTGCCAGGTGCGT AGGGCTGAGTTCCCAGGCCCTGCCAGCCCTGCACAGGGTGCAGGCATTGCACACG GTGTGAAGGGTCTACACCTGCACAGGCTGAGTTCCTGGGCTCGACCAGCCCAGCTGCG TGGGGTACAGGCATTGCACACAGTGTGAATGGGTCTACACCTGCATGGGCTGAGTCCC TGGGCTCAGACCTAGCAGCGTGGGGTAGTCCCTGGGCTCAGTCCTAGCTGCATGGGGT GCAGGCATTGCACAGAGCATGAATGGGCCTACACCTGCCAAGGCTGAATCCCTGGGCC CAGCCAGCCTGCTGCACATGGCACAGGCATTGCACACGGTGTGAGGAGTGTACACCT GCAAGGCCTGAGGCCCTGGGCCCAGTCAGCCCTGCTCAGAGTGCAGGCATTGCAC ATGGTGTGAGAAGGTCTACACCTGCAAGGGACGAGTCCCCGGGCCTGGCCAACCCTGC TGTGCAGGGTGAGGGCCATGCATGCTAGTATGAGGGGTCTACACCTGCAAGGACTGAG AGGCTTTT

38/66

Figure 54

MLDGSPLARWLAAAFGLTLLLAALRPSAAYFGLTGSEPLTILPLTLEPEAAAQAHYKACDR LKLERKQRRMCRRDPGVAETLVEAVSMSALECQFQFRFERWNCTLEGRYRASLLKRGFKE TAFLYAISSAGLTHALAKACSAGRMERCTCDEAPDLENREAWQWGGCGDNLKYSSKFVK EFLGRRSSKDLRARVDFHNNLVGVKVIKAGVETTCKCHGVSGSCTVRTCWRQLAPFHEVG KHLKHKYETALKVGSTTNEAAGEAGAISPPRGRASGAGGSDPLPRTPELVHLDDSPSFCLA GRFSPGTAGRRCHREKNCESICCGRGHNTQSRVVTRPCQCQVRWCCYVECRQCTQREEVY TCKG

Figure 55

AGCTCACCACTTGCCTCAGGGAGACCCTCTTCACAGGGGCTTCTCAAAAGACCTCCCTA TGGTGGTTGGGCATTGCCTCCTTCGGGGTTCCAGAGAAGCTGGGCTGCGCCAATTTGCC GCTGAACAGCCGCCAGAAGGAGCTGTGCAAGAGGAAACCGTACCTGCTGCCGAGCAT CCGAGAGGGCCCCGGCTGGGCATTCAGGAGTGCAGGAGCCAGTTCAGACACGAGAG ATGGAACTGCATGATCACCGCCGCCGCCACTACCGCCCGATGGGCGCCAGCCCCCTC CTGCAGGCCTGGTGCATTCTGTGACCAGGTCATGCAGTGCAGGCAACATGACAGAGTG TTCCTGTGACACCACCTTGCAGAACGGCGGCTCAGCAAGTGAAGGCTGGCACTGGGGG GGCTGCTCCGATGATGTCCAGTATGGCATGTTCAGCAGAAAGTTCCTAGATTTCCC CATCGGAAACACCACGGGCAAAGAAAACAAAGTACTATTAGCAATGAACCTACATAA CAATGAAGCTGGAAGGCAGGCTGTCGCCAAGTTGATGTCAGTAGACTGCCGCTGCCAC GGAGTTTCCGGCTCCTGTGCTGTGAAAACATGCTGGAAAACCATGTCTTCTTTTGAAAA GATTGGCCATTTGTTGAAGGATAAATATGAAAACAGTATCCAGATATCAGACAAAATA AAGAGGAAAATGCGCAGGAGAGAAAAAGATCAGAGGAAAATACCAATCCATAAGGAT GATCTGCTCTATGTTAATAAGTCTCCCAACTACTGTGTAGAAGATAAGAAACTGGGAAT CCCAGGGACACAAGGCAGAATGCAACCGTACATCAGAGGGTGCAGATGGCTGCAA CCTCCTCTGCTGTGGCCGAGGTTACAACACCCATGTGGTCAGGCACGTGGAGAGGTGT GAGTGTAAGTTCATCTGGTGCTGCTATGTCCGTTGCAGGAGGTGTGAAAGCATGACTG ATGTCCACACTTGCAAGTAACCACTCCATCCAGCCTTGGGCAAGATGCCTCAGCAATAT ACAATGGCATTGCAACCAGAGAGGTGCCCATCCCTGTGCAGCGCTAGTAAAGTTGACT CTTGCAGTGGAATCCC

Figure 56

MDRAALLGLARLCALWAALLVLFPYGAQGNWMWLGIASFGVPEKLGCANLPLNSRQKEL CKRKPYLLPSIREGARLGIQECGSQFRHERWNCMITAAATTAPMGASPLFGYELSSGTKET AFIYAVMAAGLVHSVTRSCSAGNMTECSCDTTLQNGGSASEGWHWGGCSDDVQYGMWF SRKFLDFPIGNTTGKENKVLLAMNLHNNEAGRQAVAKLMSVDCRCHGVSGSCAVKTCWK TMSSFEKIGHLLKDKYENSIQISDKTKRKMRRREKDQRKIPIHKDDLLYVNKSPNYCVEDK KLGIPGTQGRECNRTSEGADGCNLLCCGRGYNTHVVRHVERCECKFIWCCYV RCRCESMTDVHTCK

Figure 57

CACTAGCGCGCCGCCAGCCGGGAGCCAGCGAGCCGAGGCCAGGAAGGCGGGAC CAAGTTTCCGCGGCGGCGGCGGCTGCGGTACGCAGAACAGGAGCCGGGGGAGCGGGC CGAAAGCGGCTTGGGCTCGACGGAGGGCACCCGCGCAGAGGTCTCCCTGGCCGCAGG GGGAGCCGCCGCCGTGCCCTGGCAGCCCAGCGGAGCGGCGCAAGAGAGA GCCGAGAAAGTATGGCTGAGGAGGAGGCGCCTAAGAAGTCCCGGGCCGCCGGCGGTG GCGCGAGCTGGGAACTTTGTGCCGGGCGCTCTCGGCCCGGCTGGCGAGGAGGACAG CGGGGACGCCGCCGCCGCCGCCAGTTGACCCCCGGCGATTGGCGCGCCAG CTGCTGCTGCTTTGGCTGCTGGAGGCTCCGCTGCTGCTGGGGGTCCGGGCCCAGGC TCAGCAGCAACAGAGCGGCAGCAGTACAACGGCGAGCGGGCATCTCCGTCCCGGA CCACGCTATTGCCAGCCCATCTCCATCCCGCTGTGCACGGACATCGCGTACAACCAG ACCATCATGCCCAACCTGCTGGGCCACACGAACCAGGAGGACGCGGGCCTGGAGGTGC ACCAGTTCTACCCTCTAGTGAAAGTGCAGTGTTCCGCTGAGCTCAAGTTCTTCCTGTGC TCCATGTACGCGCCGTGTGCACCGTGCTAGAGCAGGCGCTGCCGCCCTGCCGCTCCCT GTGCGAGCGCGCGCCAGGGCTGCGAGGCGCTCATGAACAAGTTCGGCTTCCAGTGG CCAGACACGCTCAAGTGTGAGAAGTTCCCGGTGCACGGCGCGCGGGGGGCTGTGCGTGG GCCAGAACACGTCCGACAAGGGCACCCCGACGCCTCGCTGCTTCCAGAGTTCTGGAC CAGCAACCTCAGCACGGCGGCGGAGGGCACCGTGGCGGCTTCCCGGGGGGCGCCGG CGCGTCGGAGCGAGGCAAGTTCTCCTGCCGCGCGCCCTCAAGGTGCCCTCCTACCTCA ACTACCACTTCCTGGGGGAGAAGGACTGCGGCGCACCTTGTGAGCCGACCAAGGTGTA TGGGCTCATGTACTTCGGGCCCGAGGAGCTGCGCTTCTCGCGCACCTGGATTGGCATTT GGTCAGTGCTGCTGCGCCTCCACGCTCTTCACGGTGCTTACGTACCTGGTGGACATG CGGCGCTTCAGCTACCCGGAGCGCCCATCATCTTCTTGTCCGGCTGTTACACGGCCGT GGCCGTGGCCTACATCGCCGGCTTCCTCCTGGAAGACCGAGTGGTGTGTAATGACAAG TTCGCCGAGGACGGGCACGCACTGTGGCGCAGGGCACCAAGAAGGAGGGCTGCACC TCGCTCACCTGGTTCCTGGCGGCTGGCATGAAGTGGGGCCACGAGGCCATCGAAGCCA ACTCACAGTATTTCACCTGGCCGCCTGGGCTGTGCCGGCCATCAAGACCATCACCATC CTGGCGCTGGGCCAGGTGGACGCGATGTGCTGAGCGGAGTGTGCTTCGTGGGGCTTA ACAACGTGGACGCGCTGCGTGGCTTCGTGCTGGCGCCCCTCTTCGTGTACCTGTTTATC GGCACGTCCTTTCTGCTGGCCGGCTTTGTGTCGCTCTTCCGCATCCGCACCATCATGAA GCACGATGGCACCAAGACCGAGAAGCTGGAGAAGCTCATGGTGCGCATTGGCGTCTTC AGCGTGCTGTACACTGTGCCAGCCACCATCGTCATCGCCTGCTACTTCTACGAGCAGGC CTTCCGGGACCAGTGGGAACGCAGCTGGGTGGCCCAGAGCTGCAAGAGCTACGCTATC ACTTCACGGTCTTCATGATTAAGTACCTTATGACGCTGATCGTGGGCATCACGTCGGGC TTCTGGATCTGGTCCGGCAAGACCCTCAACTCCTGGAGGAAGTTCTACACGAGGCTCA CCAACÀGCAAACAAGGGGAGACTACAGTCTGAGACCCGGGGCTCAGCCCATGCCCAG GCCTCGGCCGGGCGCAGCGATCCCCCAAAGCCAGCGCCGTGGAGTTCGTGCCAATCC TGACATCTCGAGGTTTCCTCACTAGACAACTCTCTTTCGCAGGCTCCTTTGAACAACTC AGCTCCTGCAAAAGCTTCCGTCCCTGAGGCAAAAGGACACGAGGCCCGACTGCCAGA GGGAGGATGGACAGACCTCTTGCCCTCACACTCTGGTACCAGGACTGTTCGCTTTTATG ATTGTAAATAGCCTGTGTAAGATTTTTGTAAGTATATTTGTAATTAAATGACGACCGAT CACGCGTTTTTCTTTTCAAAAGTTTTTAATTATTTAGGGCGGTTTAACCATTTGAGGCT TTTCCTTCTTGCCCTTTTCGGAGTATTGCAAAGGAGCTAAAACTGGTGTGCAACCGCAC AGCGCTCCTGGTCCTCGCGCGCCTCTCCCTACCACGGGTGCTCGGGACGGCTGGGC GCCAGCTCCGGGGCGAGTTCAGCACTGCGGGGTGCGACTAGGGCTGCGCTGCCAGGGT GCTTGAGGTAGGGGCTCTTAAGGTACAGAACTCCACAAACCTTCCAAATCTGGAGGAG GGCCCCATACATTACAATTCCTCCCTTGCTCGGCGGTGGATTGCGAAGGCCCGTCCCT TCGACTTCCTGAAGCTGGATTTTTAACTGTCCAGAACTTTCCTCCAACTTCATGGGGGC

40/66

CCACGGTGTGGGCGCTGGCAGTCTCAGCCTCCACGGTCACCTTCAACGCCCAG ATGGGTTTGGCCAGCGTCATGGAAAGATGTGGTTACTGAGATTTGGGAAGAAGCATGA AGCTTTGTGTGGGTTGGAAGAGACTGAAGATATGGGTTATAAAATGTTAATTCTAATTG CATACGGATGCCTGGCAACCTTGCCTTTGAGAATGAGACAGCCTGCGCTTAGATTTTAC CGGTCTGTAAAATGGAAATGTTGAGGTCACCTGGAAAGCTTTGTTAAGGAGTTGATGTT TGCTTTCCTTAACAAGACAGCAAAACGTAAACAGAAATTGAAAACTTGAAGGATATTT CAGTGTCATGGACTTCCTCAAAATGAAGTGCTATTTTCTTATTTTAATCAAATAACTA GACATATATCAGAAACTTTAAAAATGTAAAAGTTGTACACTTTCAACATTTTATTACGAT TATTATTCAGCAGCACATTCTGAGGGGGGAACAATTCACACCACCAATAATAACCTGG TAAGATTTCAGGAGGTAAAGAAGGTGGAATAATTGACGGGGAGATAGCGCCTGÁAAT AAACAAAATATGGGCATGCATGCTAAAGGGAAAATGTGTGCAGGTCTACTGCATTAAA TCCTGTGTGCTCCTCTTTTGGATTTACAGAAATGTGTCAAATGTAAATCTTTCAAAGCC ATTTAAAAATATTCACTTTAGTTCTCTGTGAAGAAGAGGAGAAAAGCAATCCTCCTGAT TGTATTGTTTTAAACTTTAAGAATTTATCAAAATGCCGGTACTTAGGACCTAAATTTAT CTATGTCTGTCATACGCTAAAATGATATTGGTCTTTGAATTTGGTATACATTTATTCTGT CATATTTTAATTTCACAAATAAAAAATTCAAAGTTTTGTACAAAATTATATGGATTTT GTGCCTGAAAATAATAGAGCTTGAGCTGTCTGAACTATTTTACATTTTATGGTGTCTCA TAGCCAATCCCACAGTGTAAAAATTCA

Figure 58

MAEEAPKKSRAAGGGASWELCAGALSARLAEEGSGDAGGRRRPPVDPRRLARQLLLLL WLLEAPLLLGVRAQAAGQGPGQGPGPGQQPPPPPQQQQSGQQYNGERGISVPDHGYCQPI SIPLCTDIAYNQTIMPNLLGHTNQEDAGLEVHQFYPLVKVQCSAELKFFLCSMYAPVCTVL EQALPPCRSLCERARQGCEALMNKFGFQWPDTLKCEKFPVHGAGELCVGQNTSDKGTPTP SLLPEFWTSNPQHGGGGHRGGFPGGAGASERGKFSCPRALKVPSYLNYHFLGEKDCGAPC EPTKVYGLMYFGPEELRFSRTWIGIWSVLCCASTLFTVLTYLVDMRRFSYPERPIIFLSGCYT AVAVAYIAGFLLEDRVVCNDKFAEDGARTVAQGTKKEGCTILFMMLYFFSMASSIWW VILSLTWFLAAGMKWGHEAIEANSQYFHLAAWAVPAIKTITILALGQVDGDVLSGVCFVG LNNVDALRGFVLAPLFVYLFIGTSFLLAGFVSLFRIRTIMKHDGTKTEKLEKLMVRIGVFSV LYTVPATIVIACYFYEQA

FRDQWERSWVAQSCKSYAIPCPHLQAGGGAPPHPPMSPDFTVFMIKYLMTLIVGITSGFWIWSGKTLNSWRKFYTRLTNSKQGETTV

Figure 59

CCCGCGCTACGCCACGCTGGAGCACCCCTTCCACTGCCCGCGCGTCCTCAAGGTGCCA TCCTATCTCAGCTACAAGTTTCTGGGCGAGCGTGATTGTGCTGCGCCCTGCGAACCTGC GCGGCCGATGGTTCCATGTTCTCACAGGAGGAGACGCGTTTCGCGCGCCTCTGGA TCCTCACCTGGTCGGTGCTGTGCTGCGCTTCCACCTTCTTCACTGTCACCACGTACTTGG TAGACATGCAGCGCTTCCGCTACCCAGAGCGGCCTATCATTTTTCTGTCGGGCTGCTAC ACCATGGTGTCGGTGGCCTACATCGCGGGCTTCGTGCTCCAGGAGCGCGTGGTGTGCA ACGAGCGCTTCTCCGAGGACGGTTACCGCACGGTGGTGCAGGGCACCAAGAAGGAGG GCTGCACCATCCTCATGATGCTCTACTTCTTCAGCATGGCCAGCTCCATCTGGTGG GTCATCCTGTCGCTCACCTGGTTCCTGGCAGCCGGCATGAAGTGGGGCCACGAGGCCA CATCACCATCCTGGCCATGGGCCAGATCGACGGCGACCTGCTGAGCGGCGTGTGCTTC GTAGGCCTCAACAGCCTGGACCCGCTGCGGGGCTTCGTGCTAGCGCCGCTCTTCGTGTA CCTGTTCATCGGCACGTCCTTCCTCCTGGCCGGCTTCGTGTCGCTCTTCCGCATCCGCAC CATCATGAAGCACGACGACCAAGACCGAAAAGCTGGAGCGGCTCATGGTGCGCAT CGGCGTCTTCTCCGTGCTCTACACAGTGCCCGCCACCATCGTCATCGCTTGCTACTTCTA CGAGCAGGCCTTCCGCGAGCACTGGGAGCGCTCGTGGGTGAGCCAGCACTGCAAGAGC CTGGCCATCCCGTGCCCGGCGCACTACACGCCGCGCATGTCGCCCGACTTCACGGTCTA CATGATCAAATACCTCATGACGCTCATCGTGGGCATCACGTCGGGCTTCTGGATCTGGT CGGGCAAGACGCTGCACTCGTGGAGGAAGTTCTACACTCGCCTCACCAACAGCCGACA AACCATTTCACTTTTAGGTTGCTTTTTAAAAGAGAACTCTCTGCCCAACACCCCC

Figure 60

MRPRSALPRLLLPLLLLPAAGPAQFHGEKGISIPDHGFCQPISIPLCTDIAYNQTIMPNLLGHT NQEDAGLEVHQFYPLVKVQCSPELRFFLCSMYAPVCTVLEQAIPPCRSICERARQGCEALM NKFGFQWPERLRCEHFPRHGAEQICVGQNHSEDGAPALLTTAPPPGLQPGAGGTPGGPGG GGAPPRYATLEHPFHCPRVLKVPSYLSYKFLGERDCAAPCEPARPDGSMFFSQEETRFARL WILTWSVLCCASTFFTVTTYLVDMQRFRYPERPIIFLSGCYTMVSVAYIAGFVLQERVVCN ERFSEDGYRTVVQGTKKEGCTILFMMLYFFSMASSIWWVILSLTWFLAAGMKWGHEAIEA NSQYFHLAAWAVPAVKTITILAMGQIDGDLLSGVCFVGLNSLDPLRGFVLAPLFVYLFIGTS FLLAGFVSLFRIRTIMKHDGTKTEKLERLMVRIGVFSVLYTVPATIVIACYFYEQAFREHW ERSWVSQHCKSLAIPCPAHYTPRMSPDFTVYMIKYLMTLIVGITSGFWIWSGKTLHSWRKF YTRLTNSRHGETTV

Figure 61

GGATTTCCGGCCTTTTCTTTGTGCACTCTACGCTCCTATTTGTATGGAATATGGACGTGT AGATGTTTGGTGTTCCTTGGCCTGAAGATATGGAATGCAGTAGGTTCCCAGATTGTGAT GAGCCATATCCTCGACTTGTGGATCTGAATTTAGCTGGAGAACCAACTGAAGGAGCCC CAGTGGCAGTGCAGAGAGACTATGGTTTTTGGTGTCCCCGAGAGTTAAAAATTGATCCT GATCTGGGTTATTCTTTCTGCATGTGCGTGATTGTTCACCTCCTTGTCCAAATATGTAC TCCTGAAAGGCCTATTATATTTTATGCAGTCTGCTACATGATGGTATCCTTAATTTTCTT AGGCTTCCACAGTGACACAAGGATCTCATAATAAAGCCTGTACCATGCTTTTTATGATA CTCTATTTTTTACTATGGCTGGCAGTGTATGGTGGGTAATTCTTACCATCACATGGTTT TTAGCAGCTGTGCCAAAGTGGGGTAGTGAAGCTATTGAGAAGAAAGCATTGCTGTTTC ACGCCAGTGCATGGGGCATCCCCGGAACTCTAACCATCATCCTTTTAGCGATGAATAA AATTGAAGGTGACAATATTAGTGGCGTGTGTTTTTGTTGGCCTCTACGATGTTGATGCAT AGCTGGCATTATATCCCTAAACAGAGTTCGAATTGAGATTCCATTAGAAAAGGAGAAC CAAGATAAATTAGTGAAGTTTATGATCCGGATCGGTGTTTTCAGCATTCTTTATCTCGT ACCACTCTTGGTTGTAATTGGATGCTACTTTTATGAGCAAGCTTACCGGGGCATCTGGG AAACAACGTGGATACAAGAACGCTGCAGAGAATATCACATTCCATGTCCATATCAGGT TACTCAAATGAGTCGTCCAGACTTGATTCTCTTTCTGATGAAATACCTGATGGCTCTCA TAGTTGGCATTCCCTCTGTATTTTGGGTTGGAAGCAAAAAGACATGCTTTGAATGGGCC AGTTTTTTCATGGTCGTAGGAAAAAAGAGATAGTGAATGAGAGCCGACAGGTACTCC AGGAACCTGATTTTGCTCAGTCTCTCCTGAGGGATCCAAATACTCCTATCATAAGAAAG TCAAGGGAACTTCCACTCAAGGAACATCCACCCATGCTTCTTCAACTCAGCTGGCTAT GGTGGATGATCAAAGAAGCAAAGCAGGAAGCATCCACAGCAAAGTGAGCAGCTACCA CGGCAGCCTCCACAGATCACGTGATGGCAGGTACACGCCCTGCAGTTACAGAGGAATG GAGGAGAGACTACCTCATGGCAGCATGTCACGACTAACAGATCACTCCAGGCATAGTA GTTCTCATCGGCTCAATGAACAGTCACGACATAGCAGCATCAGAGATCTCAGTAATAA TCCCATGACTCATATCACACATGGCACCAGCATGAATCGGGTTATTGAAGAAGATGGA ACCAGTGCTTAATTTGTCTTGTCTAAGGTGGAAATCTTGTGCTGTTTAAAAAGCAGATT TTATTCTTTGCCTTTTGCATGACTGATAGCTGTACTCACAGTTAACATGCTTTCAGTCAA GTACAGATTGTGTCCACTGGAAAGGTAAATGATTGCTTTTTTATATTGCATCAAACTTG GAACATCAAGGCATCCAAAACACTAAGAATTCTATCATCACAAAAATAATTCGTCTTTC TAGGTTATGAAGAGATAATTATTTGTCTGGTAAGCATTTTTATAAACCCACTCATTTTAT ATTTAGAAAAATCCTAAATGTGTGGTGACTGCTTTGTAGTGAACTTTCATATACTATAA ACTAGTTGTGAGATAACATTCTGGTAGCTCAGTTAATAAAACAATTTCAGAATTAAAG AAATTTTCTATGCAAGGTTTACTTCTCAGATGAACAGTAGGACTTTGTAGTTTTATTTCC ACTAAGTGAAAAAAGAACTGTTTTTTAAACTGTAGGAGAATTTAATAAATCAGCAAG GGTATTTTAGCTAATAGAATAAAAGTGCAACAGAAGAATTTGATTAGTCTATGAAAGG TTCTCTTAAAATTCTATCGAAATAATCTTCATGCAGAGATATTCAGGGTTTGGATTAGC AGTGGAATAAAGAGATGGGCATTGTTTCCCCTATAATTGTGCTGTTTTTATAACTTTTGT AAATATTACTTTTTCTGGCTGTGTTTTTATAACTTATCCATATGCATGATGGAAAAATTT TAATTTGTAGCCATCTTTTCCCATGTAATAGTATTGATTCATAGAGAACTTAATGTTCAA AATTTGCTTTGTGGAGGCATGTAATAAGATAAACATCATACATTATAAGGTAACCACA ATTACAAAATGGCAAAACA

Figure 62

 ${\tt MAMTWIVFSLWPLTVFMGHIGGHSLFSCEPITLRMCQDLPYNTTFMPNLLNHYDQQTAALAMEPFHPMVNLDCSRDFRPFLCALYAPICMEYGRVTLPCRRLCQRAYSECSKLMEMFGVP}$

WPEDMECSRFPDCDEPYPRLVDLNLAGEPTEGAPVAVQRDYGFWCPRELKIDPDLGYSFL HVRDCSPPCPNMYFRREELSFARYFIGLISIICLSATLFTFLTFLIDVTRFRYPERPIIFYAVCY MMVSLIFFIGFLLEDRVACNASIPAQYKASTVTQGSHNKACTMLFMILYFFTMAGSVWWVI LTITWFLAAVPKWGSEAIEKKALLFHASAWGIPGTLTIILLAMNKIEGDNISGVCFVGLYDV DALRYFVLAPLCLYVVVGVSLLLAGIISLNRVRIEIPLEKENQDKLVKFMIRIGVFSILYLVPL LVVIGCYFYEQAYRGIWETTWIQERCREYHIPCPYQVTQMSRPDLILFLMKYLMALIVGIPS VFWVGSKKTCFEWASFFHGRRKKEIVNESRQVLQEPDFAQSLLRDPNTPIIRKSRGTSTQGT STHASSTQLAMVDDQRSKAGSIHSKVSSYHGSLHRSRDGRYTPCSYRGMEERLPHGSMSR LTDHSRHSSSHRLNEQSRHSSIRDLSNNPMTHITHGTSMNRVIEEDGTSA

Figure 63

GCCGGCTTGTGGGCTCGCCGCCTGCAGCCATGACCCTCGCAGCCTGTCCCTCGGCCTCG CCCCTCGTCGCCGCATCACACTCCCGTCCCGGGAGCTGGGAGCAGCGCGGGCAGCCG GCGCCCCGTGCAAACTGGGGGTGTCTGCCAGAGCAGCCCCAGCCGCTGCCGCTGCTA CCCCGATGCTGGCCATGGCCTGGCGGGGCGCAGGGCCGAGCGTCCCGGGGGCCCCG GGGGCGTCGGTCTCAGTCTGGGGTTGCTCCTGCAGTTGCTGCTGCTCCTGGGGCCGGCG CGGGGCTTCGGGGACGAGGAAGAGCGCGCTGCGACCCCATCCGCATCTCCATGTGCC AGAACCTCGGCTACAACGTGACCAAGATGCCCAACCTGGTTGGGCACGAGCTGCAGAC GGACGCCGAGCTGCAGCAACTTTCACACCGCTCATCCAGTACGGCTGCTCCAGC CCCCATTGGCCCATGCGGCGCATGTGTCTTTCAGTCAAGAGACGCTGTGAACCCGTCC TGAAGGAATTTGGATTTGCCTGGCCAGAGAGTCTGAACTGCAGCAAATTCCCACCACA GAACGACCACACCACATGTGCATGGAAGGGCCAGGTGATGAAGAGGTGCCCTTACCT CACAAAACCCCCATCCAGCCTGGGGAAGAGTGTCACTCTGTGGGAACCAATTCTGATC AGTACATCTGGGTGAAAAGGAGCCTGAACTGTGTGCTCAAGTGTGGCTATGATGCTGG CTTATACAGCCGCTCAGCCAAGGAGTTCACTGATATCTGGATGGCTGTGTGGGCCAGCC TGTGTTTCATCTCCACTGCCTTCACAGTACTGACCTTCCTGATCGATTCTTCTAGGTTTT CCTACCCTGAGCGCCCCATCATATTTCTCAGTATGTGCTATAATATTTATAGCATTGCTT ATATTGTCAGGCTGACTGTAGGCCGGGAAAGGATATCCTGTGATTTTGAAGAGGCAGC AGAACCTGTTCTCATCCAAGAAGGACTTAAGAACACAGGATGTGCAATAATTTTCTTGC TTTTGGCAGCAGGACTCAAATGGGGTCATGAAGCCATTGAAATGCACAGCTCTTATTTC CACATTGCAGCCTGGGCCATCCCCGCAGTGAAAACCATTGTCATCTTGATTATGAGACT GGTGGATGCAGATGACTGACTGGCTTGTGCTATGTTGGAAACCAAAATCTCGATGCC CTCACCGGGTTCGTGGTGGCTCCCCTCTTTACTTATTTGGTCATTGGAACTTTGTTCATT GCTGCAGGTTTGGTGGCCTTGTTCAAAATTCGGTCAAAATCTTCAAAAGGATGGGACAA AGACAGACAAGTTAGAAAGACTGATGGTCAAGATTGGGGTGTTCTCAGTACTGTACAC AGTTCCTGCAACGTGTGTGATTGCCTGTTATTTTTATGAAATCTCCAACTGGGCACTTTT TCGGTATTCTGCAGATGATTCCAACATGGCTGTTGAAAATGTTGAAAACTTTTATGTCTTT GTTGGTGGGCATCACTTCAGGCATGTGGATTTGGTCTGCCAAAAGTCTTCACACGTGGC ATGGTTGGGTGAAGCCTGGAAAAGGCAGTGAGACTGTGGTATAAGGCTAGTCAGCCTC CATGCTTCTTCATTTGAAGGGGGGAATGCCAGCATTTTGGAGGAAATTCTACTAAAA GTTTTATGCAGTGAATCTCAGTTTGAACAAACTAGCAACAATTAAGTGACCCCCGTCAA CCCACTGCCTCCCACCCGACCCCAGCATCAAAAAAACCAATGATTTTGCTGCAGACTTT GGAATGATCCAAAATGGAAAAGCCAGTTAGAGGCTTTCAAAGCTGTGAAAAATCAAA ACGTTGATCACTTTAGCAGGTTGCAGCTTGGAGCGTGGAGGTCCTGCCTAGATTCCAGG AAGTCCAGGGCGATACTGTTTTCCCCTGCAGGGTGGGATTTGAGCTGTGAGTTAGC TAGCAGGGAGAAATATTAACTTTTTAACCCTTTACCATTTTAAATACTAACTGGGTCT

TTCAGATAGCAAAGCAATCTATAAACACTGGAAACGCTGGGTTCAGAAAAGTGTTACA AGAGTTTTATAGTTTGGCTGATGTAACATAAACATCTTCTGTGGTGCGCTGTCTGCTGTT TAGAACTTTGTGGACTGCACTCCCAAGAAGTGGTGTTAGAATCTTTCAGTGCCTTTGTC TTTTCTTCATTTTATGTTAATGACTCAAAAAAGGTATTTTTATAGAATTTTTGTACTGCA GCATGCTTAAAGAGGGGAAAAGGAAGGGTGATTCACTTTCTGACAATCACTTAATTCA GAGGAAAATGAGATTTACTAAGTTGACTTACCTGACGGACCCCAGAGACCTATTGCAT TGAGCAGTGGGGACTTAATATTTTACTTGTGTGATTGCATCTATGCAGACGCCAGTC TGGAAGAGCTGAAATGTTAAGTTTCTTGGCAACTTTGCATTCACACAGATTAGCTGTGT AATTTTTGTGTGTCAATTACAATTAAAAGCACATTGTTGGACCATGACATAGTATACTC AACTGACTTTAAAACTATGGTCAACTTCAACTTGCATTCTCAGAATGATAGTGCCTTTA AAATTTTTTTTTTAAAGCATAAGAATGTTATCAGAATCTGGTCTACTTAGGACAA TGGAGACTTTTTCAGTTTTATAAAGGGAACTGAGGACAGCTAATCCAACTACTTGGTGC TGTAATTGTTTCCTAGTAATTGGCAAAGGCTCCTTGTAAGATTTCACTGGAGGCAGTGT AGGTCTTAATTGCCTTTAGCAGAGGTATCCAAAGCTTTTAAAATTTATGCATACGTTCT TCACAAGGGGGTACCCCCAGCAGCCTCTCGAAAATTGCACTTCTCTTAAAACTGTAACT GGCCTTTCTCTTACCTTGCCTTAGGCCTTCTAATCATGAGATCTTGGGGACAAATTGACT ATGTCACAGGTTGCTCCCTTGTAACTCATACCTGTCTGCTTCAGCAACTGCTTTGCAAT TTTTTTTTTCAATCACACTTTGTGGAAAAACATTTCCAGGGACTCAAAATTCCAAAAA GGTGGTCAAATTCTGGAAGTAAGCATTTCCTCTTTTTTAAAAATTTGGTTTGAGCCTTAT GCCCATAGTTTGACATTTCCCTTTCTTTCCTTTTTGTTTTTTTGTGTGTTCTTGAGCTC TCTGACATCAAGATGCATGTAAAGTCGATTGTATGTTTTGAAGGCAAAGTCTTGGCTTT TGAGACTGAAGTTAAGTGGGCACAGGTGGCCCCTGCTGCTGTGCCCAGTCTGAGTACC TTGGCTAGACTCTAGGTCAGGCTCCAGGAGCATGAGAATTGATCCCCAGAAGAACCAT TTTAACTCCATCTGATACTCCATTGCCTATGAAATGTAAAATGTGAACTCCCTGTGCTG CTGCCCTTACTCACGCTCTGCTCTGGTGTCTTGGGAGTTGTGCAGGGACTCTGGCCCAG GCAGGGGAAGACCAGGCGGTAGGGGACTGGTCTTGCTGTTAGAGTATAGAGGTT TGTAATGCAGTTTTCTTCATAATGTGTCAGTGATTGTGTGACCAAGGCAGCATCTAGCA GAAAGCCAGGCATGGAGTAGGTGATCGATACTTGTCAATGACTAAATAATAACAATAA AAGAGCACTTGGGTGAATCTGGGCACCTGATTTCTGAGTTTTGAGTTCTGGAGCTAGTG TTTTGACAATGCTTTGGGTTTTGACATGCCTTTTCCACAAATCTCTTGCCTTTTCAGGGC AAAGTGTATTTGATCAGAAGTGGCCATTTGGATTAGTAGCCTTAGCAATGCTACAGGGT TATAGGCCCCTCTCCCTTTCACATTCCAGACAATGGAGAGTGTTTATGGTTTCAGGAAA GCCCTGAAATAGATAATCTCTGTTCTTAACTGATCTAGGATGGGGACGCACCCAGGT CTGCTGAACTTTACTGTTCCTCTGGGAAAGGAGCAGGGACCTCTGGAATTCCCATCTGT TTCACTGTCTCCATTCCATAAATCTCTTCCTGTGTGAGCCACCACCCCAGCCTGGGTCT TGGTTTTAACAGAAAGCATCAGCTCTGCTTCGTGACAGTCTCTGGAGAAATCCCTTAGG AAĠACTATGAGAGTAGGCCACAAGGACATGGGCCCACACATCTGCTTTGGCTTTGCCG GCAATTCAGGGCTTGGGGTATTCCATGTGACTTGTATAGGTATATTTGAGGACAGCATC TTGCTAGAGAAAAGGTGAGGGTTGTTTTTCTTTCTCTGAAACCTACAGTAAATGGGTAT GATTGTAGCTTCCTCAGAAATCCCTTGGCCTCCAGAGATTAAACATGGTGCAATGGCAC CTCTGTCCAACCTCCTTTCTGGTAGATTCCTTTCTCCTGCTTCATATAGGCCAAACCTCA GGGCAAGGGAACATGGGGGTAGAGTGGTGCTGGCCAGAACCATCTGCTTGAGCTACTT GGTTGATTCATATCCTCTTTCCTTTATGGAGACCCATTTCCTGATCTCTGAGACTGTTGC

TGAACTGGCAACTTACTTGGGCCTGAAACTGGAGAAGGGGTGACATTTTTTAATTTCA GAGATGCTTTCTGATTTTCCTCTCCCAGGTCACTGTCTCACCTGCACTCTCCAAACTCAG GTTCCGGGAAGCTTGTGTCTAGATACTGAATTGAGATTCTGTTCAGCACCTTTTAGC TCTATACTCTCTGGCTCCCCTCATCCTCATGGTCACTGAATTAAATGCTTATTGTATTGA GAACCAAGATGGGACCTGAGGACACAAGATGAGCTCAACAGTCTCAGCCCTAGAGG AATAGACTCAGGGATTTCACCAGGTCGGTGCAGTATTTGATTTCTGGTGAGGTGACCAC GTTTGTTTGTTTGTTTGTTTGTTTGAGACAGGGTCTTGCTCTGCTACCCAGG CTGGGGCGCAATGGCACGATCTTGGCTCACTGCAACCTCTGCCTCCTGGGTTCAAGTGA CTACTTCTGTATTTTTAGTAGAGACGGGGTTTCACTGTGTTGGCCAGGCTGGTCTCGAA CTCCTGACCTCATGATCTGCCCGCCTCAGCCTCCCAAAGTGCTGGGATTACAAGTGTGA GCCACCACACCTGGCCTGGAAGGAACCTCTTAAAATCAGTTTACGTCTTGTATTTTGTT CTGTGATGGAGGACACTGGAGAGAGTTGCTATTCCAGTCAATCATGTCGAGTCACTGG ACTCTGAAAATCCTATTGGTTCCTTTATTTTATTTGAGTTTAGAGTTCCCTTCTGGGTTT GTATTATGTCTGGCAAATGACCTGGGTTATCACTTTTCCTCCAGGGTTAGATCATAGAT CTTGGAAACTCCTTAGAGAGCATTTTGCTCCTACCAAGGATCAGATACTGGAGCCCCAC ATAATAGATTTCACTCTAGCCTACATAGAGCTTTCTGTTGCTGTCTCTTGCCATG CACTTGTGCGGTGATTACACACTTGACAGTACCAGGAGACAAATGACTTACAGATCCC CCGACATGCCTCTTCCCCTTGGCAAGCTCAGTTGCCCTGATAGTAGCATGTTTCTGTTTC TGATGTACCTTTTTCTCTTCTTTGCATCAGCCAATTCCCAGAATTTCCCCAGGCAA TTTGTAGAGGACCTTTTTGGGGTCCTATATGAGCCATGTCCTCAAAGCTTTTAAACCTC CTTGCTCTCCTACAATATTCAGTACATGACCACTGTCATCCTAGAAGGCTTCTGAAAAG AGGGGCAAGAGCCACTCTGCGCCACAAAGGTTGGATCCATCTTCTCTCCGAGGTTGTG AAAGTTTTCAAATTGTACTAATAGGCTGGGGCCCTGACTTGGCTGTGGGCTTTGGGAGG GGTAAGCTGCTTTCTAGATCTCTCCCAGTGAGGCATGGAGGTGTTTCTGAATTTTGTCT ACCTCACAGGGATGTTGTGAGGCTTGAAAAGGTCAAAAAATGATGGCCCCTTGAGCTC TTTGTAAGAAAGGTAGATGAAATATCGGATGTAATCTGAAAAAAAGATAAAATGTGAC TTCCCCTGCTCTGTGCAGCAGTCGGGCTGGATGCTCTGTGGCNTTTCTTGGGTCCTCATG CCACCCCACAGCTCCAGGAACCTTGAAGCCAATCTGGGGACTTTCAGATGTTTGACAA GGAAATGGACCCTGCTTTTAAGGATGTACAAAAGTATGTCTGCATCGATGTCTGTACTG TAAATTTCTAATTTATCACTGTACAAAGAAAACCCCCTTGCTATTTAATTTTGTATTAAAG GAAAATAAAGTTTTGTTTGTTAAAAAAAAA

Figure 64

MAWRGAGPSVPGAPGGVGLSLGLLLQLLLLLGPARGFGDEEERRCDPIRISMCQNLGYNV TKMPNLVGHELQTDAELQLTTFTPLIQYGCSSQLQFFLCSVYVPMCTEKINIPIGPCGGMCL SVKRRCEPVLKEFGFAWPESLNCSKFPPQNDHNHMCMEGPGDEEVPLPHKTPIQPGEECHS VGTNSDQYIWVKRSLNCVLKCGYDAGLYSRSAKEFTDIWMAVWASLCFISTAFTVLTFLID SSRFSYPERPIIFLSMCYNIYSIAYIVRLTVGRERISCDFEEAAEPVLIQEGLKNTGCAIIFLLM YFFGMASSIWWVILTLTWFLAAGLKWGHEAIEMHSSYFHIAAWAIPAVKTIVILIMRLVDA DELTGLCYVGNQNLDALTGFVVAPLFTYLVIGTLFIAAGLVALFKIRSNLQKDGTKTDKLE RLMVKIGVFSVLYTVPATCVIACYFYEISNWALFRYSADDSNMAVEMLKTFMSLLVGIT SGMWIWSAKSLHTWOKCSNRLVNSGKVKREKRGNGWVKPGKGSETVV

Figure 65

CGTGGAGAGTCCTTTCCCTGGAATCCGAGCCCTAACCGTCTCTCCCCAGCCCTATCCGG CGAGGAGCGGAGCGCAGCGGAGGCACCTTCCCGAAGCAGTTTATCTTTGGA CGGTTTTCTTTAAAGGAAAAACGAACCAACAGGTTGCCAGCCCCGGCGCCACACACGA GACGCCGGAGGAGAAGCCCCGGCCCGGATTCCTCTGCCTGTGCGTCCCTCGCGGG CTGCTGGAGGCGAGGGAGGGGGGGGGGTCGGCCTGACCCATCCGCGCCGC CCTCGCTGTTGCTGCTCCTGGCGCAGCTGGTGGGCCGGGCGGCCGCCGCGTCCAA GGCCCGGTGTGCCAGGAAATCACGGTGCCCATGTGCCGCGGCATCGGCTACAACCTG ACGCACATGCCCAACCAGTTCAACCACGACACGCAGGACGAGGCGGCCTGGAGGTG CACCAGTTCTGGCCGCTGGTGGAGATCCAATGCTCGCCGGACCTGCGCTTCTTCCTATG CACTATGTACACGCCCATCTGTCTGCCCGACTACCACAAGCCGCTGCCGCCTGCCGCT CGGTGTGCGAGCGCCAAGGCCGGCTGCTCGCCGCTGATGCGCCAGTACGGCTTCGC CTGGCCCGAGCGCATGAGCTGCGACCGCCTCCCGGTGCTGGGCCGCGACGCCGAGGTC CTCTGCATGGATTACAACCGCAGCGAGGCCACCACGGCGCCCCCAGGCCTTTCCCAG TGGGGGCCCGTTCGTGCAAGTGTCGCGAGCCCTTCGTGCCCATTCTGAAGGAGTCAC ACCCGCTCTACAACAAGGTGCGGACGGGCCAGGTGCCCAACTGCGCGGTACCCTGCTA CCAGCCGTCCTTCAGTGCCGACGAGCGCACGTTCGCCACCTTCTGGATAGGCCTGTGGT CGGTGCTGTCCTCATCTCCACGTCCACCACAGTGGCCACCTTCCTCATCGACATGGAC ACGTTCCGCTATCCTGAGCGCCCCATCATCTTCCTGTCAGCCTGCTACCTGTGCGTGTC GCTGGGCTTCCTGGTCGTCGTCGTGGCCATGCCAGCGTGGCCTGCAGCCGCGAG CACAACCACATCCACTACGAGACCACGGGCCCTGCACTGTGCACCATCGTCTTCCTCCT GGTCTACTTCTCGGCATGGCCAGCTCCATCTGGTGGGTCATCCTGTCGCTCACCTGGTT CCTGGCCGCGATGAAGTGGGGCAACGAGGCCATCGCGGGCTACGGCCAGTACTTC CACCTGGCTGCGTGGCTCATCCCCAGCGTCAAGTCCATCACGGCACTGGCGCTGAGCTC CGTGGACGGGACCCAGTGGCCGGCATCTGCTACGTGGGCAACCAGAACCTGAACTCG CTGCGGCGCTTCGTGCTGGGCCCGCTGGTGCTCTACCTGCTGGTGGGCACGCTCTTCCT GCTGGCGGCTTCGTGTCGCTCTTCCGCATCCGCAGCGTCATCAAGCAGGGCGCACC AAGACGGACAAGCTGGAGAAGCTCATGATCCGCATCGGCATCTTCACGCTGCTCTACA CGGTCCCCGCCAGCATTGTGGTGGCCTGCTACCTGTACGAGCAGCACTACCGCGAGAG CTGGGAGGCGCCTCACCTGCGCCTGCCCGGGCCACGACACCGGCCAGCCGCGCCC AAGCCCGAGTACTGGGTGCTCATGCTCAAGTACTTCATGTGCCTGGTGGTGGGCATCAC GTCGGGCGTCTGGATCTGGTCGGGCAAGACGGTGGAGTCGTGGCGGCGTTTCACCAGC CGCTGCTGCCGCCCGCGGCGCGCCACAAGAGCGGGGGCGCCATGGCCGCAGGG GACTACCCCGAGGCGAGCGCCGCGCTCACAGGCAGGACCGGGCCGCCGGCCCGCC GCCACCTACCACAAGCAGGTGTCCCTGTCGCACGTGTAGGAGGCTGCCGCCGAGGGAC TCGGCCGGAGAGCTGAGGGGGGGGGGCGTTTTGTTTGGTAGTTTTGCCAAGGTCACT TCCGTTTACCTTCATGGTGCTGTTGCCCCCTCCCGCGGCGACTTGGAGAGAGGGAAGAG GGGCGTTTTCGAGGAAGAACCTGTCCCAGGTCTTCTCCAAGGGGCCCAGCTCACGTGT ATTCTATTTTGCGTTTCTTACCTGCCTTCTTTATGGGAACCCTCTTTTTAATTTATATGTA \mathbf{T}

Figure 66

MARPDPSAPPSLLLLLLAQLVGRAAAASKAPVCQEITVPMCRGIGYNLTHMPNQFNHDTQ DEAGLEVHQFWPLVEIQCSPDLRFFLCTMYTPICLPDYHKPLPPCRSVCERAKAGCSPLMR QYGFAWPERMSCDRLPVLGRDAEVLCMDYNRSEATTAPPRPFPAKPTLPGPPGAPASGGE CPAGGPFVCKCREPFVPILKESHPLYNKVRTGQVPNCAVPCYQPSFSADERTFATFWIGLW SVLCFISTSTTVATFLIDMDTFRYPERPIIFLSACYLCVSLGFLVRLVVGHASVACSREHNHIH YETTGPALCTIVFLLVYFFGMASSIWWVILSLTWFLAAAMKWGNEAIAGYGQYFHLAAWL IPSVKSITALALSSVDGDPVAGICYVGNQNLNSLRRFVLGPLVLYLLVGTLFLLAGFVSLFRI RSVIKQGGTKTDKLEKLMIRIGIFTLLYTVPASIVVACYLYEQHYRESWEAALTCACPGHD TGQPRAKPEYWVLMLKYFMCLVVGITSGVWIWSGKTVESWRRFTSRCCCRPRRGHKSGG AMAAGDYPEASAALTGRTGPPGPAATYHKQVSLSHV

Figure 67

GCAGCTCCAGTCCCGGACGCAACCCCGGAGCCGTCTCAGGTCCCTGGGGGGAACGGTG GGTTAGACGGGGACGGGACAGCGGCCTTCGACCGCCCCCGAGTAATTGACCC AGGACTCATTTTCAGGAAAGCCTGAAAATGAGTAAAATAGTGAAATGAGGAATTTGAA CATTTTATCTTTGGATGGGGATCTTCTGAGGATGCAAAGAGTGATTCATCCAAGCCATG TGGTAAAATCAGGAATTTGAAGAAAATGGAGATGTTTACATTTTTGTTGACGTGTATTT TTCTACCCCTCCTAAGAGGGCACAGTCTCTTCACCTGTGAACCAATTACTGTTCCCAGA TGTATGAAAATGGCCTACAACATGACGTTTTTCCCTAATCTGATGGGTCATTATGACCA GAGTATTGCCGCGGTGGAAATGGAGCATTTTCTTCCTCTCGCAAATCTGGAATGTTCAC CAAACATTGAAACTTTCCTCTGCAAAGCATTTGTACCAACCTGCATAGAACAAATTCAT GTGGTTCCACCTTGTCGTAAACTTTGTGAGAAAGTATATTCTGATTGCAAAAAATTAAT TGACACTTTTGGGATCCGATGGCCTGAGGAGCTTGAATGTGACAGATTACAATACTGTG ATGAGACTGTTCCTGTAACTTTTGATCCACACACAGAATTTCTTGGTCCTCAGAAGAAA ACAGAACAAGTCCAAAGAGACATTGGATTTTGGTGTCCAAGGCATCTTAAGACTTCTG GGGGACAAGGATATAAGTTTCTGGGAATTGACCAGTGTGCGCCTCCATGCCCCAACAT GTATTTTAAAAGTGATGAGCTAGAGTTTGCAAAAAGTTTTATTGGAACAGTTTCAATAT TTTGTCTTTGTGCAACTCTGTTCACATTCCTTACTTTTTAATTGATGTTAGAAGATTCA GATACCCAGAGAGACCAATTATATATTACTCTGTCTGTTACAGCATTGTATCTCTTATG TACTTCATTGGATTTTTGCTGGGCGATAGCACAGCCTGCAATAAGGCAGATGAGAAGC TAGAACTTGGTGACACTGTTGTCCTAGGCTCTCAAAATAAGGCTTGCACCGTTTTGTTC TGGTTCTTAGCTGCAGGAAGAAATGGAGTTGTGAAGCCATCGAGCAAAAAGCAGTGT GGTTTCATGCTGTTGCATGGGGAACACCAGGTTTCCTGACTGTTATGCTTCTTGCTCTGA ACAAAGTTGAAGGAGACAACATTAGTGGAGTTTGCTTTGTTGGCCTTTATGACCTGGAT TTTTAGCTGGCATTATTTCCTTAAATCATGTTCGACAAGTCATACAACATGATGGCCGG AACCAAGAAAAACTAAAGAAATTTATGATTCGAATTGGAGTCTTCAGCGGCTTGTATC TTGTGCCATTAGTGACACTTCTCGGATGTTACGTCTATGAGCAAGTGAACAGGATTACC TGGGAGATAACTTGGGTCTCTGATCATTGTCGTCAGTACCATATCCCATGTCCTTATCA GGCAAAAGCAAAAGCTCGACCAGAATTGGCTTTATTATGATAAAATACCTGATGACA TTAATTGTTGGCATCTCTGCTGTCTTCTGGGTTGGAAGCAAAAAGACATGCACAGAATG GGCTGGGTTTTTTAAACGAAATCGCAAGAGAGATCCAATCAGTGAAAGTCGAAGAGTA CTACAGGAATCATGTGAGTTTTCTTAAAGCACAATTCTAAAGTTAAACACAAAAAGA AGCACTATAAACCAAGTTCACACAAGCTGAAGGTCATTTCCAAATCCATGGGAACCAG CACAGGAGCTACAGCAAATCATGGCACTTCTGCAGTAGCAATTACTAGCCATGATTAC CTAGGACAAGAACTTTGACAGAAATCCAAACCTCACCAGAAACATCAATGAGAGAG GTGAAAGCGGACGGAGCTAGCACCCCCAGGTTAAGAGAACAGGACTGTGGTGAACCT GCCTCGCCAGCAGCATCCATCTCCAGACTCTCTGGGGAACAGGTCGACGGGAAGGGCC

48/66

ATATTACTGACACTGGCCTGGCACAGAGCAACAATTTGCAGGTCCCCAGTTCTTCAGAA CCAAGCAGCCTCAAAGGTTCCACATCTCTGCTTGTTCACCCAGTTTCAGGAGTGAGAAA AGAGCAGGGAGGTGGTTGTCATTCAGATACTTGAAGAACATTTTCTCTCGTTACTCAGA AGCAAATTTGTGTTACACTGGAAGTGACCTATGCACTGTTTTGTAAGAATCACTGTTAC GTTCTTCTTTTGCACTTAAAGTTGCATTGCCTACTGTTATACTGGAAAAAATAGAGTTC AAGAATAATATGACTCATTTCACACAAAGGTTAATGACAACAATATACCTGAAAAACAG AAATGTGCAGGTTAATAATATTTTTTAATAGTGTGGGAGGACAGAGTTAGAGGAATC TTCCTTTTCTATTTATGAAGATTCTACTCTTGGTAAGAGTATTTTAAGATGTACTATGCT ATTTTACCTTTTTGATATAAAATCAAGATATTTCTTTGCTGAAGTATTTAAATCTTATCC TTGTATCTTTTATACATATTTGAAAATAAGCTTATATGTATTTGAACTTTTTTGAAATC ${\tt CTATTCAAGTATTTTATCATGCTATTGTGATATTTTAGCACTTTTGGTAGCTTTTACACT}$ AAAGTCTTATAATAGGAATTTAACTTTAAAAAACCCACTTATTGATACCTTACCATCTAA AATGTGTGATTTTATAGTCTCGTTTTAGGAATTTCACAGATCTAAATTATGTAACTGA AATAAGGTGCTTACTCAAAGAGTGTCCACTATTGATTGTATTATGCTGCTCACTGATCC TTCTGCATATTTAAAATAAAATGTCCTAAAGGGTTAGTAGACAAAATGTTAGTCTTTTG TATATTAGGCCAAGTGCAATTGACTTCCCTTTTTTAATGTTTCATGACCACCCATTGATT GTATTATAACCACTTACAGTTGCTTATATTTTTTGTTTTAACTTTTGTTTCTTAACATTTA GAATATTACATTTTGTATTATACAGTACCTTTCTCAGACATTTTGTAG

Figure 68

MEMFTFLLTCIFLPLLRGHSLFTCEPITVPRCMKMAYNMTFFPNLMGHYDQSIAAVEMEHF LPLANLECSPNIETFLCKAFVPTCIEQIHVVPPCRKLCEKVYSDCKKLIDTFGIRWPEELECD RLQYCDETVPVTFDPHTEFLGPQKKTEQVQRDIGFWCPRHLKTSGGQGYKFLGIDQCAPPC PNMYFKSDELEFAKSFIGTVSIFCLCATLFTFLTFLIDVRRFRYPERPIIYYSVCYSIVSLMYFI GFLLGDSTACNKADEKLELGDTVVLGSQNKACTVLFMLLYFFTMAGTVWWVILTITWFLA AGRKWSCEAIEQKAVWFHAVAWGTPGFLTVMLLALNKVEGDNISGVCFVGLYDLDASRY FVLLPLCLCVFVGLSLLLAGIISLNHVRQVIQHDGRNQEKLKKFMIRIGVFSGLYLVPLVTLL GCYVYEQVNRITWEITWVSDHCRQYHIPCPYQAKAKARPELALFMIKYLMTLIVGISA VFWVGSKKTCTEWAGFFKRNRKRDPISESRRVLQESCEFFLKHNSKVKHKKKHYKPSSHK LKVISKSMGTSTGATANHGTSAVAITSHDYLGQETLTEIQTSPETSMREVKADGASTPRLRE QDCGEPASPAASISRLSGEQVDGKGQAGSVSESARSEGRISPKSDITDTGLAQSNNLQVPSSS EPSSLKGSTSLLVHPVSGVRKEQGGGCHSDT

Figure 69

CAAGGTGCCCCGTACCTGGGCTACCGCTTCCTGGGTGAGCGCGATTGTGGCGCCCCGT GCGAACCGGCCGTGCCAACGGCCTGATGTACTTTAAGGAGGAGAGAGGCGCTTCGC CCGCCTCTGGGTGGCGTGTGGTCCGTGCTGCGCCCTCGACGCTCTTTACCGTTC TCACCTACCTGGTGGACATGCGGCGCTTCAGCTACCCAGAGCGGCCCATCATCTTCCTG CGCCGTGTGCGTGGAGCGCTTCTCGGACGATGGCTACCGCACGGTGGCGCAGGGCACC AAGAAGGAGGCTGCACCATCCTCTTCATGGTGCTCTACTTCTTCGGCATGGCCAGCTC ACGAGGCCATCGAGGCCAACTCGCAGTACTTCCACCTGGCCGCGTGGGCCGTGCCCGC CGTCAAGACCATCACTATCCTGGCCATGGGCCAGGTAGACGGGGACCTGCTGAGCGGG GTGTGCTACGTTGGCCTCTCCAGTGTGGACGCGCTGCGGGGCTTCGTGCTGCCCCTCT GTTCGTCTACCTCTTCATAGGCACGTCCTTCTTGCTGGCCGGCTTCGTGTCCCTCTTCCG TATCCGCACCATCATGAAACACGACGGCACCAAGACCGAGAAGCTGGAGAAGCTCAT GGTGCGCATCGGCGTCTTCAGCGTGCTCTACACAGTGCCCGCCACCATCGTCCTGGCCT GCTACTTCTACGAGCAGGCCTTCCGCGAGCACTGGGAGCGCACCTGGCTCCTGCAGAC GTGCAAGAGCTATGCCGTGCCCTGCCCGCCCGGCCACTTCCCGCCCATGAGCCCCGACT TCACCGTCTTCATGATCAAGTACCTGATGACCATGATCGTCGGCATCACCACTGGCTTC TGGATCTGGTCGGGCAAGACCCTGCAGTCGTGGCGCCGCTTCTACCACAGACTTAGCC ACAGCAGCAAGGGGAGACTGCGGTATGAGCCCCGGCCCCTCCCCACCTTTCCCACCC GTTTCTGTAACTTTCTCCCCCTCTACTGAGAAGTGACCTGGAAGTGAGAAGTTCTTTGC AGATTTGGGGCGAGGGTGATTTGGAAAAGAAGACCTGGGTGGAAAGCGGTTTGGAT GAAAAGATTTCAGGCAAAGACTTGCAGGAAGATGATGATAACGGCGATGTGAATCGTC AAAGGTACGGCCAGCTTGTGCCTAATAGAAGGTTGAGACCAGCAGAGACTGCTGTGA GTTTCTCCCGGCTCCGAGGCTGAACGGGGACTGTGAGCGATCCCCCTGCTGCAGGGCG AGTGGCCTGTCCAGACCCCTGTGAGGCCCCGGGAAAGGTACAGCCCTGTCTGCGGTGG ${\tt CTGCTTTGTTGGAAAGAGGGGGGCCTCCTGCGGTGTGCTTGTCAAGCAGTGGTCAAA}$ CCATAATCTCTTTCACTGGGGCCAAACTGGAGCCCAGATGGGTTAATTTCCAGGGTCA GACATTACGGTCTCCCCCCCCCCCCCCCCCCGCCTGTTTTTCCTCCCGTACTGCTTTC TGAGGATGCAAAAGAAATGATGATAACATTTTGAGATAAGGCCAAGGAGACGTGGAG TAGGTATTTTGCTACTTTTCATTTTCTGGGGAAGGCAGAGGCAGAAAGACGGGTGT TTTATTTGGTCTAATACCCTGAAAAGAAGTGATGACTTGTTGCTTTTCAAAACAGGAAT GCATTTTTCCCCTTGTCTTTGTTGTAAGAGACAAAGAGGAAACAAAAGTGTCTCCCTG TGGAAAGGCATAACTGTGACGAAAGCAACTTTTATAGGCAAAGCAGCGCAAATCTGAG GTTTCCCGTTGGTTGATTTGGTTGAGATAAACATTCCTTTTTAAGGAAAAGTGAAG AGCAGTGTGCTGTCACACACCGTTAAGCCAGAGGTTCTGACTTCGCTAAAGGAAATGT AAGAGGTTTTGTTGTCTGTTTTAAATAAATTTAATTCGGAACACATGATCCAACAGACT ATGTTAAAATATTCAGGGAAATCTCTCCCTTCATTTACTTTTCTTGCTATAAGCCTATA GTCCTGTTTCCTTGGTTCCATCAATCTGTTTATTAAACATCATCCATATGCTGACCCTGT CTCTGTGTGGGTTGGGAGGCGATCAGCAGATACCATAGTGAACGAAGAGGAAGG TTTGAACCATGGGCCCCATCTTTAAAGAAAGTCATTAAAAGAAGGTAAACTTCAAAGT GATTCTGGAGTTCTTTGAAATGTGCTGGAAGACTTAAATTTATTAATCTTAAATCATGT ACTTTTTTCTGTAATAGAACTCGGATTCTTTTGCATGATGGGGTAAAGCTTAGCAGAG AATCATGGGAGCTAACCTTTATCCCACCTTTGACACTACCCTCCAATCTTGCAACACTA TCCTGTTTCTCAGAACAGTTTTTAAATGCCAATCATAGAGGGTACTGTAAAGTGTACAA GTTACTTTATATATGTAATGTTCACTTGAGTGGAACTGCTTTTTACATTAAAGTTAAAAT CGATCTTGTGTTTCTCAACCTTCAAAACTATCTCATCTGTCAGATTTTTAAAACTCCAA CACAGGTTTTGGCATCTTTTGTGCTGTATCTTTTAAGTGCATGTGAAATTTGTAAAATAG

TATTTATACATTTTACTTTGGATTTTTGTTTGTTGGCTTTAAAGGTCTACCCCACTTTA TCACATGTACAGATCACAAATAAATTTTTTTAAATAC

Figure 70

MRDPGAAAPLSSLGLCALVLALLGALSAGAGAQPYHGEKGISVPDHGFCQPISIPLCTDIAY NQTILPNLLGHTNQEDAGLEVHQFYPLVKVQCSPELRFFLCSMYAPVCTVLDQAIPPCRSLC ERARQGCEALMNKFGFQWPERLRCENFPVHGAGEICVGQNTSDGSGGPGGGPTAYPTAPY LPDLPFTALPPGASDGRGRPAFPFSCPRQLKVPPYLGYRFLGERDCGAPCEPGRANGLMYF KEEERRFARLWVGVWSVLCCASTLFTVLTYLVDMRRFSYPERPIIFLSGCYFMVAVAHVA GFLLEDRAVCVERFSDDGYRTVAQGTKKEGCTILFMVLYFFGMASSIWWVILSLTWFLAA GMKWGHEAIEANSQYFHLAAWAVPAVKTITILAMGQVDGDLLSGVCYVGLSSVDA LRGFVLAPLFVYLFIGTSFLLAGFVSLFRIRTIMKHDGTKTEKLEKLMVRIGVFSVLYTVPAT IVLACYFYEQAFREHWERTWLLQTCKSYAVPCPPGHFPPMSPDFTVFMIKYLMTMIVGITT GFWIWSGKTLQSWRRFYHRLSHSSKGETAV

Figure71

ACAGCATGGAGTGGGGTTACCTGTTGGAAGTGACCTCGCTGCTGGCCGCCTTGGCGCT GCTGCAGCGCTCTAGCGGCGCTGCGGCCTCGGCCAAGGAGCTGGCATGCCAAGAG ATCACCGTGCCGCTGTGTAAGGGCATCGGCTACAACTACACCTACATGCCCAATCAGTT CAACCACGACACGCAAGACGAGGCGGCCTGGAGGTGCACCAGTTCTGGCCGCTGGTG GAGATCCAGTGCTCGCCCGATCTCAAGTTCTTCCTGTGCAGCATGTACACGCCCATCTG CCTAGAGGACTACAAGAAGCCGCTGCCGCCCTGCCGCTGTGTGCGAGCGCGCCAAG GCCGGCTGCGCCGCTCATGCGCCAGTACGGCTTCGCCTGGCCCGACCGCATGCGCT GCGACCGGCTGCCCGAGCAAGGCAACCCTGACACGCTGTGCATGGACTACAACCGCAC GAGCAGCCGCCTTCGGGCAGCGGCCACGGCCGCCGGGGGGCCCAGGCCCCGCACC GCGGAGGCGCAGGGCGTGGCGCGGGGGACGCGCGCCCCCAGCTCGCGGCG GCGGCGGTGGCGGAAGGCGCGGCCCCTGGCGGCGCGCGGCTCCCTGCGAGCCCG CCGCGTCAAGACAGGCCAGATCGCTAACTGCGCGCTGCCCTGCCACAACCCCTTTTTCA GCCAGGACGAGCGCCTTCACCGTCTTCTGGATCGGCCTGTGGTCGGTGCTCTGCTTC GTGTCCACCTTCGCCACCGTCTCCACCTTCCTTATCGACATGGAGCGCTTCAAGTACCC GGAGCGCCCATTATCTTCCTCTCGGCCTGCTACCTCTTCGTGTCGGTGGGCTACCTAG TGCGCCTGGTGGCGGGCCACGAGAAGGTGGCGTGCAGCGGTGGCGCCGGGCGCGG CGGGCGGCCGGGCGGCGGCGAGTACGAGGAGCTGGGCGCGGTGGAGCACG TGCGCTACGAGACCACCGGCCCCGCGCTGTGCACCGTGGTCTTCTTGCTGGTCTACTTC TTCGGCATGGCCAGCTCCATCTGGTGGGTGATCTTGTCGCTCACATGGTTCCTGGCGGC CGGTATGAAGTGGGGCAACGAAGCCATCGCCGGCTACTCGCAGTACTTCCACCTGGCC GCGTGGCTTGTGCCCAGCGTCAAGTCCATCGCGGTGCTGGCGCTCAGCTCGGTGGACG GCGACCCGGTGGCGGCATCTGCTACGTGGGCAACCAGAGCCTGGACAACCTGCGCGG CTTCGTGCTGGCCGCTGGTCATCTACCTCTTCATCGGCACCATGTTCCTGCTGGCCG GCTTCGTGTCCCTGTTCCGCATCCGCTCGGTCATCAAGCAACAGGACGGCCCCACCAAG ACGCACAAGCTGGAGAAGCTGATGATCCGCCTGGGCCTGTTCACCCGTGCTCTACACCG GGAGGCCACGCACAACTGCCCGTGCCTGCGGGACCTGCAGCCCGACCAGGCACGCAG GCCCGACTACGCCGTCTTCATGCTCAAGTACTTCATGTGCCTAGTGGTGGGCATCACCT CGGGCGTGTGGGTCTGGTCCGGCAAGACGCTGGAGTCCTGGCGCTCCCTGTGCACCCG GGGGGTGGCGGCGGCGGGGGGGCGCGCGGCGGGGACCCGGCGCGCGGGGG

GGCCGGCGCGCGGGGGCTCCCTCTACAGCGACGTCAGCACTGGCCTGACGTGGCG GTCGGGCACGGCGAGCTCCGTGTCTTATCCAAAGCAGATGCCATTGTCCCAGGTCTGA GCGGAGGGGGGGGCCCCAGGAGGGGTGGGGAGGGGGGGGAGAGACCCAAGTG CAGCGAAGGGACACTTGATGGGCTGAGGTTCCCACCCCTTCACAGTGTTGATTGCTATT AGCATGATAATGAACTCTTAATGGTATCCATTAGCTGGGACTTAAATGACTCACTTAGA ACAAAGTACCTGGCATTGAAGCCTCCCAGACCCAGCCCCTTTTCCTCCATTGATGTGCG GGGAGCTCCTCCCGCCACGCGTTAATTTCTGTTGGCTGAGGAGGGTGGACTCTGCGGCG TTTCCAGAACCCGAGATTTGGAGCCCTCCCTGGCTGCACTTGGCTGGGTTTGCAGTCAG ATACACAGATTTCACCTGGGAGAACCTCTTTTTCTCCCTCGACTCTTCCTACGTAAACTC CCACCCTGACTTACCCTGGAGGAGGGTGACCGCCACCTGATGGGATTGCACGGTTT ATACACCCCACGTAAATACGGGTTTCTTACATTAGAGGATGTATTTATATAATTATTTG TTAAATTGTAAAAAAAAAAAGTGTAAAATATGTATATCCAAAGATATAGTGTGTAC ATTTTTTGTAAAAAGTTTAGAGGCTTACCCCTGTAAGAACAGATATAAGTATTCTATT TTGTCAATAAAATGACTTTTGATAAATGATTTAACCATTGCCCTCTCCCCCGCCTCTTCT GAGCTGTCACCTTTAAAGTGCTTGCTAAGGACGCATGGGGAAAATGGACATTTTCTGG CTTGTCATTCTGTACACTGACCTTAGGCATGGAGAAAATTACTTGTTAAACTCTAGTTC TTAAGTTGTTAGCCAAGTAAATATCATTGTTGAACTGAAATCAAAATTGAGTTTTTGCA CCTTCCCAAAGACGGTGTTTTCATGGGAGCTCTTTTCTGATCCATGGATAACAACTC TCACTTTAGTGGATGTAAATGGAACTTCTGCAAGGCAGTAATTCCCCTTAGGCCTTGTT

Figure 72

Figure 73

TGGGCCGGGCGCGGCGCAGTGGCACCTGCGAGAACCCCGAGAAGTTCCAGTACGT GGAGAAGAGCCGCTCGTGCGCACCGCGCTGCGGGCCCGGCGTCGAGGTGTTCTGGTCC CGGCGCGACAAGGACTTCGCGCTGGTCTGGATGGCCGTGTGGTCGGCGCTGTGCTTCTT CTCCACCGCCTTCACTGTGCTCACCTTCTTGCTGGAGCCCCACCGCTTCCAGTACCCCG AGCGCCCCATCATCTTCCTCTCCATGTGCTACAACGTCTACTCGCTGGCCTTCCTGATCC GATCCAGGAGGCCTGGAGAACACGGGCTGCACGCTGGTCTTCCTACTGCTCTACTAC TTCGGCATGGCCAGCTCGCTCTGGTGGGTGCTCACCTGACCTGGTTCCTGGCTGC CGGGAAGAATGGGGCCACGAGGCCATCGAGGCCCACGGCAGCTATTTCCACATGGCT GCCTGGGGCCTGCCGCGCTCAAGACCATCGTCATCCTGACCCTGCGCAAGGTGGCGG GTGATGAGCTGACTGGGCTTTGCTACGTGGCCAGCACGGATGCAGCAGCGCTCACGGG CTTCGTGCTGGTGCCCCTCTCTGGCTACCTGGTGCTGGGCAGTAGTTTCCTCCTGACCG GCTTCGTGGCCCTCTTCCACATCCGCAAGATCATGAAGACGGGCGGCACCAACACAGA GAAGCTGGAGAAGCTCATGGTCAAGATCGGGGTCTTCTCCATCCTCTACACGGTGCCC GCCACCTGCGTCATCGTTTGCTATGTCTACGAACGCCTCAACATGGACTTCTGGCGCCT TCGGGCCACAGAGCAGCCATGCGCAGCGGCCGCGGGGCCCGGAGGCCGGAGGGACTG CTCGCTGCCAGGGGGCTCGGTGCCCACCGTGGCGGTCTTCATGCTCAAAATTTTCATGT CACTGGTGGTGGGATCACCAGCGGCGTCTGGGTGTGGAGCTCCAAGACTTTCCAGAC CTGGCAGAGCCTGTGCTACCGCAAGATAGCAGCTGGCCGGGCCCGGGCCAAGGCCTGC CGCGCCCCGGGAGCTACGGACGTGGCACTGCCACTATAAGGCTCCCACCGTGG TCTTGCACATGACTAAGACGGACCCCTCTTTGGAGAACCCCACACACCTCTAGCCACAC AGGCCTGGCGGGGTGGCTGCTGCCCCTCCTTGCCCTCCACGCCCTGCCCCTGCAT CCCCTAGAGACAGCTGACTAGCAGCTGCCCAGCTGTCAAGGTCAGGCAAGTGAGCACC GGGGACTGAGGATCAGGGCGGGACCCCGTGAGGCTCATTAGGGGAGATGGGGGTCTC CCCTAATGCGGGGGCTGGACCAGGCTGAGTCCCCACAGGGTCCTAGTGGAGGATGTGG AGGGCGGGCAGAGGGGTCCAGCCGGAGTTTATTTAATGATGTAATTTATTGTTGCG TTCCTCTGGAAGCTGTGACTGGAATAAACCCCCGCGTGGCACTGCTGATCCTCTCTGGC TGGGAAGGGGAAGGTAGGAGGTGAGGC

Figure 74

MAVAPLRGALLLWQLLAAGGAALEIGRFDPERGRGAAPCQAVEIPMCRGIGYNLTRMPNL LGHTSQGEAAAELAEFAPLVQYGCHSHLRFFLCSLYAPMCTDQVSTPIPACRPMCEQARLR CAPIMEQFNFGWPDSLDCARLPTRNDPHALCMEAPENATAGPAEPHKGLGMLPVAPRPAR PPGDLGPGAGGSGTCENPEKFQYVEKSRSCAPRCGPGVEVFWSRRDKDFALVWMAVWSA LCFFSTAFTVLTFLLEPHRFQYPERPIIFLSMCYNVYSLAFLIRAVAGAQSVACDQEAGALY VIQEGLENTGCTLVFLLLYYFGMASSLWWVVLTLTWFLAAGKKWGHEAIEAHGSYFHMA AWGLPALKTIVILTLRKVAGDELTGLCYVASTDAAALTGFVLVPLSGYLVLGSSFLLTG FVALFHIRKIMKTGGTNTEKLEKLMVKIGVFSILYTVPATCVIVCYVYERLNMDFWRLRAT EQPCAAAAGPGGRRDCSLPGGSVPTVAVFMLKIFMSLVVGITSGVWVWSSKTFQTWQSLC YRKIAAGRARAKACRAPGSYGRGTHCHYKAPTVVLHMTKTDPSLENPTHL

Figure 75

ACACGTCCAACGCCAGCATGCAGCGCCCGGGCCCCGCCTGTGGCTGGTCCTGCAGGT GATGGGCTCGTGCGCCGCCATCAGCTCCATGGACATGGAGCGCCGGGCGACGCCAAA TGCCAGCCCATCGAGATCCCGATGTGCAAGGACATCGGCTACAACATGACTCGTATGC CCAACCTGATGGGCCACGAGAACCAGCGCGAGGCAGCCATCCAGTTGCACGAGTTCGC GCCGCTGGTGGAGTACGGCTGCCACGGCCACCTCCGCTTCTTCCTGTGCTCGCTGTACG CGCCGATGTGCACCGAGCAGGTCTCTACCCCCATCCCCGCCTGCCGGGTCATGTGCGA GCAGGCCCGGCTCAAGTGCTCCCCGATTATGGAGCAGTTCAACTTCAAGTGGCCCGAC

TCCCTGGACTGCCGGAAACTCCCCAACAAGAACGACCCCAACTACCTGTGCATGGAGG CGCCCAACACGCTCGGACGAGCCCACCGGGGCTCGGGCCTGTTCCCGCCGCTGTT CCGGCCGCAGCGCCCACAGCGCGCAGGAGCACCCGCTGAAGGACGGGGGCCCCGG GCGCGGCGCTGCGACAACCCGGGCAAGTTCCACCACGTGGAGAAGAGCGCGTCGTG CGCGCCGCTCTGCACGCCGGCGTGGACGTGTACTGGAGCCGCGAGGACAAGCGCTTC GCAGTGGTCTGGCCATCTGGGCGGTGCTGTGCTTCTTCTCCAGCGCCTTCACCGT GCTCACCTTCCTCATCGACCCGGCCCGCTTCCGCTACCCCGAGCGCCCCATCATCTTCC TCTCCATGTGCTACTGCGTCTACTCCGTGGGCTACCTCATCCGCCTCTTCGCCGGCGCC GAGAGCATCGCCTGCGACCGGGACAGCGCCAGCTCTATGTCATCCAGGAGGGACTGG AGAGCACCGGCTGCACGCTGGTCTTCCTGGTCCTCTACTACTTCGGCATGGCCAGCTCG CTGTGGTGGTGGTCCTCACGCTCACCTGGTTCCTGGCCGCCAGGAAGAAGTGGGGCC ACGAGCCATCGAAGCCAACAGCAGCTACTTCCACCTGGCAGCCTGGGCCATCCCGGC GGTGAAGACCATCCTGATCCTGGTCATGCGCAGGGTGGCGGGGGACGAGCTCACCGGG GTCTGCTACGTGGGCAGCATGGACGTCAACGCGCTCACCGGCTTCGTGCTCATTCCCCT GGCCTGCTACCTGGTCATCGGCACGTCCTTCATCCTCTCGGGCCTTCGTGGCCCTGTTCC ACATCCGGAGGGTGATGAAGACGGGCGGCGAGAACACGGACAAGCTGGAGAAGCTCA TGGTGCGTATCGGGCTCTTCTCTGTGCTGTACACCGTGCCGGCCACCTGTGTGATCGCC TGCTACTTTTACGAACGCCTCAACATGGATTACTGGAAGATCCTGGCGGCGCACACA AGTGCAAAATGAACAACCAGACTAAAACGCTGGACTGCCTGATGGCCGCCTCCATCCC CGCCGTGGAGATCTTCATGGTGAAGATCTTTATGCTGCTGGTGGTGGGGATCACCAGCG GGATGTGGATTTGGACCTCCAAGACTCTGCAGTCCTGGCAGCAGGTGTGCAGCCGTAG GTTAAAGAAGAAGACCGGAGAAAACCGGCCAGCGTGATCACCAGCGGTGGGATTTA CAAAAAAGCCCAGCATCCCCAGAAAACTCACCACGGGAAATATGAGATCCCTGCCCAG TCGCCACCTGCGTGTAACAGGGCTGGAGGGAAGGGCACAGGGGCCCCGGAGCTA AAGCAAAAGAGAAATACATAAAAAAGTGTTTACCCTGAAATTCAGGATGCTGTGATAC AGCTCCTCCAGTGAAGTAGCCTCTTGTGTAACTAATTTGTGGTAAAGTAGTTGATTCAG CCCTCAGAAGAAACTTTTGTTTAGAGCCCTCCGTAAATATACATCTGTGTATTTGAGT TGGCTTTGCTACCCATTTACAAATAAGAGGACAGATAACTGCTTTGCAAATTCAAGAGC CTCCCTGGGTTAACAAATGAGCCATCCCCAGGGCCCACCCCCAGGAAGGCCACAGTG CTGGGCGCATCCCTGCAGAGGAAAGACAGGACCCGGGGCCCGCCTCACACCCCAGTG GATTTGGAGTTGCTTAAAATAGACTCTGGCCTTCACCAATAGTCTCTCTGCAAGACAGA AACCTCCATCAAACCTCACATTTGTGAACTCAAACGATGTGCAATACATTTTTTTCTCTT TCTCCTAACAAAAGAACTAAGAGGCCCAGCCCTCAGAAACCCTTCAGTGCTACATTTT GTGGCTTTTTAATGGAAACCAAGCCAATGTTATAGACGTTTGGACTGATTTGTGGAAAG GAGGGGGGAAGAGGAGAAGGATCATTCAAAAGTTACCCAAAGGGCTTATTGACTCTT TCTATTGTTAAACAAATGATTTCCACAAACAGATCAGGAAGCACTAGGTTGGCAGAGA CACTTTGTCTAGTGTATTCTCTTCACAGTGCCAGGAAAGAGTGGTTTCTGCGTGTGTAT ${\sf ATTTGTAATATGATATTTTCATGCTCCACTATTTATTAAAAAATAAAATATGTTCTT}$ TAAAAAA

Figure 76

MQRPGPRLWLVLQVMGSCAAISSMDMERPGDGKCQPIEIPMCKDIGYNMTRMPNLMGHE NQREAAIQLHEFAPLVEYGCHGHLRFFLCSLYAPMCTEQVSTPIPACRVMCEQARLKCSPI MEQFNFKWPDSLDCRKLPNKNDPNYLCMEAPNNGSDEPTRGSGLFPPLFRPQRPHSAQEH PLKDGGPGRGGCDNPGKFHHVEKSASCAPLCTPGVDVYWSREDKRFAVVWLAIWAVLCF FSSAFTVLTFLIDPARFRYPERPIIFLSMCYCVYSVGYLIRLFAGAESIACDRDSGQLYVIQEG LESTGCTLVFLVLYYFGMASSLWWVVLTLTWFLAAGKKWGHEAIEANSSYFHLAAWAIP AVKTILILVMRRVAGDELTGVCYVGSMDVNALTGFVLIPLACYLVIGTSFILSGFVAL

FHIRRVMKTGGENTDKLEKLMVRIGLFSVLYTVPATCVIACYFYERLNMDYWKILAAQHK CKMNNQTKTLDCLMAASIPAVEIFMVKIFMLLVVGITSGMWIWTSKTLQSWQQVCSRRLK KKSRRKPASVITSGGIYKKAQHPQKTHHGKYEIPAQSPTCV

Figure 77

CCTGCAGCCTCCGGAGTCAGTGCCGCGCGCCCCCCCGCGCCCTTCCTGCTCGCCGC CCGACCGCAGGCCGAGGGCCGCCACTGGCCGGGGGGACCGGGCAGCAGCTTGCGGCC GCGGAGCCGGCAACGCTGGGGACTGCGCCTTTTGTCCCCGGAGGTCCCTGGAAGTTT GCGCAGGACGCGCGGGGAGGCGCGGAGGCCCCGACGTCGCGGAGAACAGG GCGCAGAGCCGGCATGGGCATCGGGCGCAGCGAGGGGCCCGCCGCGGGGCCCTGGG CGTGCTGCTGGCGCTGGGCGCGCTTCTGGCCGTGGGCTCGGCCAGCGAGTACGAC TACGTGAGCTTCCAGTCGGACATCGGCCCGTACCAGAGCGGGCGCTTCTACACCAAGC CACCTCAGTGCGTGGACATCCCCGCGGACCTGCGGCTGTGCCACAACGTGGGCTACAA GAAGATGGTGCTGCCAACCTGCTGGAGCACGAGACCATGGCGGAGGTGAAGCAGCA GGCCAGCAGCTGGTGCCCCTGCTCAACAAGAACTGCCACGCCGGGACCCAGGTCTTC CTCTGCTCGCTCTTCGCGCCCGTCTGCCTGGACCGGCCCATCTACCCGTGTCGCTGGCT CTGCGAGGCCGTGCGACTCGTGCGAGCCGGTCATGCAGTTCTTCGGCTTCTACTGGC CCGAGATGCTTAAGTGTGACAAGTTCCCGGAGGGGGACGTCTGCATCGCCATGACGCC GCCCAATGCCACCGAAGCCTCCAAGCCCCAAGGCACAACGGTGTGTCCTCCCTGTGAC AACGAGTTGAAATCTGAGGCCATCATTGAACATCTCTGTGCCAGCGAGTTTGCACTGA GGATGAAAATAAAAGAAGTGAAAAAAGAAAATGGCGACAAGAAGATTGTCCCCAAGA AGAAGAAGCCCCTGAAGTTGGGGCCCATCAAGAAGAAGGACCTGAAGAAGCTTGTGC TGTACCTGAAGAATGGGGCTGACTGTCCCTGCCACCAGCTGGACAACCTCAGCCACCA CTTCCTCATCATGGGCCGCAAGGTGAAGAGCCAGTACTTGCTGACGGCCATCCACAAG TGGGACAAGAAAACAAGGAGTTCAAAAACTTCATGAAGAAAATGAAAAACCATGAG GCACTGCCCTGTCAGTAGTGGACATTGTAATCCAGTCGGCTTGTTCTTGCAGCATTCCC GCTCCCTTCCCTCCATAGCCACGCTCCAAACCCCAGGGTAGCCATGGCCGGGTAAAG CAAGGCCATTTAGATTAGGAAGGTTTTTAAGATCCGCAATGTGGAGCAGCAGCACT GCACAGGAGGAGGTGACAAACCATTTCCAACAGCAACAGCCACTAAAACACAAAA AGGGGGATTGGGCGGAAAGTGAGAGCCAGCAGCAAAAACTACATTTTGCAACTTGTTG GTGTGGATCTATTGGCTGATCTATGCCTTTCAACTAGAAAATTCTAATGATTGGCAAGT CACGTTGTTTCAGGTCCAGAGTAGTTTCTTTCTGTCTGCTTTAAATGGAAACAGACTC ATACCACACTTACAATTAAGGTCAAGCCCAGAAAGTGATAAGTGCAGGGAGGAAAAG TGCAAGTCCATTATCTAATAGTGACAGCAAAGGGACCAGGGGAGAGGCATTGCCTTCT CTGCCCACAGTCTTTCCGTGTGATTGTCTTTGAATCTGAATCAGCCAGTCTCAGATGCC CCAAAGTTTCGGTTCCTATGAGCCCGGGGCATGATCTGATCCCCAAGACATGTGGAGG CGGCGATTTTCGGGCTGAGAAGGCAGTAGTTTTCAAAACACATAGTTA

Figure 78

MGIGRSEGGRRGAALGVLLALGAALLAVGSASEYDYVSFQSDIGPYQSGRFYTKPPQCVDI PADLRLCHNVGYKKMVLPNLLEHETMAEVKQQASSWVPLLNKNCHAGTQVFLCSLFAPV CLDRPIYPCRWLCEAVRDSCEPVMQFFGFYWPEMLKCDKFPEGDVCIAMTPPNATEASKP QGTTVCPPCDNELKSEAIIEHLCASEFGLSLKMIVGSSHNSCCTLGPSHPNSSKRQEQELGTP ERRLGYGLLLHFIQGNLPPPCAQARSRMRLKTEATPLALGRSAPGLFADCPERPLPVCSFPH

HTEEVGKLRIHSFLLQVKGFSMKGLCAPSTLRYLYYLKTSMQHVHQEYQAHSAQVWANM PPAERCKDEEDKAMFSK

Figure 79

GAATTCGTTCAGCCTGGTTAAGTCCAAGCTGGCTCATTCTGCTCCCCCGGGTCGGAGCC TTCTCCGCGCCCCAGCCGCCGGCTGCCAGCTTTTCGGGGCCCCGAGTCGCACCCAGCGA AGAGAGCGGCCCGGGACAAGCTCGAACTCCGGCCGCCTCGCCCTTAACCAGCTCCGT CCCTCTACCCCTAGGGGTCGCGCCCACGATGCTGCAGGGCCCTGGCTCGCTGCTG CTCTTCCTCGCCTCGCACTGCTGCCTGGGCTCGGCGCGCGGGCTCTTCCTCTTTGGCCA GCCGACTTCTCCTACAAGCGCAGCAATTGCAAGCCCATCCCGGCCAACCTGCAGCTG TGCCACGGCATCGAATACCAGAACATGCGGCTGCCCAACCTGCTGGGCCACGAGACCA TGAAGGAGGTGCTGGAGCAGGCCGGCGCTTGGATCCCGCTGGTCATGAAGCAGTGCCA CCCGGACACCAAGAAGTTCCTGTGCTCGCTCTTCGCCCCCGTCTGCCTCGATGACCTAG ACGAGACCATCCAGCCATGCCACTCTCGNTGCGTGCAGGTGAAGGATCGCTGCGCCCC GGTCATGTCCGCCTTCCCCTGGCCCGACATGCTTGAGTGCGACCGTTTCCCCCAGGACA TCCAAAGGTATGTGAAGCCTGCAAAAATAAAAATGATGATGACAACGACATAATGGA AACGCTTTGTAAAAATGATTTTGCACTGAAAATAAAAGTGAAGGAGATAACCTACATC AACCGT

Figure 80

MLQGPGSLLLLFLASHCCLGSARGLFLFGQPDFSYKRSNCKPIPANLQLCHGIEYQNMRLPNLLGHETMKEVLEQAGAWIPLVMKQCHPDTKKFLCSLFAPVCLDDLDETIQPCHSRCVQVKDRCAPVMSAFPWPDMLECDRFPQDNDLCIPLASSDHLLPATEEAPKVCEACKNKNDDDNDIMETLCKNDFALKIKVKEITYINR

Figure 81

GCAAGACCATTTACAAGCTGAACGGTGTGTCCGAAAGGGACCTGAAGAAATCGGTGCT
GTGGCTCAAAGACAGCTTGCAGTGCACCTGTGAGGAGATGAACGACATCAACGCGCCC
TATCTGGTCATGGGACAGAAACAGGGTGGGGAGCTGGTGATCACCTCGGTGAAGCGGT
GGCAGAAGGGGCAGAGAGAGTTCAAGCGCATCTCCCGCAGCATCCGCAAGCTGCAGT
GCTAGTCCCGGCATCCTGATGGCTCCGACAGGCCTGCTCCAGAGCACGGCTGACCATTT
CTGCTCCGGGATCTCAGCTCCCGTTCCCCAAGCACACTCCTAGCTGCTCCAGTCTCAGC
CTGGGCAGCTTCCCCCTGCCTTTTGCACGTTTGCATCCCCAGCATTTCCTGAGTTATAAG
GCCACAGGAGTGGATAGCTGTTTTCACCTAAAGGAAAAGCCCACCCGA
ATCTTGTAGAAATATTCAAACTAATAAAATCATGAATATTTTTATGAAGTTT

Figure 82

MLQGPGSLLLLFLASHCCLGSARGLFLFGQPDFSYKRSNCKPIPANLQLCHGIEYQNMRLP NLLGHETMKEVLEQAGAWIPLVMKQCHPDTKKFLCSLFAPVCLDDLDETIQPCHSLCVQV KDRCAPVMSAFGFPWPDMLECDRFPQDNDLCIPLASSDHLLPATEEAPKVCEACKNKNDD DNDIMETLCKNDFALKIKVKEITYINRDTKIILETKSKTIYKLNGVSERDLKKSVLWLKDSL QCTCEEMNDINAPYLVMGQKQGGELVITSVKRWQKGQREFKRISRSIRKLQC

Figure 83

ACGGGGCCTGGCGSAGGGGCGTGGCTGGAGCTCGGTAAAGCTCGTGGGACCCCAT TGGGGGAATTTGATCCAAGGAAGCGGTGATTGCCGGGGGAGGAGAAGCTCCCAGATCC GCGCGGCTGCACCCTGCCCATCCTGCCGGGATCATGGTCTGCGGCAGCCCGGGAGGG ATGCTGCTGCGGGCCGGGCTGCTTGCCCTGGCTGCTCTGCCTGCTCCGGGTGCC CGGGGCTCGGGCTGCAGCCTGTGAGCCCGTCCGCATCCCCTGTGCAAGTCCCTGCCCT GGAACATGACTAAGATGCCCAACCACCTGCACCACAGCACTCAGGCCAACGCCATCCT GGCCATCGAGCAGTTCGAAGGTCTGCTGGGCACCCACTGCAGCCCCGATCTGCTCTTCT TCCTCTGTGCCATGTACGCGCCCATCTGCACCATTGACTTCCAGCACGAGCCCATCAAC CCCTGTAAGTCTGTGCGAGCGGGCCGGCAGGGCTGTGAGCCCATACTCATCAAGT ACCGCCACTCGTGGCCGAGAACCTGGCCTGCGAGGAGCTGCCAGTGTACGACAGGGG CGTGTGCATCTCCCGAGGCCATCGTTACTGCGGACGGAGCTGATTTTCCTATGGATT CTAGTAACGGAAACTGTAGAGGGGCAAGCAGTGAACGCTGTAAATGTAAGCCTATTAG AGCTACACAGAAGACCTATTTCCGGAACAATTACAACTATGTCATTCGGGCTAAAGTT AAAGAGATAAAGACTAAGTGCCATGATGTGACTGCAGTAGTGGAGGTGAAGGAGATT CTAAAGTCCTCTCTGGTAAACATTCCACGGGACACTGTCAACCTCTATACCAGCTCTGG CTGCCTCTGCCCTCCACTTAATGTTAATGAGGAATATATCATCATGGGCTATGAAGATG AGGAACGTTCCAGATTACTCTTGGTGGAAGGCTCTATAGCTGAGAAGTGGAAGGATCG ACTCGGTAAAAAAGTTAAGCGCTGGGATATGAAGCTTCGTCATCTTGGACTCAGTAAA AGTGATTCTAGCAATAGTGATTCCACTCAGAGTCAGAAGTCTGGCAGGAACTCGAACC CCCGGCAAGCACGCAACTAAATCCCGAAATACAAAAAGTAACACAGTGGACTTCCTAT TAAGACTTACTTGCATTGCTGGACTAGCAAAGGAAAATTGCACTATTGCACATCATATT CTATTGTTTACTATAAAAATCATGTGATAACTGATTATTACTTCTGTTTCTCTTTTGGTTT CTGCTTCTCTCTCAACCCCTTTGTAATGGTTTGGGGGCAGACTCTTAAGTATATT GTGAGTTTTCTATTTCACTAATCATGAGAAAAACTGTTCTTTTGCAATAATAATAAATT AAACATGCTGTTA

Figure 84

MVCGSPGGMLLLRAGLLALAALCLLRVPGARAAACEPVRIPLCKSLPWNMTKMPNHLHH STQANAILAIEQFEGLLGTHCSPDLLFFLCAMYAPICTIDFQHEPIKPCKSVCERARQGCEPIL IKYRHSWPENLACEELPVYDRGVCISPEAIVTADGADFPMDSSNGNCRGASSERCKCKPIR ATQKTYFRNNYNYVIRAKVKEIKTKCHDVTAVVEVKEILKSSLVNIPRDTVNLYTSSGCLC PPLNVNEEYIIMGYEDEERSRLLLVEGSIAEKWKDRLGKKVKRWDMKLRHLGLSKSDSSN SDSTQSQKSGRNSNPRQARN

Figure 85

CAGCGGCCGCTGAATTCTAGGGCGGGTTCGCGCCCCGAAGGCTGAGAGCTGGCGCTGC TCGTGCCTGTGTGCCAGACGGCGGAGCTCCGCGGCCGGACCCCGCGGCCCCGCTTTG CTGCCGACTGGAGTTTGGGGGAAGAACTCTCCTGCGCCCCAGAAGATTTCTTCCTCGG GGTCGCAGCGCGAGAGGGCAGTGCCATGTTCCTCTCCATCCTAGTGGCGCTGTGCCTGT GGCTGCACCTGGCGCTGCGCGCGCGCGCCCTGCGAGGCGGTGCGCATCCCTAT GTGCCGGCACATGCCCTGGAACATCACGCGGATGCCCAACCACCTGCACCACAGCACG CAGGAGAACGCCATCCTGGCCATCGAGCAGTACGAGGAGCTGGTGGACGTGAACTGC AGCGCCGTGCTGCGCTTCTTCTGTGCCATGTACGCGCCCATTTGCACCCTGGAGTT GAGCCCCTCATGAAGATGTACAACCACAGCTGGCCCGAAAGCCTGGCCTGCGACGAGC TGCCTGTCTATGACCGTGGCGTGTGCATTTCGCCTGAAGCCATCGTCACGGACCTCCCG GAGGATGTTAAGTGGATAGACATCACACCAGACATGATGGTACAGGAAAGGCCTCTTG ATGTTGACTGTAAACGCCTAAGCCCCGATCGGTGCAAGTGTAAAAAGGTGAAGCCAAC TTTGGCAACGTATCTCAGCAAAAACTACAGCTATGTTATTCATGCCAAAATAAAAGCTG TGCAGAGGAGTGGCTGCAATGAGGTCACAACGGTGGTGGATGTAAAAGAGATCTTCAA GTCCTCATCACCCATCCCTCGAACTCAAGTCCCGCTCATTACAAATTCTTCTTGCCAGT GTCCACACATCCTGCCCCATCAAGATGTTCTCATCATGTGTTACGAGTGGCGTTCAAGG ATGATGCTTCTTGAAAATTGCTTAGTTGAAAAATGGAGAGATCAGCTTAGTAAAAGAT CCATACAGTGGGAAGAGGGCTGCAGGAACAGCGGAGAACAGTTCAGGACAAGAAGA AAACAGCCGGGCGCACCAGTCGTAGTAATCCCCCCAAACCAAAGGGAAAGCCTCCTGC TCCCAAACCAGCCAGTCCCAAGAAGAACATTAAAACTAGGAGTGCCCAGAAGAGAAC AAACCGAAAAGAGTGTGAGCTAACTAGTTTCCAAAGCGGAGACTTCCGACTTCCTTA CAGGATGAGGCTGGGCATTGCCTGGGACAGCCTATGTAAGGCCATGTGCCCCTTGCCC TAACAACTCACTGCAGTGCTCTTCATAGACACATCTTGCAGCATTTTTCTTAAGGCTAT GCTTCAGTTTTCTTTGTAAGCCATCACAAGCCATAGTGGTAGGTTTGCCCTTTGGTACA GAAGGTGAGTTAAAGCTGGTGGAAAAGGCTTATTGCATTGCATTCAGAGTAACCTGTG TGCATACTCTAGAAGAGTAGGGAAAATAATGCTTGTTACAATTCGACCTAATATGTGC ATTGTAAAATAAATGCCATATTTCAAACAAAACACGTAATTTTTTTACAGTATGTTTTA TTACCTTTTGATATCTGTTGCTATGTTAGTGATGTTTTAAAATGTGATGAAAATATA ATGTTTTAAGAAGGAACAGTAGTGGAATGAATGTTAAAAGATCTTTATGTGTTTATGG ATGGAAAATTATAATGTGTTTTTTTACCAATGACTTCAGTTTCTGTTTTTAGCTAGAAAC TTAAAAACAAAATAATAATAAAGAAAAATAAATAAAAGGAGGGCAGACAATGTC TGGATTCCTGTTTTTTGGTTACCTGATTTCCATGATCATGATGCTTCTTGTCAACACCCT CTTAAGCAGCACCAGAAACAGTGAGTTTGTCTGTACCATTAGGAGTTAGGTACTAATTA GTTGGCTAATGCTCAAGTATTTTATACCCACAAGAGAGGTATGTCACTCATCTTACTTC CCAGGACATCCACCCTGAGAATAATTTGACAAGCTTAAAAATGGCCTTCATGTGAGTG CCAAATTTTGTTTTCTTCATTTAAATATTTTCTTTGCCTAAATACATGTGAGAGGAGTT AAATATAAATGTACAGAGAGGAAAGTTGAGTTCCACCTCTGAAATGAGAATTACTTGA CAGTTGGGATACTTTAATCAGAAAAAAAGAACTTATTTGCAGCATTTTATCAACAAATT TCATAATTGTGGACAATTGGAGGCATTTATTTTAAAAAAACAATTTTATTGGCCTTTTGCT

AACACAGTAAGCATGTATTTTATAAGGCATTCAATAAATGCACAACGCCCAAAGGAAA
TAAAATCCTATCTAATCCTACTCTCCACTACACAGAGGTAATCACTATTAGTATTTTGG
CATATTATTCTCCAGGTGTTTGCTTATGCACTTATAAAATGATTTGAACAAATAAAACT
AGGAACCTGTATACATGTGTTTCATAACCTGCCTCCTTTGCTTGGCCCTTTATTGAGATA
AGTTTTCCTGTCAAGAAAGCAGAAACCATCTCATTTCTAACAGCTGTGTTATATTCCAT
AGTATGCATTACTCAACAAACTGTTGTGCTATTGGATACTTAGGTGGTTTCTTCACTGA
CAATACTGAATAAACATCTCACCGGAATTC

Figure 86

MFLSILVALCLWLHLALGVRGAPCEAVRIPMCRHMPWNITRMPNHLHHSTQENAILAIEQY EELVDVNCSAVLRFFLCAMYAPICTLEFLHDPIKPCKSVCQRARDDCEPLMKMYNHSWPE SLACDELPVYDRGVCISPEAIVTDLPEDVKWIDITPDMMVQERPLDVDCKRLSPDRCKCKK VKPTLATYLSKNYSYVIHAKIKAVQRSGCNEVTTVVDVKEIFKSSSPIPRTQVPLITNSSCQC PHILPHQDVLIMCYEWRSRMMLLENCLVEKWRDQLSKRSIQWEERLQEQRRTVQDKKKT AGRTSRSNPPKPKGKPPAPKPASPKKNIKTRSAQKRTNPKRV

Figure 87

AAGCTTGATATCGAATTCGCGGCCGCGTCGACGGAGGCGCCAGGATCAGTCGGGGCA CCCGCAGCGCAGCTGCCACCACCTGGGCGACCTCCGCGGCGGCGGCGGCGGCGGCT GGGTAGAGTCAGGGCCGGGGGCGCACGCCGGAACACCTGGGCCGCCGGGCACCGAGC GCGCCGGGGGGCGTGCGGACGCCGCGCTGCTGCTGCTGGGGGCGCTGCACTGG GCGCCGGCGCGCGAGGAGTACGACTACTATGGCTGCAGGCCGAGCCGCTGCACG GCCGCTCCTACTCCAAGCCGCCGCAGTGCCTTGACATCCCTGCCGACCTGCCGCTCTGC CACACGGTGGGCTACAAGCGCATGCGGCTGCCCAACCTGCTGGAGCACGAGAGCCTGG CCGAAGTGAAGCAGCAGCGAGCAGCTGCTGCCGCTGCCGAAGCGCTGCCACTC ACCCGTGCCGCTGTGCGAGGCCGTGCGCGCCGCTGCGCGCCGCTCATGGAGGC CTACGGCTTCCCCTGGCCTGAGATGCTGCACTGCCACAAGTTCCCCCTGGACAACGACC TGCGCCCAGTGTGAGATGGAGCACAGTGCTGACGGCCTCATGGAGCAGATGTGCTCCA GTGACTTTGTGGTCAAAATGCGCATCAAGGAGATCAAGATAGAGAATGGGGACCGGA AGCTGATTGGAGCCCAGAAAAAGAAGAAGCTGCTCAAGCCGGGCCCCCTGAAGCGCA AGGACACCAAGCGGCTGGTGCTGCACATGAAGAATGGCGCGGGCTGCCCCTGCCCACA CTGCTCATGGCCGTCTACCGCTGGGACAAGAAGAATAAGGAGATGAAGTTTGCAGTCA AATTCATGTTCTCCTACCCCTGCTCCCTCTACTACCCTTTCTTCTACGGGGCGGCAGAGC GCCCAACTTCCAGGCTGACCCGGCCCTACTGGAGGGTGTTTTCACGAATGTTGTTACT GGCACAAGGCCTAAGGGATGGGCACGGAGCCCAGGCTGTCCTTTTTGACCCAGGGGTC CTGGGGTCCCTGGGATGTTGGGCTTCCTCTCAGGAGCAGGGCTTCTTCATCTGGGTG AAGACCTCAGGGTCTCAGAAAGTAGGCAGGGGAGGGAGAGGGTAAGGGAAAGGTGGAG GGGCTCAGGGCACCCTGAGGCGGAGGTTTCAGAGTAGAAGGTGATGTCAGCTCCAGCT CCCCTCTGTCGGTGGTGGGCCTCACCTTGAAGAGGGAAGTCTCAATATTAGGCTAAG CTATTTGGGAAAGTTCTCCCCACCGCCCTGTACGCGTCATCCTAGCCCCCCTTAGGAA AGGAGTTAGGGTCTCAGTGCCTCCAGCCACACCCCCTGCCTTCCCCAGCTTGCCCATTT

Figure 88

TEILPALCVLIHHTDVNILVDTVWALSYLTDAGNEQIQMVIDSGIVPHLVPLLSHQEVKVQT AALRAVGNIVTGTDEQTQVVLNCDALSHFPALLTHPKEKINKEAVWFLSNITAGNQQQVQ AVIDANLVPMIIHLLDKGDFGTQKEAAWAISNLTISGRKDQVAYLIQQNVIPPFCNLLTVKD AQVVQVVLDGLSNILKMAEDEAETIGNLIEECGGLEKIEQLQNHENEDIYKLAYEIIDQFFSS DDIDEDPSLVPEAIQGGTFGFNSSANVPTEGFQF

Figure 89

Figure 90

MHLLLFQLLVLLPLGKTTRHQDGRQNQSSLSPVLLPRNQRELPTGNHEEAEEKPDLFVAVP HLVATSPAGEGQRQREKMLSRFGRFWKKPEREMHPSRDSDSEPFPPGTQSLIQPIDGMKME KSPLREEAKKFWHHFMFRKTPASQGVILPIKSHEVHWETCRTVPFSQTITHEGCEKVVVQN NLCFGKCGSVHFPGAAQHSHTSCSHCLPAKFTTMHLPLNCTELSSVIKVVMLVEECQCKV KTEHEDGHILHAGSQDSFIPGVSA

Figure 91

GGAATTACTGCAAAAATGGAATATGTGTGTCTTCTGATCAAAATCATTTCCGAGGAGA AATTGAGGAAACCATCACTGAAAGCTTTGGTAATGATCATAGCACCTTGGATGGGTAT TCCAGAAGAACCACCTTGTCTTCAAAAATGTATCACACCAAAGGACAAGAAGGTTCTG TTTGTCTCCGGTCATCAGACTGTGCCTCAGGATTGTGTTGTGCTAGACACTTCTGGTCCA AGATCTGTAAACCTGTCCTGAAAGAAGGTCAAGTGTGTACCAAGCATAGGAGAAAAGG TACAGAAAGATCACCATCAAGCCAGTAATTCTTCTAGGCTTCACACTTGTCAGAGACAC TAAACCAGCTATCCAAATGCAGTGAACTCCTTTTATATAATAGATGCTATGAAAACCTT TTATGACCTTCATCAACTCAATCCTAAGGATATACAAGTTCTGTGGTTTCAGTTAAGCA TTCCAATAACACCTTCCAAAAACCTGGAGTGTAAGAGCTTTGTTTCTTTATGGAACTCC CCTGTGATTGCAGTAAATTACTGTATTGTAAATTCTCAGTGTGGCACTTACCTGTAAAT ${\tt GCAATGAAACTTTTAATTATTTTCTAAAGGTGCTGCACTGCCTATTTTTCCTCTTGTTA}$ TGTAAATTTTTGTACACATTGATTGTTATCTTGACTGACAAATATTCTATATTGAACTGA AGTAAATCATTTCAGCTTATAGTTCTTAAAAGCATAACCCTTTACCCCATTTAATTCTAG AGTCTAGAACGCAAGGATCTCTTGGAATGACAAATGATAGGTACCTAAAATGTAACAT GAAAATACTAGCTTATTTTCTGAAATGTACTATCTTAATGCTTAAATTATATTTCCCTTT AGGCTGTGATAGTTTTTGAAATAAAATTTAACATTTAATATCATGAAATGTTATAAGTA **GACAT**

Figure 92

MMALGAAGATRVFVAMVAAALGGHPLLGVSATLNSVLNSNAIKNLPPPLGGAAGHPGSA VSAAPGILYPGGNKYQTIDNYQPYPCAEDEECGTDEYCASPTRGGDAGVQICLACRKRRK RCMRHAMCCPGNYCKNGICVSSDQNHFRGEIEETITESFGNDHSTLDGYSRRTTLSSKMYH TKGQEGSVCLRSSDCASGLCCARHFWSKICKPVLKEGQVCTKHRRKGSHGLEIFQRCYCG EGLSCRIQKDHHQASNSSRLHTCQRH

Figure 93

GCGGGTCTCGCTTGGGTTCCGCTAATTTCTGTCCTGAGGCGTGAGACTGAGTTCATAGG GTCCTGGGTCCCCGAACCAGGAAGGGTTGAGGGAACACAATCTGCAAGCCCCCGCGAC CCAAGTGAGGGCCCCGTGTTGGGGTCCTCCCTCCCTTTGCATTCCCACCCCTCCGGGC TTTGCGTCTTCCTGGGGACCCCCTCGCCGGGAGATGGCCGCGTTGATGCGGAGCAAGG ATTCGTCCTGCTGCTCCTACTGGCCGCGGTGCTGATGGTGGAGAGCTCACAGATC GGCAGTTCGCGGGCCAAACTCAACTCCATCAAGTCCTCTCTGGGCGGGGAGACGCCTG GTCAGGCCGCCAATCGATCTGCGGGCATGTACCAAGGACTGGCATTCGGCGGCAGTAA GAAGGGCAAAAACCTGGGGCAGGCCTACCCTTGTAGCAGTGATAAGGAGTGTGAAGTT GGGAGGTATTGCCACAGTCCCCACCAAGGATCATCGGCCTGCATGGTGTGTCGGAGAA AAAAGAAGCGCTGCCACCGAGATGGCATGTGCTGCCCCAGTACCCGCTGCAATAATGG CATCTGTATCCCAGTTACTGAAAGCATCTTAACCCCTCACATCCCGGCTCTGGATGGTA CTCGGCACAGAGATCGAAACCACGGTCATTACTCAAACCATGACTTGGGATGGCAGAA TCTAGGAAGACCACACTAAGATGTCACATATAAAAGGGCATGAAGGAGACCCCTGC CTACGATCATCAGACTGCATTGAAGGGTTTTGCTGTGCTCGTCATTTCTGGACCAAAAT CTGCAAACCAGTGCTCCATCAGGGGGAAGTCTGTACCAAACAACGCAAGAAGGGTTCT CATGGGCTGGAAATTTTCCAGCGTTGCGACTGTGCGAAGGGCCTGTCTTGCAAAGTATG GAAAGATGCCACCTACTCCCAAAGCCAGACTCCATGTGTGTCAGAAAATTTGATCA CCATTGAGGAACATCATCAATTGCAGACTGTGAAGTTGTGTATTTAATGCATTATAGCA TGGTGGAAAATAAGGTTCAGATGCAGAAGAATGGCTAAAATAAGAAACGTGATAAGA ATATAGATGATCAC

Figure 94

MAALMRSKDSSCCLLLLAAVLMVESSQIGSSRAKLNSIKSSLGGETPGQAANRSAGMYQG LAFGGSKKGKNLGQAYPCSSDKECEVGRYCHSPHQGSSACMVCRRKKKRCHRDGMCCPS TRCNNGICIPVTESILTPHIPALDGTRHRDRNHGHYSNHDLGWQNLGRPHTKMSHIKGHEG DPCLRSSDCIEGFCCARHFWTKICKPVLHQGEVCTKQRKKGSHGLEIFQRCDCAKGLSCKV WKDATYSSKARLHVCQKI

Figure 95

CGAGAAATTCACAAGATAACCAACAACCAGACTGGACAAATGGTCTTTTCAGAGACAG TTATCACATCTGTGGGAGACGAAGAAGGCAGAAGGAGCCACGAGTGCATCATCGACG AGGACTGTGGGCCCAGCATGTACTGCCAGTTTGCCAGCTTCCAGTACACCTGCCAGCC TGTGTCTGGGGTCACTGCACCAAAATGGCCACCAGGGGCAGCAATGGGACCATCTGTG ACAACCAGAGGGACTGCCAGCCGGGGCTGTGCTGTGCCTTCCAGAGAGGCCTGCTGTT CCTGTGTGCACACCCTGCCGTGGAGGGCGAGCTTTGCCATGACCCCGCCAGCCGG CTTCTGGACCTCATCACCTGGGAGCTAGAGCCTGATGGAGCCTTGGACCGATGCCCTTG TGCCAGTGGCCTCTCTGCCAGCCCACAGCCACAGCCTGGTGTATGTGTGCAAGCCG ACCTTCGTGGGGAGCCGTGACCAAGATGGGGAGATCCTGCTGCCCAGAGAGGTCCCCG ATGAGTATGAAGTTGGCAGCTTCATGGAGGAGGTGCGCCAGGAGCTGGAGGACCTGGA GAGGAGCCTGACTGAAGAGATGGCGCTGGGGGAGCCTGCGGCTGCCGCCGCTGCACTG CTGGGAGGGGAAGAGATTTAGATCTGGACCAGGCTGTGGGTAGATGTGCAATAGAAATAGCTAATTTATTTCCCCAGGTGTGTGCTTTAGGCGTGGGCTGACCAGGCTTCTTCCTAC ATCTTCTCCCAGTAAGTTTCCCCTCTGGCTTGACAGCATGAGGTGTTGTGCATTTGTTC GTTAAACTGCAGGAGCAGTTTGCCACCCCTGTCCAGATTATTGGCTGCTTTGCCTCTAC CAGTTGGCAGACAGCCGTTTGTTCTACATGGCTTTGATAATTGTTTGAGGGGAGGAGAT GGAAACAATGTGGAGTCTCCCTCTGATTGGTTTTTGGGGAAATGTGGAGAAGAGTGCCC TGCTTTGCAAACATCAACCTGGCAAAAATGCAACAAATGAATTTTCCACGCAGTTCTTT CCATGGGCATAGGTAAGCTGTGCCTTCAGCTGTTGCAGATGAAATGTTCTGTTCACCCT GCATTACATGTGTTTATTCATCCAGCAGTGTTGCTCAGCTCCTACCTCTGTGCCAGGGC AGCATTTCATATCCAAGATCAATTCCCTCTCTCAGCACAGCCTGGGGAGGGGGTCATT GTTCTCCTCGTCCATCAGGGATCTCAGAGGNCTCAGAGACTGCAAGCTGCTTGCCCAA GTCACACAGCTAGTGAAGACCAGAGCAGTTTCATCTGGTTGTGACTCTAAGCTCAGTGC AGAATGGGATTTTTCTTTTGAGGCATGCACATCTGGAATTAAGGTCAAACTAATTCTCA CATCCTCTAAAAGTAAACTACTGTTAGGAACAGCAGTGTTCTCACAGTGTGGGGCAG CCGTCCTTCTAATGAAGACAATGATATTGACACTGTCCCTCTTTGGCAGTTGCATTAGT AACTTTGAAAGGTATATGACTGAGCGTAGCATACAGGTTAACCTGCAGAAACAGTACT TAGGTAATTGTAGGGCGAGGATTATAAATGAAATTTGCAAAATCACTTAGCAGCAACT GAAGACAATTATCAACCACGTGGAGAAAATCAAACCGAGCAGGGCTGTGTGAAACAT GGTTGTAATATGCGACTGCGAACACTGAACTCTACGCCACTCCACAAATGATGTTTTCA GGTGTCATGGACTGTTGCCACCATGTATTCATCCAGAGTTCTTAAAGTTTAAAGTTGCA CATGATTGTATAAGCATGCTTTCTTTGAGTTTTAAATTATGTATAAACATAAGTTGCATT TAGAAATCAAGCATAAATCAC

Figure 96

MQRLGATLLCLLLAAAVPTAPAPAPTATSAPVKPGPALSYPQEEATLNEMFREVEELMEDT QHKLRSAVEEMEAEEAAAKASSEVNLANLPPSYHNETNTDTKVGNNTIHVHREIHKITNNQ TGQMVFSETVITSVGDEEGRRSHECIIDEDCGPSMYCQFASFQYTCQPCRGQRMLCTRDSE CCGDQLCVWGHCTKMATRGSNGTICDNQRDCQPGLCCAFQRGLLFPVCTPLPVEGELCHD PASRLLDLITWELEPDGALDRCPCASGLLCQPHSHSLVYVCKPTFVGSRDQDGEILLPREVP DEYEVGSFMEEVRQELEDLERSLTEEMALGEPAAAAAALLGGEEI

Figure 97

Figure 98

MVAAVLLGLSWLCSPLGALVLDFNNIRSSADLHGARKGSQCLSDTDCNTRKFCLQPRDEK PFCATCRGLRRRCQRDAMCCPGTLCVNDVCTTMEDATPILERQLDEQDGTHAEGTTGHPV QENQPKRKPSIKKSQGRKGQEGESCLRTFDCGPGLCCARHFWTKICKPVLLEGQVCSRRGH KDTAQAPEIFQRCDCGPGLLCRSQLTSNRQHARLRVCQKIEKL

Figure 99

AGTGTGAAATCAGCAAATGCCCACAACCCTGTCGAAATGGAGGTAAATGCATTGGTAA AAGCAAATGTAAGTGTTCCAAAGGTTACCAGGGAGACCTCTGTTCAAAGCCTGTCTGC GAGCCTGGCTGTGGTGCACATGGAACCTGCCATGAACCCAACAATGCCAATGTCAAG GAGCGCAGCGCCCAGCTCAGGCAGCACCCCTTCACTTAAAAAGGCCGAGGAG CGGCGCATCCACCTGAATCCAATTACATCTGGTGAACTCCGACATCTGAAACGTTTTA AGTTACACCAAGTTCATAGCCTTTGTTAACCTTTCATGTGTTGAATGTTCAAATAATGTT CATTACACTTAAGAATACTGGCCTGAATTTTATTAGCTTCATTATAAATCACTGAGCTG ATATTTACTCTTCCTTTTAAGTTTTCTAAGTACGTCTGTAGCATGATGGTATAGATTTTC TTGTTTCAGTGCTTTGGGACAGATTTTATATTATGTCAATTGATCAGGTTAAAATTTTCA GTGTGTAGTTGGCAGATATTTTCAAAATTACAATGCATTTATGGTGTCTGGGGGCAGGG GAACATCAGAAAGGTTAAATTGGGCAAAAATGCGTAAGTCACAAGAATTTGGATGGTG CATTTTAAAAATTGCTCTTAATTTTTAAACTCTCAATACAATATATTTTGACCTTACCA TTATTCCAGAGATTCAGTATTAAAAAAAAAAAAATTACACTGTGGTAGTGGCATTTAA ACAATATAATATTCTAAACACAATGAAATAGGGAATATAATGTATGAACTTTTTGCA TTGGCTTGAAGCAATATAATATTGTAAACAAAACACAGCTCTTACCTAATAAACATT

Figure 100

MARRSAFPAAALWLWSILLCLLALRAEAGPPQEESLYLWIDAHQARVLIGFEEDILIVSEGK MAPFTHDFRKAQQRMPAIPVNIHSMNFTWQAAGQAEYFYEFLSLRSLDKGIMADPTVNVP LLGTVPHKASVVQVGFPCLGKQDGVAAFEVDVIVMNSEGNTILQTPQNAIFFKTCLQAECP GGCRNGGFCNERRICECPDGFHGPHCEKALCTPRCMNGGLCVTPGFCICPPGFYGVNCDK ANCSTTCFNGGTCFYPGKCICPPGLEGEQCEISKCPQPCRNGGKCIGKSKCKCSKGYQGDL CSKPVCEPGCGAHGTCHEPNKCQCQEGWHGRHCNKRYEASLIHALR PAGAQLRQHTPSLKKAEERRDPPESNYIW

TTATACTGTTTGTATGTATAAAATAAAGGTGCTGCTTTAGTTTTC

Figure 101

ATGGGCATCGGGCGCGGGGGGGGGGCCGCGGGGCAGCCCTGGGCGTGCTGCTG GCGCTGGGCGCGCGCTTCTGGCCGTGGGCTCGGCCAGCGAGTACGACTACGTGAGCT TCCAGTCGGACATCGGCCCGTACCAGAGCGGCGCTTCTACACCAAGCCACCTCAGTG CGTGGACATCCCCGCGGACCTGCGGCTGTGCCACAACGTGGGCTACAAGAAGATGGTG CTGCCCAACCTGCTGGAGCACGAGACCATGGCGGAGGTGAAGCAGCAGCAGCAGC TGGGTGCCCTGCTCAACAAGAACTGCCACGCCGGCACCCAGGTCTTCCTCTGCTCGCT CTTCGCGCCCGTCTGCCTGGACCGGCCCATCTACCCGTGTCGCTGGCTCTGCGAGGCCG TGCGCGACTCGTGCGAGCCGGTCATGCAGTTCTTCGGCTTCTACTGGCCCGAGATGCTT AAGTGTGACAAGTTCCCCGAGGGGGACGTCTGCATCGCCATGACGCCGCCCAATGCCA CCGAAGCCTCCAAGCCCCAAGGCACAACGGTGTGTCCTCCCTGTGACAACGAGTTGAA ATCTGAGGCCATCATTGAACATCTCTGTGCCAGCGAGTTTGGGCTGAGTTTAAAGATGA TTGTGGGTAGCTCCCATAACTCATGCTGCACGCTGGGTCCTTCTCATCCCAACTCCTCA AAGCGGCAGGAGCAGGAACTGGGGACTCCTGAGAGAAGGCTTGGATATGGCCTTTTAT TACACTTCATCCAAGGAAATCTGCCCCCACCTGTGCCCAGGCCCGATCACGCATGAG GCTAAAGACGGAGGCCACTCCGCTGGCTCTGGGTAGATCTGCCCCTGGACTGTTTGCC GACTGCCGGAGCGCCCTCTGCCGGTCTGCAGCTTCCCACACCACACGGAAGAAGTGG GGAAACTGAGGATACATTCTTTCCTCCTCCAGGTAAAGGGATTCTCAATGAAGGGCTTG TGTGCACCTTCCACACTTAGATACCTCTACTACCTGAAAACCAGCATGCAGCATGTACA TCAAGAGTACCAGGCACATAGTGCTCAAGTCTGGGCTAATATGCCACCTGCAGAGAGA TGTAAAGATGAAGAAGACAAAGCCATGTTTTCAAAGTGA

Figure 102

MGIGRSEGGRRGAALGVLLALGAALLAVGSASEYDYVSFQSDIGPYQSGRFYTKPPQCVDI PADLRLCHNVGYKKMVLPNLLEHETMAEVKQQASSWVPLLNKNCHAGTQVFLCSLFAPV CLDRPIYPCRWLCEAVRDSCEPVMQFFGFYWPEMLKCDKFPEGDVCIAMTPPNATEASKP QGTTVCPPCDNELKSEAIIEHLCASEFGLSLKMIVGSSHNSCCTLGPSHPNSSKRQEQELGTP ERRLGYGLLLHFIQGNLPPPCAQARSRMRLKTEATPLALGRSAPGLFADCPERPLPVCSFPH HTEEVGKLRIHSFLLQVKGFSMKGLCAPSTLRYLYYLKTSMQHVHQEYQAHSAQVWANM PPAERCKDEEDKAMFSK

Figure 103

GGCGGTTCGCGCCCCGAAGGCTGAGAGCTGGCGCTGCTCGTGCCCTGTGTGCCAGAC GGCGGAGCTCCGCGGCCGGACCCCGCGCCCCGCTTTGCCGACTGGAGTTTGGGG GAAGAAACTCTCCTGCGCCCCAGAAGATTTCTTCCTCGGCGAAGGGACAGCGAAAGAT GAGGGTGGCAGGAAGAGAGGCGCTTTCTGTCTGCCGGGGTCGCAGCGCGAGAGGGC AGTGCCATGTTCCTCCATCCTAGTGGCGCTGTGCCTGTGGCTGCACCTGGCGCTGGG CGTGCGCGCGCCCTGCGAGGCGGTGCGCATCCCTATGTGCCGGCACATGCCCTGG AACATCACGCGGATGCCCAACCACCTGCACCACAGCACGCAGGAGAACGCCATCCTGG CCATCGAGCAGTACGAGGAGCTGGTGGACGTGAACTGCAGCGCCGTGCTGCGCTTCTT CTTCTGTGCCATGTACGCGCCCATTTGCACCCTGGAGTTCCTGCACGACCCTATCAAGC CGTGCAAGTCGGTGTGCCAACGCGCGCGACGACTGCGAGCCCCTCATGAAGATGTA CAACCACAGCTGGCCGAAAGCCTGGCCTGCGACGAGCTGCCTGTCTATGACCGTGGC GTGTGCATTTCGCCTGAAGCCATCGTCACGGACCTCCCGGAGGATGTTAGTGGATAGA CATCACACCAGACATGATGGTACAGGAAAGGCCTCTTGATGTTGACTGTAAACGCCTA AGCCCCGATCGGTGCAAGTGTAAAAAGGTGAAGCCAACTTTGGCAACGTATCTCAGCA AAAACTACAGCTATGTTATTCATGCCAAAATAAAAGCTGTGCAGAGGAGTGGCTGCAA TGAGGTCACAACGGTGGTGGATGTAAAAGAGATCTTCAAGTCCTCATCACCCATCCCTC GAACTCAAGTCCCGCTCATTACAAATTCTTCTTGCCAGTGTCCACACATCCTGCCCCAT CAAGATGTTCTCATCATGTGTTACGAGTGGCGTTCAAGGATGATGCTTCTTGAAAATTG CTTAGTTGAAAAATGGAGAGATCAGCTTAGTAAAAGATCCATACAGTGGGAAGAGAG GCTGCAGGAACAGCGGAGAACAGTTCAGGACAAGAAGAAAACAGCCGGGCGCACCAG AAGAAGAACATTAAAACTAGGAGTGCCCAGAAGAGAACAAACCCGAAAAGAGTGTGA GCTAACTAGTTTCCAAAGCGGAGACTTCCGACTTCCTTACAGGATGAGGCTGGGCATTG CCTGGGACAGCCTATGTAAGGCCATGTGCCCCTTGCCCTAACAACTCACTGCAGTGCTC TTCATAGACACATCTTGCAGCATTTTTCTTAAGGCTATGCTTCAGTTTTTCTTTGTAAGC CATCACAAGCCATAGTGGTAGGTTTGCCCTTTGGTACAGAAGGTGAGTTAAAGCTGGT GGAAAAGGCTTATTGCATTGCATTCAGAGTAACCTGTGTGCATACTCTAGAAGAGTAG TTCAAACAAAACACGTAATTTTTTTACAGTATGTTTTATTACCTTTTTGATATCTGTTGTT AGTGGAATGAAAGATCTTTATGTGTTTATGGTCTGCAGAAGGATTTTTGTGA TGAAAGGGGATTTTTTGAAAAATTAGAGAAGTAGCATATGGAAAATTATAATGTGTTT TTTTACCAATGACTTCAGTTTCTGTTTTTAGCTAGAAACTTAAAAACAAAAATAATAAT AAAGAAAAAAAAAAGGAGGCAGACAATGTCTGGATTCCTGTTTTTTGGTTA

CCTGATTTCCATGATCATGATGCTTCTTGTCAACACCCTCTTAAGCAGCACCAGAAACA
GTGAGTTTGTCTGTACCATTAGGAGTTAGGTACTAATTAGTTGGCTAATGCTCAAGT
ATTTTATACCCACAAGAGAGAGGTATGTCACTCATCTTACTTCCCAGGACATCCACCCTGA
GAATAATTTGACAAGCTTAAAAATGGCCTTCATGTGAGTGCCAAATTTTGTTTTTCTTC
ATTTAAATATTTTCTTTGCCTAAATACATGTGAGAGGAGTTAAATATAAATGTACAGAG
AGGAAAGTTGAGTTCCACCTCTGAAATGAGAATTACTTGACAGTTGGGATACTTTAATC
AGAAAAAAAGAACTTATTTGCAGCATTTTATCAACAAATTTCATAATTGTGGACAATTG
GAGGCATTTATTTTAAAAAAACAATTTTATTGGCCTTTTGCTAACACAGTAAGCATGTAT
TTTATAAGGCATTCAATAAATGCACAAACGCCCAAAGGAAATAAAATCCTATCTCAATCC
TACTCTCCACTACACAGAGGTAATCACTATTAGTATTTTGGCATATTATTCTCCAGGTGT
TTGCTTATGCACTTATAAAATGATTTGAACAAATAAAACTAGGAACCTGTATACATGTG
TTTCATAACCTGCCTCCTTTGCTTGGCCCTTTATTGAGATAAGTTTTCCTGTCAAGAAAG
CAGAAACCATCTCATTTCTAACAGCTGTGTTATATTCCATAGTATTACTCAACAA
ACTGTTGTGCTATTGGATACTTAGGTGGTTTCTTCACTGACAATAAACATCT
CACCGGAATTC

Figure 104

MFLSILVALCLWLHLALGVRGAPCEAVRIPMCRHMPWNITRMPNHLHHSTQENAILAIEQY EELVDVNCSAVLRFFFCAMYAPICTLEFLHDPIKPCKSVCQRARDDCEPLMKMYNHSWPES LACDELPVYDRGVCISPEAIVTDLPEDVKWIDITPDMMVQERPLDVDCKRLSPDRCKCKKV KPTLATYLSKNYSYVIHAKIKAVQRSGCNEVTTVVDVKEIFKSSSPIPRTQVPLITNSSCQCP HILPHQDVLIMCYEWRSRMMLLENCLVEKWRDQLSKRSIQWEERLQEQRRTVQDKKKTA GRTSRSNPPKPKGKPPAPKPASPKKNIKTRSAQKRTNPKRV

WO 02/077204 PCT/GB02/01195

66/66




Figure 105